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1.1  Background 
The phenomenon of alloimmunization is an important adverse effect that follows transfusions 
with allogeneic blood (Walker et al., 1989; Heddle et al., 1995) and pregnancy (Moise, 1993; 
Moise, 2005). It results from an immune response due to genetic differences between the blood 
donor and recipient of the same species on the one hand, and the mother and fetus on the other. 
Immune alloantibodies against red blood cell (RBC) antigens are generally formed early in the 
course of multiple transfusions, usually before the 10th transfusion (Blumberg et al., 1983; Fluit 
et al., 1990). Upon further transfusion exposures, patients who have formed antibodies showed a 
4 - 5 times increased risk for developing additional alloantibodies (Schonewille et al., 2006; 
Schonewille et al., 2009). Antibodies may also be formed against class I human leucocyte 
antigens (HLA) and human platelet antigens (HPA) when whole blood, platelets and 
granulocytes are transfused. Sickle cell disease (SCD) patients and other multiply transfused 
(OMT) blood recipients are at high risk of being alloimmunized. Once immunized, obtaining 
compatible blood for their future transfusions can pose complex serological problems and the 
need for an RBC typed donor inventory. The antibodies can cause alloimmune haemolysis 
presenting as haemolytic disease of the fetus and newborn (HDFN) or acute and delayed 
haemolytic transfusion reactions (HTRs), with potentially serious morbidity and mortality. 
No data were available on the frequency of post-transfusion and maternal RBC alloimmunization 
in Uganda before the commencement of this research project. In the well-resourced parts of the 
world, the incidence and prevalence of RBC alloantibody formation are reported to be less than 
1% up to more than 40% respectively. The frequency of post-transfusion RBC alloimmunization 
is generally high in patients with haemoglobinopathies, ranging up to 37% in thalassaemia and to 
65% in sickle cell anaemia (Wang et al., 2006; Ameen et al., 2009). Factors assumed to 
influence the rate of alloimmunization are antigen immunogenicity, duration of transfusion 
therapy, and genetic and environmental factors, but their individual contribution is unknown.  
In Uganda, pre-transfusion testing is currently limited to ABO/D typing plus room temperature 
(RT) saline cross-matches, and most of the patients are given whole blood transfusions instead of 
blood components. No screening for immune RBC alloantibodies is carried out in antenatal and 
pre-transfusion settings. Also, Rh immune globulin (RhIG) prophylaxis is not routinely 
administered to RhD negative mothers who deliver RhD positive babies. Therefore, there was a 
need to determine the magnitude of the problem of post-transfusion and maternal RBC 
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alloimmunization in Uganda. In this thesis, recommendations are given on the prevention of 
RBC alloimmunization and the delivery of improved blood transfusion and related obstetric 
services in Uganda. The proposed changes in policy and practice are aimed at reducing the 
morbidity and mortality associated with the consequences of RBC alloimmunization. 
 
1.2  Outline of the thesis 
This thesis provides results of a series of studies on the occurrence of RBC alloantibodies in 
blood transfusion recipients and pregnant women in Uganda.  
We tried to answer the following research questions: 
• Is there sufficient documentation on the clinical transfusion process and on post-transfusion 
complications related to RBC alloimmunization in Ugandan hospitals? (Chapter 3) 
• What is the frequency and nature of RBC alloimmunization in SCD patients in Uganda? 
(Chapter 4)  
• Does the rate of RBC alloimmunization differ among SCD patients compared to OMT 
Ugandan blood recipients? (Chapter 5)  
• What is the prevalence of RhD negativity and maternal RBC alloimmunization in Ugandan 
pregnant women? (Chapter 6) 
• Is it cost-effective to introduce RBC alloantibody screening as part of pre-transfusion testing 
in Uganda? (Chapter 7)  
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2.1  A short history of post-transfusion and maternal RBC alloimmunization 
Alloimmunization to RBC antigens, a consequence of blood transfusion or pregnancy, was 
recognized following the discovery of the Rhesus (now Rh) blood group system in 1939 by 
Philip Levine and Rufus Stetson. They reported a case of a woman who delivered a stillborn 
infant and suffered a severe haemolytic transfusion reaction (HTR) following transfusion with 
apparently ABO compatible blood from her husband. Her serum was found to contain an 
alloagglutinin (reacting at 37C) which agglutinated RBCs of her husband and those of 85% of 
blood donors. Levine and Stetson showed that this new antigen, which they did not name, was 
independent of the then known blood groups ABO, MN and P.  They postulated that the cause of 
this case of haemolytic disease of the newborn (HDN) was a maternal antibody entering the fetal 
circulation leading to fetal RBC destruction (Levine & Stetson, 1939). In 1940, Landsteiner and 
Wiener made an antibody by injecting Rhesus monkey RBCs into rabbits and guinea pigs 
(Landsteiner & Wiener, 1941). The resulting antiserum (anti-Rh) agglutinated not only Rhesus 
monkey RBCs but also those of 85% Caucasians. This specificity appeared identical to that of 
antibodies in the sera of patients who suffered HTRs after receiving ABO-identical blood 
(Wiener & Peters, 1940).  In 1941, Levine and co-workers reported that the antibody responsible 
for HDN had the same specificity as the anti-Rh produced by Landsteiner and Wiener, later 
shown to be anti-LW. Levine and Stetson were indeed describing anti-D although they identified 
it as anti-Rh in these earliest publications. In 1945, Coombs, Mourant and Race described the use 
of antihuman globulin (later known as the “Coombs’ test”) to identify “incomplete” antibodies. 
A year later, they used this test to detect Rh antibodies on RBCs of babies suffering from HDN 
(Coombs et al., 1946). Thereafter, the versatility of the Coombs’ test in immunohaematology for 
the detection of post-transfusion and maternal RBC alloantibodies became evident. 
 
2.2  Human blood group diversity and function  
Human blood groups are unique, inherited polymorphic structures located on mostly non-
polymorphic proteins, glycoproteins, and glycolipids on the extracellular surface of RBCs. Blood 
groups are detected by a specific alloantibody, implying that the antigens are immunogenic for 
individuals lacking the blood group. Currently, 33 blood group systems, which include a total of 
about 339 antigens, have been established by the International Society of Blood Transfusion 
(ISBT Committee on Terminology for Red Cell Surface Antigens, Cancun 2012). In addition, 
 
195050-bw-Natukunda.indd   16 23-4-13   14:10
16 Chapter 2 17Review on RBC alloimmunization
CONTENTS 
2.1  A short history of post-transfusion and maternal RBC alloimmunization 
2.2  Human blood group diversity and function 
2.3  Pathophysiology of the post-transfusion alloimmune response 
2.4  Nature of RBC alloantibodies 
2.5  Pre-transfusion compatibility testing  
2.6  Prevalence of post-transfusion RBC alloimmunization 
2.7  Haemolytic transfusion reactions 











2.1  A short history of post-transfusion and maternal RBC alloimmunization 
Alloimmunization to RBC antigens, a consequence of blood transfusion or pregnancy, was 
recognized following the discovery of the Rhesus (now Rh) blood group system in 1939 by 
Philip Levine and Rufus Stetson. They reported a case of a woman who delivered a stillborn 
infant and suffered a severe haemolytic transfusion reaction (HTR) following transfusion with 
apparently ABO compatible blood from her husband. Her serum was found to contain an 
alloagglutinin (reacting at 37C) which agglutinated RBCs of her husband and those of 85% of 
blood donors. Levine and Stetson showed that this new antigen, which they did not name, was 
independent of the then known blood groups ABO, MN and P.  They postulated that the cause of 
this case of haemolytic disease of the newborn (HDN) was a maternal antibody entering the fetal 
circulation leading to fetal RBC destruction (Levine & Stetson, 1939). In 1940, Landsteiner and 
Wiener made an antibody by injecting Rhesus monkey RBCs into rabbits and guinea pigs 
(Landsteiner & Wiener, 1941). The resulting antiserum (anti-Rh) agglutinated not only Rhesus 
monkey RBCs but also those of 85% Caucasians. This specificity appeared identical to that of 
antibodies in the sera of patients who suffered HTRs after receiving ABO-identical blood 
(Wiener & Peters, 1940).  In 1941, Levine and co-workers reported that the antibody responsible 
for HDN had the same specificity as the anti-Rh produced by Landsteiner and Wiener, later 
shown to be anti-LW. Levine and Stetson were indeed describing anti-D although they identified 
it as anti-Rh in these earliest publications. In 1945, Coombs, Mourant and Race described the use 
of antihuman globulin (later known as the “Coombs’ test”) to identify “incomplete” antibodies. 
A year later, they used this test to detect Rh antibodies on RBCs of babies suffering from HDN 
(Coombs et al., 1946). Thereafter, the versatility of the Coombs’ test in immunohaematology for 
the detection of post-transfusion and maternal RBC alloantibodies became evident. 
 
2.2  Human blood group diversity and function  
Human blood groups are unique, inherited polymorphic structures located on mostly non-
polymorphic proteins, glycoproteins, and glycolipids on the extracellular surface of RBCs. Blood 
groups are detected by a specific alloantibody, implying that the antigens are immunogenic for 
individuals lacking the blood group. Currently, 33 blood group systems, which include a total of 
about 339 antigens, have been established by the International Society of Blood Transfusion 
(ISBT Committee on Terminology for Red Cell Surface Antigens, Cancun 2012). In addition, 
 
195050-bw-Natukunda.indd   17 23-4-13   14:10
18 Chapter 2 19Review on RBC alloimmunization
antigens not yet fulfilling the requirements for classification into a system have been gathered 
into collections or series of high- and low-frequency antigens (Daniels et al., 2009). In blood 
group nomenclature, antigens encoded by the same gene, or cluster of two or more closely linked 
homologous genes with virtually no recombination events occurring among them, are assigned to 
the same blood group system.  
Each blood group system is genetically discrete from other blood group systems and 
accommodates from 1-50 antigens. The two most important blood group systems from the point 
of view of clinical transfusion medicine are ABO and Rh. Rh and MNS are the most complex 
systems, with 61 and 46 antigens respectively. Most blood group polymorphisms are the result of 
single nucleotide polymorphisms (SNPs) encoding amino acid substitutions in an extracellular 
domain of an RBC surface protein. All blood group systems represent a single gene, apart from 
Rh, Xg and Chido/Rodgers, which have two closely linked genes, and MNS with three genes. In 
null phenotypes, the whole protein is absent from the membrane usually as a result of a gene 
deletion or an inactivating mutation. Genes that encode all the blood group systems present on 
RBCs have been identified (Storry & Olsson, 2004; Storry et al., 2011).  
The development of DNA sequencing techniques, and then the polymerase chain reaction (PCR) 
has paved the way for the rapid molecular characterization of the genes encoding blood group 
antigens (Beiboer et al., 2005). As the molecular basis of many blood group antigens has been 
determined (Reid & Lomas-Francis, 2004), it is now feasible to predict the blood group antigen 
profile of an individual by testing the DNA. Such molecular analyses can be used to overcome 
the limitations of haemagglutination in clinical transfusion practice e.g. typing of multiply 
transfused patients, determination of paternal RHD zygosity, fetal genotyping from amniocytes 
or maternal plasma to determine the risk for HDFN, typing of RBCs with a positive direct 
antiglobulin test (DAT), detection of altered D antigens (weak D or partial D) and screening 
donor units for antigens (Doa, Dob, Jsa, Kpa, Coa, Yta, etc.) for which there are no commercial 
reagents (Legler et al., 2001; Reid, 2003; Harper et al., 2004).   
The RBC membrane protein structures bearing blood group antigens exhibit diverse functional 
heterogeneity. The following functions have been attributed to blood group antigens. Some are 
membrane transporters e.g. band 3 (the Diego antigen) provides an anion channel for HCO3- and 
Cl- ions; the Kidd glycoprotein is a urea transporter; the Colton glycoprotein, aquaporin 1, is a 
water channel; and RhAG is probably a gas channel. The Lutheran, LW, and Indian (CD44) 
 
glycoproteins are adhesion molecules while the Duffy glycoprotein is a chemokine receptor. The 
Cromer and Knops antigens are markers for decay accelerating factor (CD55) and complement 
receptor 1(CD35) respectively (Catron & Colin, 2001; Telen, 2005). 
 
2.3  Pathophysiology of the post-transfusion alloimmune response  
2.3.1  Blood transfusions may lead to either alloimmunization or tolerance induction 
RBC transfusion for anaemia is both the oldest and the most widely employed transplantation 
procedure. Multiple allogeneic blood transfusions introduce a multitude of foreign antigens and 
living cells into the recipient that persist for a variable period of time. These can affect the 
immune response in two opposite ways, leading to either alloimmunization or to tolerance 
induction. Alloimmunization is reflected by the development of alloantibodies against RBC 
antigens (Lostumbo et al., 1966), HLA antigens (Perkins et al., 1966) and other cellularly 
expressed or soluble antigens; and by T cell activation leading to CD8 positive cytotoxic T cells.  
T cell receptors specific for alloantigens develop in utero. Intrauterine transfusion of allogeneic 
blood before the 14th week of gestation may result in tolerance and (transient) establishment of 
low dose chimerism (Hayward et al., 1998). The full capacity to produce immune antibodies 
develops slowly after birth. Although anti-HLA antibodies have been reported after non-
leucocyte depleted whole blood transfusion (Bedford-Russel et al., 1993), the immunization rate 
in preterm infants is very low to negligible due to functionally immature B cells (Marshall-
Clarke, 2000). 
The induction of tolerance is suggested by the enhanced graft survival in transfused versus non-
transfused solid organ recipients (Opelz & Terasaki, 1978). Also, recipients of allogeneic blood 
transfusions have been reported to be at a greater risk of post-operative infections referred to as 
transfusion-related immunomodulation (TRIM). Moreover, allogeneic blood transfusions have 
been shown to lead to suppressive effects in immunologic function in recipients ex vivo i.e. a 
decrease in the CD4:CD8 ratio of circulating T cells, reduced natural killer cell function, 
defective antigen presentation, suppression of lymphocyte blastogenesis, and reduction in 
delayed type hypersensitivity (Blajchman & Bordin, 1994). In general, contaminating leucocytes 
are thought to play a pivotal role in the above immunomodulatory effects of blood transfusions; 
with leucocyte depletion preventing both HLA alloimmunization and tolerance induction 
(Merryman, 1989).  
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glycoproteins are adhesion molecules while the Duffy glycoprotein is a chemokine receptor. The 
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(Merryman, 1989).  
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 2.3.2  Pathways for immune recognition of alloantigens 
Two recipient T cell recognition mechanisms have been shown to be critical for the initiation of 
alloimmunity. The direct pathway occurs when recipient T helper (Th) cells directly interact with 
major histocompatibility complex (MHC) class II molecules on donor antigen presenting cells 
(APCs). The T cell activation by this direct pathway is only exerted by allogeneic class II 
bearing cells, such as in fetomaternal transfusion and by leukocyte-containing blood products. 
Approximately 100 times more T cells can be activated by the direct pathway as compared to the 
indirect pathway, which reflects the normal immune response. Indirect recognition occurs when 
foreign (allogeneic donor) molecules are processed by recipient APCs and presented to self Th 
cells. Within the context of indirect allorecognition, T cells recognize protein antigens that are 
degraded or processed within APCs to peptides which combined with MHC molecules are 
transported to the cell surface and bound within the antigen-binding grooves of either MHC class 
I or class II molecules (Sayegh et al., 1994). The spectrum of antigen processing ranges from the 
simple unfolding of conformational determinants to the proteolytic exposure of primary structure 
by pH-dependent enzymes (e.g. cathepsins). Generally, APCs process exogenously derived 
proteins via endosomal compartments that shunt the processed peptides to intracellular 
compartments rich in MHC class II molecules. This pathway is necessary for the activation of 
CD4+ Th cells to provide helper factors for B cell activation and eventual IgG antibody 
production. Endogenous proteins (e.g. self-proteins or when infected with virally derived 
proteins), are generally processed by large-molecular-weight proteosomes within the cell cytosol 
and are subsequently transported to the luminal surface of the endoplasmic reticulum for loading 
onto MHC class I molecules and  foreign molecules can be recognized by CD8+ (cytotoxic) T 
cells. For both direct and indirect pathways, the loaded MHC molecules are expressed on the 
surface of the APC and are available for presentation to circulating T cells (Watts, 1997). 
However, after T cell recognition a second signal provided by costimulatory molecules is needed 
to activate the Th cells. 
2.3.3  Role of costimulatory molecules 
As depicted above, both antibody production and cytotoxic T cell development depend on the 
stimulation of the recipient antigen-specific CD4+ (helper) T cells. The key requirements for 
CD4 stimulation are the simultaneous expression of at least two different signals (Schwartz, 
1989). The first signal, occupancy of the clonotypic T-cell receptor (TCR), is provided by MHC-
 
peptide on the APCs. TCR binding leads to a cascade of events culminating in IL-2 expression 
but not IL-2 secretion (Mueller et al., 1989). A second, costimulatory signal is required for the 
expression of the IL-2 gene with consequent secretion of IL-2 and cell proliferation (Mincheff & 
Merryman, 1990). On APC, the B7-1 protein, delivers a costimulatory signal through binding 
with the CD28 (positive) and CTLA-4 (negative) T-cell receptors, which regulate IL-2 secretion. 
Lack or impairment of this second signal has been shown to lead to T cell unresponsiveness or 
anergy (Nossal, 1989). In the case of allogeneic transfusions, the alloantigens on donor class II 
bearing APCs will be recognized by recipient T cells through the direct pathway (Pouteil-Noble 
et al., 1991). The imunogenicity of those alloantigens will then be determined by the ability of 
the donor APCs to present the costimulatory signals to the recipient T cells. After 2 weeks’ 
storage in vitro at 2 - 6C, APCs lose costimulatory molecules (Mincheff & Merryman 1990). 
Besides leukocytes, unmodified RBCs often contain large numbers of platelets which are rich in 
both cell surface and soluble CD40L (Henn et al., 1998). This costimulatory molecule activates 
B cells and is critical for IgM-to-IgG class switching (Grewal & Flavell, 1996). WBC reduction 
removes class II bearing donor APCs (e.g. dendritic cells, B-cells, and monocytes) and reduces 
HLA immunization in particular in case of platelet transfusions, provided that the residual white 
cell count is less than 1 – 5 x 106 per unit (Claas et al., 1981, Sirchia et al., 1986; van Marwijk et 
al., 1991; Oksanen et al., 1991; Saarinen et al., 1993; Blumberg et al., 2003). However, WBC 
removal has no demonstrable effect on the formation of RBC alloantibodies (Schonewille et al., 
2005), indicating that these are mainly elicited through the indirect antigen presentation pathway.   
2.3.4  Type 1 and type 2 immune responses 
Immunologic responses can become polarized to favour cells and cytokines of Type 1 (Th1) or 
Type 2 (Th2) responses (Mosmann & Sad, 1996). Type 1 responses involve cytokines such as γ-
interferon (IFN-γ), IL-12, and IL-2, enhancing cellular immune responses such as delayed type 
hypersensitivity. Type 2 responses involve cytokines such as IL-4, IL-5 and IL-10 and enhance 
humoral immune responses, particularly those involving specific IgG subclasses, as well as IgA 
and IgE (Romagnani, 1996). Allogeneic leukocyte-containing blood transfusions have been 
shown to elicit immune deviation favouring Type 2 responses and downregulation of Type 1 
responses (Kirkley et al., 1995). This immunological mechanism could account for the 
unfavourable associations of allogeneic transfusions with the development of alloantibodies to 
RBCs, WBCs, platelets, and plasma proteins; presumed increased tumour recurrence; and post-
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operative bacterial infection, and favourable associations with reduced spontaneous abortions 
and increased tolerance of solid organ allografts (Blumberg & Heal, 1996).  
2.4  Nature of RBC alloantibodies 
Alloantibodies against RBC antigens may be “naturally occurring” or “immune” in nature. 
Naturally occurring antibodies are most often IgM class, reacting at a temperature optimum 
below 37C, but may be partly IgG and are found in individuals who have never been transfused 
with RBCs or who have not been pregnant with a fetus carrying the relevant RBC antigen. 
Natural antibodies are not present at birth, but arise early in life presumably due to cross-
reactivity with ingested antigens. Immune antibodies are most often IgG but may be IgM or a 
mixture of IgG and IgM; they may sometimes have an IgA component. An antibody is 
considered to be clinically significant if examples with that specificity are known to have caused 
HTRs, HDFN or unacceptably short survival of the transfused RBCs (Walker, 1993). RhD is by 
far the most immunogenic antigen followed by K and c. Development of alloantibodies may 
compromise the care of chronically transfused patients since the deleterious effects of RBC 
alloimmunization, including delayed HTRs and HDFN, are increased (Moise, 1993). Antibodies 
may appear as early as 7 - 10 days after transfusion in primary immunization and within 2 - 7 
days in a secondary response. The optimal screening times for the detection of post-transfusion 
RBC alloimmunization are not known and depend on the nature of the antigen, dose and 
recipient immunocompetence, although testing after 2 - 4 weeks and 3 - 6 months have been 
suggested. Schonewille et al. (2006) reported that anti-Jka and anti-Jkb were predominant 
antibodies found in patients tested within one month, whereas anti-K and anti-Fya were most 
encountered after more than 3 months following blood transfusion. 
Antibodies against HLA class I may cause confusion in RBC immunohaematologic testing.   
HLA class I antigens are widely distributed and, in general, can be detected on all nucleated 
cells.  In peripheral blood, platelets and RBCs (which lack nuclei in their mature forms) can also 
express HLA class I antigens (Rosenfield et al., 1967), sometimes referred to as Bg (Bennet-
Goodspeed) antigens on RBCs. The numbers of molecules expressed per platelet have been 
estimated to be in the range of 14,000 to 82,000 (Kao et al., 1986), being far fewer on RBCs, 
with a range of 40 to 550 per cell (Giles et al., 1990). In contrast, the number of HLA class I 
molecules on T lymphocytes is about 100,000 per cell and on B lymphocytes, there are about 
 
260,000 molecules per cell (Everett et al., 1987; Mollison et al., 1997). In view of the low 
number of HLA class I molecules on most RBCs, there has been speculation whether they are 
integral membrane components or they are acquired on the membrane by adsorption from 
plasma, which contains both membrane-shed and secreted forms (Krangel, 1987). It has been 
reported that RBCs do not synthesise HLA per se, but HLA class I molecules are produced by 
their nucleated precursor cells (Rivera & Scornick, 1986). Three principal antigens – Bga, Bgb 
and Bgc – have been defined and correlated with HLA class I antigens B7, B17 and A28 
respectively (Morton et al., 1969). Unwanted positive results in cross-matching due to HLA are 
common because antibodies to HLA-A28 and HLA-B7 are frequently present in sera and anti-
Bga has been found in more than 10% of multiply transfused patients and can be the cause of 
HTRs (Nordhagen & Aas, 1978; Panzer et al., 1987; Mollison et al., 1997).  
2.5  Pre-transfusion compatibility testing  
The goal of pre-transfusion compatibility testing is to provide the patient with a beneficial and 
safe transfusion (Shulman et al., 2001; Lieb & Aldridge, 2005). The transfused blood 
components should have acceptable survival in vivo. Pre-transfusion testing, including the 
antiglobulin phase, is very important because adverse effects of accelerated RBC destruction can 
be severe. Even recipient's RBCs, albeit less frequently, sometimes undergo accelerated 
destruction (bystander or autoantibody mediated). Most HTRs result from errors in patient or 
sample identity; and in some cases blood group alloantibodies to private antigens are not 
detected by standard serological techniques using RBC panels. When testing samples from 
antenatal patients and patients transfused within the last 3 months, a fresh sample is obtained for 
compatibility testing if more than 3 days have elapsed since the original sample was collected. If 
performed properly, pre-transfusion testing will ensure that a patient is issued the designated 
blood components, it will verify that the blood is ABO compatible and will detect the most 
clinically significant unexpected antibodies. 
2.6  Prevalence of post-transfusion RBC alloimmunization 
2.6.1  RBC alloimmunization in sickle cell disease patients 
In heavily transfused SCD subjects, the RBC alloimmunization rate may approach 30% (Orlina 
et al., 1978). Acute or delayed HTRs may occur if an alloimmunized patient is exposed to the 
same foreign antigen during subsequent transfusion. In the Cooperative Study of Sickle Cell 
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Disease, Rosse et al. (1990) reported an overall rate of RBC alloimmunization of 18.6% in 1,814 
multiply transfused SCD patients. They identified a positive linear correlation between the 
number of SCD patients sensitized and the number of RBC exposures. Seventeen percent of the 
alloimmunized patients demonstrated four or more antibodies with a predominance of anti-C, 
anti-E and anti-K. In the same study, children less than 10 years old had a lower rate of 
alloimmunization than those in older age groups. In SCD, nulliparous women are more likely to 
become sensitized to RBC antigens than multiparous females (Reisner et al., 1987). The 
suggested mechanisms underlying the increased incidence of alloimmunization in SCD patients 
include an altered immune response, increased frequency of certain HLA antigens, or lack of 
phenotypic compatibility between donor and recipient (Ambruso et al., 1987; Cox et al., 1988). 
Alarif et al. (1986) found a significant association between RBC alloimmunization and HLA-
B35 among SCD patients. Caccese et al. (1987) demonstrated an increased functional activity in 
monocytes from patients with SCD reflecting an ongoing inflammatory state, when compared 
with monocytes derived from normal individuals. 
When the distribution of antigens is different in the donor and recipient populations, greater 
alloimmunization may be expected. In a retrospective study, Vichinsky et al. (1990) found that 
racial and ethnic blood group antigen profiles between donor and recipient groups contribute to 
RBC alloimmunization in SCD. The frequencies of Duffy and Rh blood group system antigens 
are known to be distinctly different in Blacks and Caucasians. Despite the fact that 68% of 
Blacks lack the Fya and Fyb and 99.9% of Caucasians have one or both antigens (Daniels, 2002), 
very few of the Fy(a-b-) Blacks form Duffy antibodies no matter how often they are transfused 
with Fy(a+) and/or Fy(b+) blood. This is because individuals of the Fy(a-b-) phenotype do not 
recognize the Duffy antigen as ‘foreign’ due to the presence of the Duffy glycoprotein on their 
tissue cells (Issitt & Anstee, 1998). In Brazil, where less heterogeneity between the donor and 
recipient groups exists, RBC alloimmunization rates in SCD are still substantial, suggesting that 
other mechanisms may be operative (Moriera et al., 1996).  
Following alloimmunization, antibodies to the Rh and Kell system antigens are most often 
detected, followed by antibodies to antigens of the Duffy and Kidd systems, while transfusion-
induced antibodies to other RBC antigens are rarely found (Schroeder, 1999). To prevent the 
occurrence of alloimmunization, Davies et al. (1986) recommended extended RBC phenotyping 
of all SCD patients at the beginning of their transfusion therapy. This helps in deciding what 
 
blood should be transfused and also aids in the identification of any antibodies that might 
develop. Thereafter, blood for transfusion should be matched for at least C, E and K antigens 
(Murphy, 2001). The stroke prevention trial (Vichinsky et al., 2001) demonstrated that when 
SCD patients were given WBC-reduced RBCs that were matched for C, E and K antigens, the 
alloimmunization rate dropped from 3% to 0.5% per unit and HTRs dropped by 90%. 
There is growing evidence that alloimmunization may lead to the production of autoantibodies 
and vice versa (Aygun et al., 2002). Castellino et al., (1999) reported the frequency of 
autoantibody formation as approximately 7.6% in a review of a large series of multiply 
transfused children with SCD. They also reported a strong association between autoantibody 
formation and the presence of RBC alloantibodies. The etiology behind the formation of these 
autoantibodies is poorly understood and not much information exists to suggest ways in which to 
lower the incidence of autoantibody formation. However, Ahrens et al., (2007) found that blood 
transfusion appears to play a role in the majority of cases of autoantibodies associated with RBC 
alloimmunization. Clinically, it is important to recognize that post-transfusion haemolysis in 
which both autologous and transfused RBCs are destroyed may occur in patients with SCD.  
2.6.2  RBC alloimmunization in other multiply transfused patients 
In a retrospective study undertaken by Blumberg et al. (1983) on patients with disorders that 
often require multiple transfusions, the rate of alloimmunization (i.e. the proportion of patients 
with new antibodies) to RBC antigens was 11% in the aplastic anaemia, and 16% in the chronic 
myeloid leukaemia (CML) disease groups. In the same study, other groups of multitransfused 
patients had similar rates of alloantibody formation e.g. patients with renal failure (14%) and 
those with gastrointestinal bleeding (11%). Patients receiving chemotherapy for CML did not 
seem to be suppressed in terms of their ability to produce blood group alloantibodies when the D 
antigen was respected in the selection of the donor units.  In contrast, none of the 99 patients 
with chronic lymphocytic leukemia (CLL) followed up for over a 10-year period produced blood 
group antibodies. Lymphoid leukemia patients are generally characterized by a lack of 
immunologic response and alloimmunization to RBC antigens following multiple transfusions, 
in this setting, is uncommon (Han et al., 1981; Fluit et al., 1990). There is often 
hypogammaglobulinaemia in lymphoid leukemia, which may be attributed to impaired 
functionality of B cells that are unable to upregulate HLA class II and costimulatory molecules 
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recognize the Duffy antigen as ‘foreign’ due to the presence of the Duffy glycoprotein on their 
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induced antibodies to other RBC antigens are rarely found (Schroeder, 1999). To prevent the 
occurrence of alloimmunization, Davies et al. (1986) recommended extended RBC phenotyping 
of all SCD patients at the beginning of their transfusion therapy. This helps in deciding what 
 
blood should be transfused and also aids in the identification of any antibodies that might 
develop. Thereafter, blood for transfusion should be matched for at least C, E and K antigens 
(Murphy, 2001). The stroke prevention trial (Vichinsky et al., 2001) demonstrated that when 
SCD patients were given WBC-reduced RBCs that were matched for C, E and K antigens, the 
alloimmunization rate dropped from 3% to 0.5% per unit and HTRs dropped by 90%. 
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and vice versa (Aygun et al., 2002). Castellino et al., (1999) reported the frequency of 
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transfusion appears to play a role in the majority of cases of autoantibodies associated with RBC 
alloimmunization. Clinically, it is important to recognize that post-transfusion haemolysis in 
which both autologous and transfused RBCs are destroyed may occur in patients with SCD.  
2.6.2  RBC alloimmunization in other multiply transfused patients 
In a retrospective study undertaken by Blumberg et al. (1983) on patients with disorders that 
often require multiple transfusions, the rate of alloimmunization (i.e. the proportion of patients 
with new antibodies) to RBC antigens was 11% in the aplastic anaemia, and 16% in the chronic 
myeloid leukaemia (CML) disease groups. In the same study, other groups of multitransfused 
patients had similar rates of alloantibody formation e.g. patients with renal failure (14%) and 
those with gastrointestinal bleeding (11%). Patients receiving chemotherapy for CML did not 
seem to be suppressed in terms of their ability to produce blood group alloantibodies when the D 
antigen was respected in the selection of the donor units.  In contrast, none of the 99 patients 
with chronic lymphocytic leukemia (CLL) followed up for over a 10-year period produced blood 
group antibodies. Lymphoid leukemia patients are generally characterized by a lack of 
immunologic response and alloimmunization to RBC antigens following multiple transfusions, 
in this setting, is uncommon (Han et al., 1981; Fluit et al., 1990). There is often 
hypogammaglobulinaemia in lymphoid leukemia, which may be attributed to impaired 
functionality of B cells that are unable to upregulate HLA class II and costimulatory molecules 
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(Marshall-Clark, 2000) as is also observed in multiply transfused infants during the first few 
months of life (Ludvigsen et al., 1987; Strauss et al., 1999). Similarly absence of 
alloimmunization has been reported in some RhD negative AIDS patients receiving RhD positive 
RBC transfusions (Boctor et al., 2003). This may be attributable to the decrease in CD4+ T 
lymphocytes in AIDS. However, the hypergammaglobulinaemia associated with a positive DAT 
(Levine & Liebman, 1995) and the persistent immune activation (Eggena et al., 2005) in the 
course of HIV infection may explain the post-transfusion alloimmunization that is occasionally 
reported. Seyfried and Walewska (1990) found that the highest rate of immune response to RBC 
antigens occurred in multitransfused patients (defined as 3 or more blood transfusions) with 
autoimmune haemolytic anaemia (28%), liver cirrhosis (31.5%) and the myelodysplastic 
syndromes (40.9%). In a retrospective study, Fluit et al. (1990) found that 22 out of 186 (11.8%) 
multitransfused patients with haematological disorders developed antibodies over a 3-month 
period, after receiving at least six RBC transfusions. Anti-E and anti-K were the antibodies most 
frequently found; they were detected in 12 and 15 patients respectively. In patients with 
transfusion-dependent thalassaemia, the rate of allo-immunization to RBC antigens was found to 
range from 5 to 37%, with a lower prevalence in children starting transfusions before an age of 
two years (Spanos et al., 1990; Coles et al., 1981; Wang et al., 2006). A female preponderance 
of RBC alloimmunization upon transfusions is controversial (Raki 1999; Blumberg et al. 1984; 
Redman et al. 1996). In a recent review of literature, Verduin et al (2012) observed a higher 
RBC alloimmunization rate in transfused females with SCD only and not in other diseases that 
require multiple blood transfusions. 
As discussed in section 2.3.2, HLA class II antigens present blood group peptides to CD4 T cells. 
Some peptides may be more optimally presented by the antigen-presenting groove formed by 
particular class II molecules. Reviron et al. (2005) and Chu et al. (2009) reported associations of 
anti-Jka alloimmunization with particular HLA-BRB1 alleles and anti-Mia alloimmunization with 
HLA-DRB1*0901 allele respectively, suggesting a role for MHC restriction in some cases of 
RBC antigen presentation (Picard et al., 2009; Hoppe et al., 2009).  
2.7  Haemolytic transfusion reactions 
Haemolytic transfusion reactions are one of the recognized consequences of post-transfusion 
RBC alloimmunization. An acute HTR is defined as the haemolysis of donor RBCs, within 24 
 
hours of transfusion, by preformed alloantibodies in the recipient. Clerical errors (mislabelling of 
blood or misidentification of patients) account for 80% of acute HTRs, confirmed by national 
haemovigilance schemes which have been operational for several years in Europe and North 
America (Goodman et al., 2003; SHOT, 2009). Symptoms and signs of acute HTRs are non-
specific and include fever, chills, rigors, chest/back/abdominal pain, pain at the infusion site, 
nausea, vomiting, dyspnoea, hypotension, haemoglobinuria, oliguria/anuria, and disseminated 
intravascular coagulation (DIC). Most frequently, the offending antibodies are high titer IgM 
anti-A and/or anti-B although complement-fixing IgG antibodies in the recipient may be 
responsible as well. Immune-mediated haemolytic reactions can also rarely occur because of 
RBC antibodies in the plasma of the transfused product, be it in RBCs, fresh frozen plasma 
(FFP) or platelets. Cases of HTRs after transfusion of group O plasma containing products such 
as platelets, with high titer anti-A or anti-B to non-group O patients have been reported (Larsson 
et al., 2000; Lozano & Cid, 2003; Josephson et al., 2004).  
Delayed HTRs are more common but usually less severe than acute haemolysis. Delayed 
reactions occur when a patient previously sensitized by pregnancy or blood transfusion receives 
“incompatible RBCs” because the low titers of circulating alloantibodies (typically against Rh 
and Kidd system antigens) escape detection by pre-transfusion testing. However, there is a rapid 
anamnestic response after transfusion of antigen-positive RBCs, leading to haemolysis. Delayed 
HTR often go unrecognized because they occur several days (usually within 5 - 10 days) after 
transfusion, which often means after hospital discharge. Delayed serologic transfusion reactions 
(DSTRs) are reactions identified serologically but not clinically. Delayed HTRs and DSTRs 
occur in approximately 1 in 1500 transfusions, with DSTRs being detected at rates two to 
fourfold higher than delayed HTRs (Ness et al., 1990; Pineda et al., 1999; Hendrickson & 
Hillyer, 2009). Obtaining a transfusion history and selecting offending antigen-negative RBCs 
for transfusion of patients with a history of clinically significant RBC alloantibodies is critical in 
decreasing the risk of delayed HTRs or DSTRs (Hendrickson & Hillyer, 2009). Patients with 
SCD or other major haemoglobinopathy syndromes who are chronically transfused are at 
greatest risk of alloantibody formation to RBC antigens and consequent HTRs. About 25% of the 
clinically significant RBC alloantibodies become undetectable over time, potentially 
confounding future transfusions and placing the patient at risk of an anamnestic antibody 
production and severe delayed HTRs (Rosse et al., 1990; Schonewille et al., 2000). 
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frequently found; they were detected in 12 and 15 patients respectively. In patients with 
transfusion-dependent thalassaemia, the rate of allo-immunization to RBC antigens was found to 
range from 5 to 37%, with a lower prevalence in children starting transfusions before an age of 
two years (Spanos et al., 1990; Coles et al., 1981; Wang et al., 2006). A female preponderance 
of RBC alloimmunization upon transfusions is controversial (Raki 1999; Blumberg et al. 1984; 
Redman et al. 1996). In a recent review of literature, Verduin et al (2012) observed a higher 
RBC alloimmunization rate in transfused females with SCD only and not in other diseases that 
require multiple blood transfusions. 
As discussed in section 2.3.2, HLA class II antigens present blood group peptides to CD4 T cells. 
Some peptides may be more optimally presented by the antigen-presenting groove formed by 
particular class II molecules. Reviron et al. (2005) and Chu et al. (2009) reported associations of 
anti-Jka alloimmunization with particular HLA-BRB1 alleles and anti-Mia alloimmunization with 
HLA-DRB1*0901 allele respectively, suggesting a role for MHC restriction in some cases of 
RBC antigen presentation (Picard et al., 2009; Hoppe et al., 2009).  
2.7  Haemolytic transfusion reactions 
Haemolytic transfusion reactions are one of the recognized consequences of post-transfusion 
RBC alloimmunization. An acute HTR is defined as the haemolysis of donor RBCs, within 24 
 
hours of transfusion, by preformed alloantibodies in the recipient. Clerical errors (mislabelling of 
blood or misidentification of patients) account for 80% of acute HTRs, confirmed by national 
haemovigilance schemes which have been operational for several years in Europe and North 
America (Goodman et al., 2003; SHOT, 2009). Symptoms and signs of acute HTRs are non-
specific and include fever, chills, rigors, chest/back/abdominal pain, pain at the infusion site, 
nausea, vomiting, dyspnoea, hypotension, haemoglobinuria, oliguria/anuria, and disseminated 
intravascular coagulation (DIC). Most frequently, the offending antibodies are high titer IgM 
anti-A and/or anti-B although complement-fixing IgG antibodies in the recipient may be 
responsible as well. Immune-mediated haemolytic reactions can also rarely occur because of 
RBC antibodies in the plasma of the transfused product, be it in RBCs, fresh frozen plasma 
(FFP) or platelets. Cases of HTRs after transfusion of group O plasma containing products such 
as platelets, with high titer anti-A or anti-B to non-group O patients have been reported (Larsson 
et al., 2000; Lozano & Cid, 2003; Josephson et al., 2004).  
Delayed HTRs are more common but usually less severe than acute haemolysis. Delayed 
reactions occur when a patient previously sensitized by pregnancy or blood transfusion receives 
“incompatible RBCs” because the low titers of circulating alloantibodies (typically against Rh 
and Kidd system antigens) escape detection by pre-transfusion testing. However, there is a rapid 
anamnestic response after transfusion of antigen-positive RBCs, leading to haemolysis. Delayed 
HTR often go unrecognized because they occur several days (usually within 5 - 10 days) after 
transfusion, which often means after hospital discharge. Delayed serologic transfusion reactions 
(DSTRs) are reactions identified serologically but not clinically. Delayed HTRs and DSTRs 
occur in approximately 1 in 1500 transfusions, with DSTRs being detected at rates two to 
fourfold higher than delayed HTRs (Ness et al., 1990; Pineda et al., 1999; Hendrickson & 
Hillyer, 2009). Obtaining a transfusion history and selecting offending antigen-negative RBCs 
for transfusion of patients with a history of clinically significant RBC alloantibodies is critical in 
decreasing the risk of delayed HTRs or DSTRs (Hendrickson & Hillyer, 2009). Patients with 
SCD or other major haemoglobinopathy syndromes who are chronically transfused are at 
greatest risk of alloantibody formation to RBC antigens and consequent HTRs. About 25% of the 
clinically significant RBC alloantibodies become undetectable over time, potentially 
confounding future transfusions and placing the patient at risk of an anamnestic antibody 
production and severe delayed HTRs (Rosse et al., 1990; Schonewille et al., 2000). 
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Approximately 40% of SCD patients who are alloimmunized have or will experience a delayed 
HTR (Knowles, 2001). Importantly, delayed HTRs can mimic various complications of SCD and 
should be suspected when patients present with appropriate symptoms (e.g. pain, fever, 
accelerated haemolysis) after a recent transfusion (Diamond et al., 1980).  
Another complication of RBC alloimmunization is the hyperhaemolysis syndrome which has a 
reported incidence of 4 - 11% (Aygun et al., 2002; Talano et al., 2003). In patients with SCD, 
clinical findings in the hyperhaemolysis syndrome occur approximately 1 week after the RBC 
transfusion and include the onset of increased haemolysis associated with pain and profound 
anaemia. The haemoglobin level often drops to below pre-transfusion levels. In many reported 
adult cases, the DAT remains negative and no new alloantibody is detected as the cause for these 
transfusion reactions (Talano et al., 2003). Continuation of blood transfusion may be lethal, as 
this can further exacerbate haemolysis (Friedman et al., 1993). It has been suggested that 
transfusion be withheld in severe haemolytic episodes, until hemolysis has faded spontaneously 
or after treatment with corticosteroids, high dose intravenous immunoglobulin or rituximab, a 
monoclonal antibody against B cells. The exact pathophysiologic mechanism of this syndrome is 
not well understood. A bystander haemolytic mechanism and transfusion suppression of 
erythropoiesis have been proposed (Petz et al., 1997; King et al., 1997). There is a broad clinical 
spectrum of autoantibody formation in association with red blood cell transfusions and reactions 
range from asymptomatic serologic detection to severe, life-threatening haemolysis (Sosler et al. 
1989; Zumberg et al., 2001; Garratty (2004). 
2.8  Haemolytic disease of the fetus and newborn  
Haemolytic disease of the newborn was first described in 1609 in a set of twins by a French 
midwife called Louise Bourgeois: the first twin was oedematous and stillborn, and the second 
was deeply jaundiced and subsequently died of what is now called kernicterus (Bowman, 1988). 
Over the centuries, this clinical picture was recognized and reported as two separate conditions. 
Diamond et al. (1932) realized that congenital anaemia, icterus gravis and hydrops, were 
manifestations of the same disease, which they named erythroblastosis fetalis. The identification 
of the cause of the haemolysis had to await the discovery of the Rh system (Landsteiner & 
Wiener, 1940) and the determination soon thereafter that HDFN occurred in an RhD-positive 
 
fetus carried by an RhD-negative woman who had been immunized by the transplacental passage 
of RhD-positive RBCs during a prior pregnancy (Levine et al., 1941).  
Alloimmunization to the D surface antigen is the commonest cause of HDFN, which, before the 
introduction of anti-D immunoprophylaxis affected 1% of all newborns and was responsible for 
the death of one baby in every 2200 births (Kumar & Regan, 2005). By the 1970s, routine 
antenatal care in well-resourced countries included screening of all expectant mothers to select 
Rh-D negative cases and giving preventive treatment with anti-D after birth of a Rh-D positive 
child. This led to a dramatic decrease in the incidence of HDFN, particularly severe cases that 
were responsible for stillbirths and neonatal deaths (Mollison et al., 1997). Despite the 
widespread use of this prophylaxis, a significant number of women still become alloimmunized 
for a variety of reasons, including no administration or insufficient dosage of RhIG in case of 
unrecognized miscarriage, leakage of fetal RBCs into the maternal circulation late in pregnancy, 
large fetomaternal hemorrhage (FMH) or exposure to traumatic deliveries including Caesarean 
sections, manual removal of the placenta, stillbirths and intrauterine deaths, blunt abdominal 
trauma during the third trimester, twin pregnancies (at delivery), external cephalic version, 
chorionic villous sampling, antepartum haemorrhage, ectopic pregnancy and an unexplained 
hydrops fetalis (Sebring & Polesky, 1990; Bowman, 1997). FMH involves smaller amounts: in 
3% of the women, fetal RBCs are detectable in the maternal circulation during the first trimester 
of pregnancy; in 12% during the second trimester; in 46% during the third trimester; and in 64% 
of the women after delivery, usually in amounts less than 20 ml of fetal blood (Bowman et al., 
1986). It is not uncommon for there to be silent leaks of RBCs from the fetus into the mother 
(with no pain or bleeding), especially in the third trimester. The maternal IgG antibodies traverse 
the placenta to the fetal circulation during gestation and cause RBC destruction with 
complications before birth, or anaemia and hyperbilirubinaemia after birth, or both. In its most 
severe form, HDFN produces hydrops fetalis, which is characterized by total body oedema, 
hepatosplenomegaly and heart failure, and can lead to intrauterine death. HDFN may also follow 
blood transfusion with antigen positive blood that is incompatible with the mother. Virtually all 
alloantibodies reactive by the IAT have been implicated in HDFN in different populations. The 
prevalence of D-negativity varies in different ethnic groups with 15% of Caucasians, 8% of 
Blacks and 1% of Asians being D-negative (Reid & Lomas-Francis, 2004). The D antigen 
accounts for about 50% of cases of maternal alloimmunization; the remainder is mainly due to 
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incompatibility to K, c, C/G, E, and Fya antigens and to low incidence antigens in the Rh, MNS, 
and Diego blood group systems (Heddle et al., 1993). Anti-D formation is more frequent in D 
positive individuals of African descent than in Europeans, which is probably a result of the high 
frequency of aberrant RHD alleles belonging to the three African D clusters i.e. DIVa, weak D 
type 4 and DAU in some African populations (Touinssi et al., 2009).  Also, because the number 
of copies of the D antigen on each RBC is higher in the R2 haplotype (range: 14,000 to 16,000) 
than in the R1 haplotype (range: 9,000 to 14,600), fetuses whose RBCs are R2 have more severe 
anemia than their R1 counterparts (Mollison et al., 1997). Ulm et al. (1999) reported that male 
fetuses were 13 times more likely to develop hydrops than female fetuses, and perinatal mortality 
was 3 times higher in male fetuses. However, this was not confirmed by other inestigators 
(Ramsey & Sherman, 1999). 
From the perspective of prevention an initial step is to estimate fetal risk by establishing paternal 
RHD zygosity. After paternal testing has revealed the possibility of a heterozygous state for 
RHD, fetal testing is indicated. Fetal D antigen determination through noninvasive DNA testing 
from maternal plasma is now routine practice in some countries (Lo et al., 1998; Daniels et al., 
2004). If the maternal race is black, then the presence of a maternal pseudogene or Ccdes gene 
should be considered in the scheme of fetal testing (Faas et al., 1997; Singleton et al., 2000). The 
presence of one of these genes in the fetus can lead to a false positive molecular diagnosis yet the 
fetus would be found to be D-negative by serology after birth, leading to unnecessary fetal 
interventions such as antenatal RhIG administration. Whenever an IAT-reactive antibody is 
detected during pregnancy, a cord blood sample at birth should be tested by DAT and if positive, 
the haemoglobin (Hb) and bilirubin levels monitored to initiate treatment (BCSH Guidelines, 
1996). Monitoring maternal anti-D during pregnancy is very important to predict the severity of 
antenatal HDFN. In most centres, a critical titre for anti-D between 8 and 32 is usually used 
(Moise, 2005; Moise, 2008). Because the titre is not very reliable predicting fetal hemolysis, 
functional assays such as the monocyte monolayer assay (MMA) or antibody-dependent cellular 
cytotoxicity (ADCC) are performed in reference laboratories. Once sensitization has occurred the 
fetus should be monitored by preferentially non-invasive echo-doppler techniques to estimate the 
degree of fetal anemia. The following therapeutic options are open: controlled early delivery or 
intrauterine transfusion of which the latter has the best prognosis but requires a specialized centre 
(Urbaniak & Greiss, 2000; van Kamp et al., 2004).  
 
Interestingly, a fetus that is ABO incompatible with the maternal anti-A/B is less likely to have 
HDFN due to anti-D, presumably due to rapid removal of the ABO-incompatible RBCs by the 
naturally occurring anti-A/B. Although maternal-fetal ABO incompatibility is common, in 
general haemolysis is mild and the clinical course is relatively benign needing only phototherapy 
(Grundbacher, 1980; Drabik-Clary et al., 2006). In cases of ABO incompatibility between the 
mother and the fetus, group O mothers are more likely to become sensitized (Ozolek et al., 
1994).  This process occurs to a much less extent in group A or B neonates who are born to 
heterospecific A or B mothers, because in this situation, the respective anti-A or anti-B 
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RHD zygosity. After paternal testing has revealed the possibility of a heterozygous state for 
RHD, fetal testing is indicated. Fetal D antigen determination through noninvasive DNA testing 
from maternal plasma is now routine practice in some countries (Lo et al., 1998; Daniels et al., 
2004). If the maternal race is black, then the presence of a maternal pseudogene or Ccdes gene 
should be considered in the scheme of fetal testing (Faas et al., 1997; Singleton et al., 2000). The 
presence of one of these genes in the fetus can lead to a false positive molecular diagnosis yet the 
fetus would be found to be D-negative by serology after birth, leading to unnecessary fetal 
interventions such as antenatal RhIG administration. Whenever an IAT-reactive antibody is 
detected during pregnancy, a cord blood sample at birth should be tested by DAT and if positive, 
the haemoglobin (Hb) and bilirubin levels monitored to initiate treatment (BCSH Guidelines, 
1996). Monitoring maternal anti-D during pregnancy is very important to predict the severity of 
antenatal HDFN. In most centres, a critical titre for anti-D between 8 and 32 is usually used 
(Moise, 2005; Moise, 2008). Because the titre is not very reliable predicting fetal hemolysis, 
functional assays such as the monocyte monolayer assay (MMA) or antibody-dependent cellular 
cytotoxicity (ADCC) are performed in reference laboratories. Once sensitization has occurred the 
fetus should be monitored by preferentially non-invasive echo-doppler techniques to estimate the 
degree of fetal anemia. The following therapeutic options are open: controlled early delivery or 
intrauterine transfusion of which the latter has the best prognosis but requires a specialized centre 
(Urbaniak & Greiss, 2000; van Kamp et al., 2004).  
 
Interestingly, a fetus that is ABO incompatible with the maternal anti-A/B is less likely to have 
HDFN due to anti-D, presumably due to rapid removal of the ABO-incompatible RBCs by the 
naturally occurring anti-A/B. Although maternal-fetal ABO incompatibility is common, in 
general haemolysis is mild and the clinical course is relatively benign needing only phototherapy 
(Grundbacher, 1980; Drabik-Clary et al., 2006). In cases of ABO incompatibility between the 
mother and the fetus, group O mothers are more likely to become sensitized (Ozolek et al., 
1994).  This process occurs to a much less extent in group A or B neonates who are born to 
heterospecific A or B mothers, because in this situation, the respective anti-A or anti-B 
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SUMMARY 
The aim of this study was to determine the indications for transfusion, blood ordering practices 
and post-transfusion complications at Mbarara Regional Referral Hospital (MRRH) in Mbarara, 
Uganda; and to assess the clinical transfusion practice at MRRH. There are no guidelines on the 
appropriate use of blood at MRRH. Therefore, there was need to assess the local clinical 
transfusion practice. Patients’ hospital files were studied for evidence of blood transfusions in 
2008. All five wards were reviewed and details on the transfusion process recorded. One 
thousand seven hundred and thirty patients (median age, 19.0 years; range, 1 day to 88 years; 
female-to-male ratio, 1.4), for whom blood was cross-matched, were studied. Of these, 1674 
(96.8%) patients actually received transfusions, which were as whole blood in 58.4% of 
recipients. The mean number of units per recipient was 1.7 and the crossmatch-to-transfusion 
ratio was 1.3. The three most frequent indications for transfusion were malaria (38.8%), bleeding 
(27.1%) and other infections (16.1%). There were no records for pre-transfusion haemoglobin, 
compatibility testing, transfusion start-times and vital signs in 30.2%, 51.8%, 21.5% and 97.6% 
of recipients, respectively. Transfusion reactions were recorded for ten (0.6%) patients. Although 
there was no evidence of blood wastage, inadequacies were noted in the documentation of the 
transfusion process. There is need to train staff in blood transfusion and to design a ‘blood 
transfusion form’ for easy monitoring and evaluation. A hospital transfusion committee and 
guidelines on the appropriate use of blood should be put in place at MRRH. 
 




According to the World Health Organization (WHO), Transfusion Medicine is defined as that 
part of the health care system which undertakes the appropriate provision and use of human 
blood resources (WHO, 1992). Transfusion Medicine practitioners must maintain quality and 
work to increase the safety of blood and blood products. The specialty is unique because it links 
one sector of the community (the donors) with another (the patients) in an altruistic and 
potentially life-saving activity. The transfusion process includes a series of events comprising of 
ordering of blood or blood components for transfusion, taking pre-transfusion blood samples, 
laboratory practices, collection and administration of blood or blood components, monitoring of 
the transfused patient, managing adverse events and documenting the transfusion events and 
outcomes.  
Blood transfusion is an essential and integral part of patient care: when used correctly, it saves 
lives and improves health. However, transfusion carries a potential risk of acute and/or delayed 
transfusion reactions and transfusion transmitted infections. WHO recommends that national 
health programs should develop policies and strategies to reduce the need for blood transfusion, 
minimize unnecessary transfusions and ensure the safe and appropriate use of blood and blood 
components (WHO, 2002). The effective development and maintenance of satisfactory standards 
of Transfusion Medicine practice requires an organization-wide approach and adoption of a 
quality management system. In the absence of a quality infrastructure, errors will occur with 
potential outcomes such as wastage of blood, hypoxia or coagulopathy as a result of delays or 
incompatible transfusions that may be fatal (Knowles, 2001). Safe transfusion therapy depends 
on a complex process that requires integration and coordination among multiple hospital services 
including laboratory medicine, nursing, anaesthesiology, surgery, clerical support, and 
transportation. The multidisciplinary hospital transfusion committee has been traditionally 
charged with oversight of transfusion safety. Transfusion errors are usually rooted in the failure 
to follow clerical or technical procedures and/or in the breakdown in professional practice or 
judgement (Dzik et al., 2003).  
In Uganda, regional blood banks of the Uganda Blood Transfusion Service (UBTS) collect blood 
from voluntary non-remunerated donors; routinely screen the donated blood for HIV, syphilis, 
hepatitis B and C viruses; perform ABO/Rh D typing; and distribute the blood to hospitals free 
of charge in accordance with the national transfusion policy (Ministry of Health, Uganda, 2005). 
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So far, only the Central regional blood bank at the UBTS headquarters in Kampala is able to 
produce blood components for transfusion. The Ministry of Health, with assistance from the 
United States President’s Emergency Plan for AIDS Relief (PEPFAR) project, meets the 
financial needs of the UBTS. Even in times of increased demand for blood products e.g. during 
malaria seasons, the UBTS does not recruit paid or replacement donors. However, there are no 
specific written guidelines on the appropriate use of blood in hospitals. The aim of this study was 
to assess the clinical transfusion practice at a regional referral hospital in Uganda. 
 
STUDY DESIGN AND METHODS 
Study setting and design 
A one-year retrospective study was conducted at Mbarara Regional Referral Hospital (MRRH), 
the teaching hospital for Mbarara University of Science and Technology (MUST) Medical 
School. MRRH is a 330-bed hospital and it serves as the regional referral centre for South 
Western Uganda. The hospital transfusion laboratory receives its blood supply from the Mbarara 
Regional Blood Bank located about 2 kilometres away. The study was approved by the Research 
and Ethics Committee at MUST.  
Patients and methods 
Medical records for patients admitted at MRRH in 2008 were reviewed for evidence of having 
received blood transfusion(s). Patients of both sexes and all ages admitted to the five main wards 
at MRRH (i.e. Paediatric, Accident and Emergency [A&E], Surgical, Obstetric and 
Gynaecological [OBGY], and Medical), for whom blood was ordered and crossmatched, were 
included in the study. The medical and transfusion histories were studied and the following data 
collected: age and sex of the recipient; ward of admission; date of transfusion; clinical diagnosis; 
pre-transfusion haemoglobin level; indication(s) for blood transfusion; number of units of blood 
ordered; number of units of blood transfused; number of transfusion episodes; type of blood 
component transfused; presence of compatibility form(s) in the patient’s file; record of times for 
the beginning of the transfusion; record of vital signs during the transfusion; and a record of any 





The information on the patients’ transfusion history and laboratory tests was recorded using data 
collection forms. Statistical software package Excel 5.0 (Microsoft, Redmond, WA, USA) and 
Statistical Package for the Social Sciences 12.0 (SPSS, Inc., Chicago, IL, USA) were used for 
data management and analysis, respectively. The chi-square test was used to test for differences 
in frequencies between groups of recipients. Groups were assumed to differ significantly when 
the p-values were less than 0.05. 
 
RESULTS 
A total of 1,730 patients (median age, 19.0 years; range, 1 day to 88 years; female-to-male ratio, 
1.3), for whom blood was ordered and cross-matched, were studied. Of these, 1,674 (96.8%) 
patients were actually transfused. 
  
Table 1. Patients whose blood was cross-matched and those who                                                            
received transfusions on each ward at MRRH in 2008 
Number of patients Paediatric Medical OBGY A&E Surgical Total 
Cross-matched 726 453 346 180 25 1,730 
Transfused (%) 724 (99.7) 453 (100) 318 (91.9) 158 (87.8) 21 (84.0) 1,674 
 
 
Table 1 shows the number of patients for whom blood was cross-matched and transfused on the 
five wards at MRRH. No autologous blood transfusions were recorded in the whole year. One 
hundred and nine (6.5%) patients received emergency blood transfusions at the A&E ward due to 
surgery or trauma.  
The three most frequent indications for blood transfusion were: malaria (38.8%), bleeding 
(27.1%), and other infections (16.1%).  The indications for blood transfusion at MRRH in 2008 
are shown in Table 2. 
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Table 2. Indications for blood transfusion with the respective crossmatch-to-transfusion (CT)                          
ratios at MRRH in 2008 
Indication for transfusion 
Patients     
(n, %) 
Units cross-  
matched (n, %) 
Units transfused    
(n, %) 
CT ratio 
Malaria 672 (38.8) 1022 (27.8) 918 (33.1) 1.1 
Bleeding 468 (27.0) 1245 (33.9) 823 (29.6) 1.5 
Non-malarial infections 278 (16.1) 715 (19.5) 533 (19.2) 1.3 
Cancer 115 (6.6) 287 (7.8) 217 (7.8) 1.3 
Organ disorders (kidney, heart, liver) 56 (3.2) 155 (4.2) 118 (4.2) 1.3 
Trauma 50 (2.8) 101 (2.7) 63 (2.3) 1.6 
Surgery 48 (2.7) 97 (2.6) 55 (1.9) 1.8 
Malnutrition 35 (2.0) 39 (1.1) 39 (1.4) 1.0 
Sickle Cell Disease 8 (0.5) 12 (0.3) 11 (0.4) 1.1 
Total 1,730 3,673 2,777 1.3 
 
There were 672 recipients with malaria, 556 (82.7%) of whom were children admitted to the 
Paediatric ward. Figure 1 shows the number of patients with severe anaemia due to malaria and 
other non-malarial indications who received blood transfusions in each month of 2008. Obstetric 
haemorrhage accounted for 55.7% of all bleeding patients at MRRH who received transfusions; 
and for 75.4 % of all recipients at the OBGY ward.  
 
Figure 1 Patients at Mbarara Regional 
Referral Hospital for whom blood 
transfusions were ordered because of 
severe malarial anaemia (n=672) and other 
non-malarial indications (n=1058) in each 
month of 2008. Two malaria seasons in the 
months of May - August and November - 





















Malaria patients Non-malaria cases
 
 
Table 3 shows a breakdown of the types of haemorrhage for the 468 recipients at MRRH whose 
indication for transfusion was ‘bleeding’. The most frequent bacterial infections among 
transfused patients were tuberculosis (3.9%) and septicaemia (3.5%). One hundred and nine 
(24.1%) recipients on the Medical ward had AIDS and 48 (44.0%) of them presented with severe 
anaemia following anti-retroviral therapy (ART) regimens containing the nucleoside analog 
reverse transcriptase inhibitor, zidovudine (AZT).  
 
Table 3. Nature of haemorrhage for the 468 patients at MRRH                                                             
whose indication for blood transfusion was ‘bleeding’ 
Type of bleeding 
Patients (n; 
%) 
Obstetric haemorrhage 261 (55.7)  
Gastrointestinal bleeding 99 (21.2) 
Penetrating soft tissue injury 31 (6.6) 
Epistaxis 27 (5.8) 
Umbilical cord bleeding 22 (4.7) 
Cephalhaematoma 15 (3.2) 
Others [including Purpura, Haemoptysis, Tooth bud (‘false teeth’) extraction]  13 (2.8) 
 
All the 453 transfused patients on the Medical ward received whole blood transfusions. There 
were five additional units of random donor platelet transfusions in two recipients (0.4%). No 
other platelet transfusions were given on other wards. Overall, 58.4% of all recipients at MRRH 
were given whole blood transfusions. Approximately 97.0% of the Paediatric ward recipients 
were transfused with packed red blood cells (RBCs). Overall a total of 3,673 units of whole 
blood and RBCs were ordered and out of 
these, 2,777 units (75.6%) were transfused. 
The mean number of units given per recipient was 1.7 and the overall crossmatch-to-transfusion 
(CT) ratio was 1.3. Three hundred and sixty seven (38.6%) adult transfusion patients received 
only one unit of blood. Figure 2 shows the utilization of blood at MRRH in each month of 2008. 
There were no records for compatibility testing and monitoring of vital signs in 51.8% and 
97.6% of the recipients’ files respectively.   
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Table 2. Indications for blood transfusion with the respective crossmatch-to-transfusion (CT)                          
ratios at MRRH in 2008 
Indication for transfusion 
Patients     
(n, %) 
Units cross-  
matched (n, %) 
Units transfused    
(n, %) 
CT ratio 
Malaria 672 (38.8) 1022 (27.8) 918 (33.1) 1.1 
Bleeding 468 (27.0) 1245 (33.9) 823 (29.6) 1.5 
Non-malarial infections 278 (16.1) 715 (19.5) 533 (19.2) 1.3 
Cancer 115 (6.6) 287 (7.8) 217 (7.8) 1.3 
Organ disorders (kidney, heart, liver) 56 (3.2) 155 (4.2) 118 (4.2) 1.3 
Trauma 50 (2.8) 101 (2.7) 63 (2.3) 1.6 
Surgery 48 (2.7) 97 (2.6) 55 (1.9) 1.8 
Malnutrition 35 (2.0) 39 (1.1) 39 (1.4) 1.0 
Sickle Cell Disease 8 (0.5) 12 (0.3) 11 (0.4) 1.1 
Total 1,730 3,673 2,777 1.3 
 
There were 672 recipients with malaria, 556 (82.7%) of whom were children admitted to the 
Paediatric ward. Figure 1 shows the number of patients with severe anaemia due to malaria and 
other non-malarial indications who received blood transfusions in each month of 2008. Obstetric 
haemorrhage accounted for 55.7% of all bleeding patients at MRRH who received transfusions; 
and for 75.4 % of all recipients at the OBGY ward.  
 
Figure 1 Patients at Mbarara Regional 
Referral Hospital for whom blood 
transfusions were ordered because of 
severe malarial anaemia (n=672) and other 
non-malarial indications (n=1058) in each 
month of 2008. Two malaria seasons in the 
months of May - August and November - 
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Table 3 shows a breakdown of the types of haemorrhage for the 468 recipients at MRRH whose 
indication for transfusion was ‘bleeding’. The most frequent bacterial infections among 
transfused patients were tuberculosis (3.9%) and septicaemia (3.5%). One hundred and nine 
(24.1%) recipients on the Medical ward had AIDS and 48 (44.0%) of them presented with severe 
anaemia following anti-retroviral therapy (ART) regimens containing the nucleoside analog 
reverse transcriptase inhibitor, zidovudine (AZT).  
 
Table 3. Nature of haemorrhage for the 468 patients at MRRH                                                             
whose indication for blood transfusion was ‘bleeding’ 
Type of bleeding 
Patients (n; 
%) 
Obstetric haemorrhage 261 (55.7)  
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Others [including Purpura, Haemoptysis, Tooth bud (‘false teeth’) extraction]  13 (2.8) 
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Figure 2 Blood utilization at Mbarara 
Regional Referral Hospital in each month 
of 2008. Total units ordered and 
crossmatched = 3,673; total units 
transfused = 2,777. 



























Transfusion start-times were documented in 78.5% of the cases. In 1,208 patients (69.8%), pre-
transfusion haemoglobin levels had been estimated and recorded in the hospital files. Absence of 
pre-transfusion haemoglobin records was strongly associated with transfusions in states of acute 
blood loss (i.e. bleeding, surgery and trauma) compared to other indications (p<0.0001) and with 
surplus ordering of blood i.e. CT ratios greater than unity (385/1208 versus 217/522 patients; 
p=0.0001).  
 
Table 4. Transfusion practices and outcomes in the five wards at MRRH in 2008 
Variables assessed in patients’ files OBGY      (n=346) 








Mean units of blood ordered  
(range; total) 
2.7         
(1-13; 920) 
3.1          
(1-20; 1421) 
2.0   
(1-3; 50) 
1.7         
(1-7; 893) 
2.2          
(1-10; 389) 
Crossmatch-to-transfusion (CT) ratio  1.7 1.3 1.8 1.0 1.5 
Compatibility form present in file 167 (48.3) 266 (58.7) 16 (64.0) 271 (37.3) 114 (63.3) 
Record of pre-transfusion 
haemoglobin 
181 (52.3) 371 (81.9) 19 (76.0) 544 (74.9) 93 (51.7) 
Record of patients’ vital signs  1 (0.3) 25 (5.5) 1 (4.0) 14 (1.9) 0 (0) 
Record of transfusion start-times  241 (69.7) 440 (97.1) 14 (56.0) 526 (72.3) 137 (76.l) 
Record of adverse events  2 (0.6) 5 (1.1) 0 (0) 2 (0.3) 1 (0.6) 
Additional transfusions after  
≥ 48 hour  
15 (4.3) 62 (13.7) 0 (0) 98 (13.5) 5 (2.8) 
Data presented as number (n) and % unless stated otherwise 
 
Acute transfusion reactions were observed in ten patients (0.6%) in twelve months. In 180 
recipients (10.4%), additional blood transfusions were given 48 hours or more after completion 
of the initial transfusion episode and this was not significantly associated with any transfusion 
 
indication. A comparison of the transfusion practices and outcomes in the five wards at MRRH is 
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Figure 3 Blood ordering and transfusion 
practices in five wards at Mbarara 
Regional Referral Hospital (Paediatric, 
Obstetric & Gynaecological [OBGY], 
Medical, Surgical, and Accident & 
Emergency [A&E]) in 2008. Total units of 
blood ordered = 3,673; total units 
transfused = 2,777; overall crossmatch-to-
transfusion ratio = 1.3.  
DISCUSSION 
In a period of twelve months, 2,777 units of whole blood and RBCs were transfused to 1,674 
patients on the five major wards at MRRH. Records at MRRH showed that there were 
approximately 16,000 patients admitted in 2008. Therefore, 10.5% of all in-patients at MRRH 
received blood transfusion support as part of their treatment and care. Of these, 42.0% were 
children admitted with severe anemia largely due to malaria (76.6%). Rates of blood transfusion 
for malaria were highest in the two malaria seasons of May - August and November - February 
(Figure 1). The overall CT ratio was 1.3 indicating that there was no significant wastage of blood 
resources at MRRH in 2008. However, there might have been shortages of blood for transfusion 
since 367 (38.6%) adult patients received only one unit of blood. Due to the absence of records 
for post-transfusion haemoglobins and/or haematocrits, we were unable to determine rates of 
under-transfusion or over-transfusion. The low number of blood recipients on the Surgical ward 
is explained by the fact that 109 (6.5%) patients received blood transfusions at the A&E ward 
following surgery or trauma.  
Our data indicate that a significant number of children received blood transfusions because of 
severe malarial anaemia compared to adult patients. This was expected because malaria is a 
leading cause of morbidity and death in childhood in Sub-Saharan Africa (WHO, 2009). In 
contrast to children, adults were transfused mainly because of bleeding and bacterial or viral 
infections (p<0.0001). While the CT ratios for both the Medical and Surgical sections of MRRH 
were within normal limits (Table 4), surgeons (CT ratio; 1.8) and obstetricians (CT ratio; 1.7) 
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children admitted with severe anemia largely due to malaria (76.6%). Rates of blood transfusion 
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(Figure 1). The overall CT ratio was 1.3 indicating that there was no significant wastage of blood 
resources at MRRH in 2008. However, there might have been shortages of blood for transfusion 
since 367 (38.6%) adult patients received only one unit of blood. Due to the absence of records 
for post-transfusion haemoglobins and/or haematocrits, we were unable to determine rates of 
under-transfusion or over-transfusion. The low number of blood recipients on the Surgical ward 
is explained by the fact that 109 (6.5%) patients received blood transfusions at the A&E ward 
following surgery or trauma.  
Our data indicate that a significant number of children received blood transfusions because of 
severe malarial anaemia compared to adult patients. This was expected because malaria is a 
leading cause of morbidity and death in childhood in Sub-Saharan Africa (WHO, 2009). In 
contrast to children, adults were transfused mainly because of bleeding and bacterial or viral 
infections (p<0.0001). While the CT ratios for both the Medical and Surgical sections of MRRH 
were within normal limits (Table 4), surgeons (CT ratio; 1.8) and obstetricians (CT ratio; 1.7) 
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ordered significantly more units of blood that were not transfused (p<0.0001). However, more 
patients on the Medical ward received additional transfusions 48 hours or more after completion 
of the initial transfusion episodes as compared to all the other wards combined (p<0.0001). The 
fact that a total of 180 patients (10.4%) at MRRH received additional blood transfusion(s) 48 
hours or more after completion of the initial transfusion episode(s) may partly suggest that there 
could have been shortage of blood for immediate additional transfusions; that there might have 
been delays in post-transfusion evaluation by the clinical and/or laboratory staff or that the 
patients could have experienced delayed haemolytic transfusion reactions. Since there are no pre- 
or post-transfusion alloantibody detection tests carried out at MRRH (and in the whole of 
Uganda), it is difficult to examine the occurrence of haemolytic transfusion reactions in this 
setting. However, 33 (18.3%) of such patients had been transfused primarily because of bleeding 
problems and the bleeding might have recurred.  
There were inadequacies regarding the documentation of pre-transfusion tests and bedside 
monitoring of the transfused patients: there were no records for pre-transfusion haemoglobin 
levels, compatibility testing, transfusion start-times, and vital signs in 30.2%, 51.8%, 21.5% and 
97.6% of all recipients respectively. Missing pre-transfusion haemoglobin records were strongly 
associated with transfusions in states of acute blood loss i.e. following bleeding, trauma and 
surgery compared to other indications (p<0.0001) and with surplus ordering of blood i.e. CT 
ratios >1.0 (p=0.0001). Thus, in the absence of haemoglobin results, clinicians made decisions to 
transfuse basing on clinical symptoms and signs. However, Bates et al. (2001) reported that 
when clinicians relied entirely on clinical judgement to guide transfusion practice, significant 
numbers of inappropriate transfusions were observed at a district hospital in Malawi. Our data 
also indicate that there were limitations on the availability of blood components (apart from 
packed RBCs) for transfusion at MRRH. This was illustrated by the finding that on the Medical 
ward, for example, all recipients were given whole blood transfusions except two patients (0.4%) 
that received additional five units of random donor platelets. Yet on the same ward, 7.7% and 
23.4% of the recipients respectively had haematological malignancies and bleeding problems and 
might have required transfusions with platelet concentrates and/or fresh frozen plasma if 
available. Almost half of the blood recipients with AIDS on the Medical ward had AZT-related 
anaemia. This underscores the important role of blood transfusions in this category of patients, 
given a 5.4% national prevalence of HIV infection among adults (UNAIDS, 2008) plus the 
 
increasing availability and use of ART. Ten patients (0.6%) were reported to have developed 
immediate transfusion reactions during transfusion. Apart from the record in the case notes that 
‘the patient reacted and blood was stopped’, there were no details on the nature of these 
transfusion reactions and on their management. Although we did not have comprehensive data 
from other hospitals in Uganda, the inadequacies herein outlined most likely apply to other 
clinical settings in the country. Similarly, Kajja et al. (2008) and de Graaf et al. (2009) have 
respectively observed poor blood ordering practices and lack of appropriate guidelines for blood 
transfusion at Mulago National Referral Hospital in Kampala, Uganda.  
In conclusion, there is need to improve the clinical practice of Transfusion Medicine in Uganda. 
It is therefore recommended that an in-hospital quality management system for blood transfusion 
should be developed through the creation of awareness on appropriate clinical use of blood. A 
standard form (a ‘Blood Transfusion Form’) for documenting the entire transfusion process 
should be designed. This would be incorporated in patients’ hospital files to allow easy 
monitoring and evaluation of blood transfusions and to provide a basis for the development of 
evidence based clinical transfusion practice in Uganda. To increase the availability of platelets 
and other blood components, arrangements should be made to process whole blood locally at the 
regional blood banks. Currently, platelets are only processed and supplied from the UBTS 
headquarters - about 300 kilometres away - in Kampala. The UBTS should encourage the design 
and implementation of clinical guidelines for the appropriate use of blood as well as the set up of 
Hospital Transfusion Committees or clinical review groups. The latter will monitor and evaluate 
the usage of blood and transfusion outcomes so as to improve the overall quality of clinical 
transfusion practice in Uganda. Above all, there is need to train nursing, biomedical and medical 
students and clinical staff on the significance of safe and appropriate blood transfusions in the 
management and care of patients. 
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ABSTRACT 
BACKGROUND: Blood transfusion is an integral part in the management of sickle cell disease 
(SCD) patients. Alloimmunization is a recognized complication of red blood cell (RBC) 
transfusions with consequences including delayed hemolytic transfusion reactions and 
difficulties in getting compatible blood for future transfusions. The objective of this study was to 
determine the frequency of RBC alloimmunization in SCD patients in Uganda where pre-
transfusion screening for alloantibodies is not practiced.  
STUDY DESIGN AND METHODS: In a cross-sectional study, SCD patients at Mulago 
Hospital Sickle Cell Clinic, Kampala, Uganda, were investigated. The demographic 
characteristics and transfusion history were recorded. Blood samples were drawn from 
consenting, previously transfused patients and RBC alloimmunization was demonstrated using 
immunohematological techniques. 
RESULTS: There were 428 patients (median age, 12; F/M ratio, 1.0) and they had received a 
median 3 units in a median 3 transfusion episodes. Twenty six patients (6.1%) possessed RBC 
alloantibodies and 21 (80.7%) of them had received up to 10 transfusions. A total of 30 
alloantibodies was found; 20 (66.7%) and 5 (16.6%) belonged to Rh and MNS blood groups 
respectively. Five of the alloimmunized patients had multiple antibodies.  
CONCLUSION: The rate of RBC alloimmunization in Ugandan SCD patients was 6.1%. The 
homogeneity between donors and SCD patients plus the low transfusion load may explain this 
immunization frequency. Nevertheless, our study confirms the significance of RBC 
alloimmunization as a complication in Ugandan SCD patients. Therefore, there is need to 
improve immunohematological testing in Uganda so that RBC alloimmunization and its 
consequences may be prevented.  
 
Keywords: Alloimmunization, Sickle cell disease, Red blood cell, Uganda. 
 
INTRODUCTION 
Sickle Cell Disease (SCD) is the most common genetic disease in Uganda where about 5 million 
people (20% of the total population) have the sickle cell trait and about 25,000 children are born 
with the disease each year.1 Blood transfusion is an important therapeutic tool in the 
management of SCD: it increases the oxygen carrying capacity of the blood by increasing the 
hemoglobin concentration and decreasing the percentage of sickle hemoglobin by dilution.2 
However, red blood cell (RBC) alloimmunization is one of the complications of allogeneic blood 
transfusions and in general the risk increases with the number of blood transfusions, although 
many patients become alloimmunized early during transfusion therapy.3 Various frequencies of 
RBC alloimmunization in SCD patients ranging from 2.6-76% have been reported in a number 
of studies.4 – 16  
Alloimmunization may limit the availability of compatible blood for future transfusions and can 
contribute to perinatal morbidity due to hemolytic disease of the newborn.17 In addition, delayed 
hemolytic transfusion reactions can mimic a sickle cell crisis and may be responsible for major 
morbidity in the SCD patient.10, 16, 18 In the Cooperative Study of Sickle Cell Disease in the 
United States, multiple antibodies were detected in over 50% of alloimmunized subjects.8 With 
time, many of the antibodies become undetectable, potentially confounding future transfusions 
and placing the patient at risk of anamnestic antibody production and delayed hemolytic 
transfusion reactions.2, 19  The antigens most frequently involved belong to the Rh, Kell, Kidd, 
Duffy, Lewis and MNS blood group systems.7, 8, 10, 11, 13, 20 - 22 Factors implicated in RBC 
alloantibody formation include recipient gender and age, history of pregnancy, number and 
timing of blood transfusions, recipient clinical diagnosis and treatment, genetic factors related to 
the antigenic response, and racial differences between donors and recipients.7, 8, 20, 23 - 25  
The prevalence of post transfusion alloimmunization in Uganda, where blood donors and SCD 
patients are more racially homogeneous and where pretransfusion testing is only limited to 
ABO/D grouping plus a room temperature saline cross-match, is not known. The objective of 
this study was to determine the frequency and nature of RBC alloimmunization in SCD patients 
in Uganda. 
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ABSTRACT 
BACKGROUND: Blood transfusion is an integral part in the management of sickle cell disease 
(SCD) patients. Alloimmunization is a recognized complication of red blood cell (RBC) 
transfusions with consequences including delayed hemolytic transfusion reactions and 
difficulties in getting compatible blood for future transfusions. The objective of this study was to 
determine the frequency of RBC alloimmunization in SCD patients in Uganda where pre-
transfusion screening for alloantibodies is not practiced.  
STUDY DESIGN AND METHODS: In a cross-sectional study, SCD patients at Mulago 
Hospital Sickle Cell Clinic, Kampala, Uganda, were investigated. The demographic 
characteristics and transfusion history were recorded. Blood samples were drawn from 
consenting, previously transfused patients and RBC alloimmunization was demonstrated using 
immunohematological techniques. 
RESULTS: There were 428 patients (median age, 12; F/M ratio, 1.0) and they had received a 
median 3 units in a median 3 transfusion episodes. Twenty six patients (6.1%) possessed RBC 
alloantibodies and 21 (80.7%) of them had received up to 10 transfusions. A total of 30 
alloantibodies was found; 20 (66.7%) and 5 (16.6%) belonged to Rh and MNS blood groups 
respectively. Five of the alloimmunized patients had multiple antibodies.  
CONCLUSION: The rate of RBC alloimmunization in Ugandan SCD patients was 6.1%. The 
homogeneity between donors and SCD patients plus the low transfusion load may explain this 
immunization frequency. Nevertheless, our study confirms the significance of RBC 
alloimmunization as a complication in Ugandan SCD patients. Therefore, there is need to 
improve immunohematological testing in Uganda so that RBC alloimmunization and its 
consequences may be prevented.  
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MATERIALS AND METHODS 
Patients 
In a cross-sectional study, patients with homozygous SCD attending the Sickle Cell Clinic (SCC) 
at Mulago National Referral Hospital in Kampala, Uganda, were investigated. The study took 
place between 1st February and 31st July, 2008. Informed consent was obtained from the 
patients or their parents/guardians. Eligibility criteria included SCD patients who were at least 2 
years of age and had received at least 2 previous allogeneic blood transfusions – the last 
transfusion episode being longer than 2 weeks before enrollment into the study. These criteria 
were chosen so as to study a group of patients that were most likely to have become 
alloimmunized at an appropriate age and time after exposures to RBC antigens. In general, 
patients received packed RBC transfusions compatible with their ABO and D phenotypes and 
which were not leukoreduced. 
Data collection 
Records at the SCC regarding the recruited SCD patients were reviewed for their demographic 
characteristics and the transfusion history. In cases of incomplete or missing records, older 
patients or accompanying parents and relatives were asked for additional information on the 
above history. The number of transfusion episodes, number of units of blood transfused, date of 
transfusion, indication for transfusion, age of first transfusion and a history of pregnancy were 
recorded in a data collection form. For patients who were first transfused in childhood and could 
not recall their exact age at first transfusion, we entered the age of 3 years in the database for 
analysis. The study was approved by the research and ethical committees at Mbarara University 
of Science and Technology and Makerere University Medical School.  
Laboratory investigations 
After consent, blood was drawn for laboratory investigations. Frozen plasma and buffy coat 
samples were shipped to the Sanquin Blood Bank in Leiden, The Netherlands, for 
immunohematological studies. The plasma samples were screened for the presence of RBC 
alloantibodies by use of a standard 3-cell panel of reagent group O RBCs. For the indirect 
antiglobulin test (IAT), a LISS-enhanced gel centrifugation technique (DiaMed ID, Micro 
Typing System, Cressier sur Morat, Switzerland) with polyspecific antihuman globulin (rabbit 
anti-IgG and monoclonal anti-C3d) was used. When the antibody screening was positive, 
 
antibody identification was performed by testing the plasma samples with commercial panels of 
reagent RBCs of selected phenotypes. Patients were considered to be alloimmunized if 
antibodies to one or more RBC antigens were identified. DNA was extracted from buffy coat 
samples (using the QIAamp DNA Blood Midi Kit, Qiagen) of patients who possessed anti-D 
alloantibodies and D genotyping using an RHD multiplex polymerase chain reaction (PCR) was 
performed as described by Maaskant-van Wijk and co-workers.26  
Statistical methods 
Statistical software packages Excel 5.0 (Microsoft, Redmond, CA, USA) and Statistical Package 
for the Social Sciences 12.0 (SPSS Inc., Chicago, IL, USA) were used for data management and 
analysis respectively. For univariate analysis of possible associations between alloimmunization 
and age at the time of enrollment, age at first transfusion, gender, pregnancy history, number of 
transfusion episodes, number of units received and the indication for transfusion, the Chi-square 
test or Fisher’s exact test were used for discrete variables. Logistic regression analysis was used 
for continuous variables of a non-Gaussian distribution. Groups were assumed to differ 




We recruited a total of 428 transfused SCD patients during the study period. Of these, 217 (51%) 
were females and among them, 19 (8.8%) had a history of pregnancy. The median age at the time 
of blood draw was 12 (range, 2-44) years. The patients were transfused with a total of 3,366 
(median, 3; range, 2-100) units of blood in 2,463 (median, 3; range, 2-80) transfusion episodes. 
Twenty six patients (6.1%; 95% CI: 4.0-9.0%) were found to be alloimmunized to RBC 
antigens; 21 (80.7%) of them having received up to a maximum of 10 blood transfusions.  There 
were 57 patients (13.3%) who had been transfused in childhood and could not recall their exact 
time when they were first transfused and an age of 3 years was used in the analysis as their age 
of first transfusion. The number of units of blood transfused was significantly associated with the 
rate of alloimmunization (p=0.02). There was a trend towards statistical significance between the 
number of transfusion episodes and the rate of RBC alloimmunization (p=0.08). Other 
demographic and transfusion characteristics of alloimmunized patients were not significantly 
different to those in the non-immunized group (Table 1).   
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Patients (n, %)  26 (6.1)  402 (93.9)  
Female-to-male ratio 1.8 1.0 NS 
Age in years  13 (2-35) 12 (2-44) NS 
History of pregnancy (%)   11.8 8.5 NS 
Age of first transfusion < 10years (%) 80.8 89.1 NS 
Transfusion episodes  3.5 (2-32) 3 (2-80) 0.08 
≤ 10 transfusion episodes (%)  80.7 90.2 NS 
Units of blood transfused  5 (2-60) 3 (2-100) 0.02 
History suggestive of a ‘febrile illness’ at 
the time of transfusion (%) 
73.1 70.8 NS 
Number of years since the last transfusion      1.0 (0-8) 1.0 (0-8) NS 
Number of years between first and last 
transfusions        
6.0 (0-22) 4.0 (0-41) NS 
        Data are presented as median and range unless otherwise stated, NS = p-value ≥ 0.1 
 
RBC antibodies 
The 26 alloimmunized patients produced a total of 30 RBC alloantibody specificities. This 
implies that after transfusion with 3,366 RBC units, the alloimmunization rate was 0.9% per 
RBC unit transfused. Two of the patients possessed panreactive antibodies. Table 2 shows the 
specificities of the antibodies identified, with 20 (66.7%) belonging to the Rh blood group 
system. MNS was the next frequent blood group system involved contributing 5 (16.6%) 
alloantibodies, 4 (80%) of these being of anti-S specificity. Eleven of the alloantibodies (36.7%) 
presented as multiple antibody combinations. Of the immunized patients with specific 
antibodies, 19 (79.2%) produced only one antibody while 5 (20.8%) had multiple antibodies.  
 
D genotyping 
Seven of the allommunized patients possessed anti-D antibodies and their RHD genotyping 
revealed the following results: one was D negative; five had partial D (i.e. four patients were of 
category DVa and one was a probable category DIIIb) and the last had a probable Rh D 
pseudogene. The D negative individual was a 5-year old girl who had been transfused four times 
 
in the previous two years while the patient with a probable Rh D pseudogene was an 11-year old 
boy with a history of three blood transfusions since the age of 1 year. Both patients had been 
typed as D negative by serology. Most likely, they received D positive RBC transfusions despite 
the local transfusion policy of matching for the D antigen.   
 









Rh E, D, C, Cw 10, 7, 2, 1 
MNS S, M 4, 1 
Kidd Jka 2 
Kell K 1 
Duffy Fya 1 
Lewis Lea 1 
N.A. Panreactive 2 
N.A. = not applicable 
 
DISCUSSION 
This is the first ever study carried out to determine the frequency and nature of RBC 
alloimmunization following blood transfusions in Uganda. It also involves one of the largest 
numbers of SCD patients ever investigated for RBC alloimmunization, in a cross-sectional 
survey. We observed an RBC alloimmune response rate of 6.1% in 428 SCD patients (or 0.9% 
per RBC unit transfused) and multiple antibodies were present in 20.8% of immunized patients 
with specific alloantibodies. Two patients possessed panreactive antibodies 5 years after their 
last transfusions. However, we could not rule out the presence of post-transfusion 
autoimmunization because we lacked autologous RBCs and DATs were not done. The number of 
immunized patients is lower than that reported in most of the literature on RBC 
alloimmunization in SCD.4, 5, 8-11, 13, 15 The presumed high phenotypic compatibility between 
blood donors and SCD patients (who were black Ugandans in both cases) and the low 
transfusion load may explain the low rate in RBC alloantibody formation. Studies need to be 
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performed to confirm the phenotypic similarities between blood donors and SCD patients in 
Uganda. The 6.1% rate of alloantibody formation in Ugandan SCD patients is comparable with 
the 2.6% alloimmunization reported by Olujohungbe et al.14 in a Jamaican cohort of SCD 
patients where there was less heterogeneity among donors and patients. It also compares well 
with the 5.3% frequency of RBC alloimmunization reported in a study by Sarnaik et al.11 in 
which children with SCD, who were not on a prophylactic transfusion program and had received 
a low transfusion load, became alloimmunized. The findings in this study show that the rate of 
RBC alloimmunization was associated with the number of units of blood transfused and the 
number of transfusion episodes, although the association was not statistically significant in the 
latter case (the calculated p values were 0.02 and 0.08 respectively). These findings are 
consistent with previous reports which have shown an association between RBC 
alloimmunization and increased number of donor exposures.4, 8 - 10  
The SCD patients mainly received acute simple RBC transfusions and they were not heavily 
transfused (median number of units of blood transfused = 3) compared to their counterparts in 
the developed world who may be on chronic transfusion programs. Most patients (71%) and/or 
their parents described having presented with symptoms of fever, body pains, general weakness 
or severe anemia at the time of hospital admission and prior to blood transfusion. Unfortunately, 
the true picture of this ‘febrile illness’ could not be ascertained from the available medical 
records but it might have been a sickle cell painful crisis, a delayed hemolytic transfusion 
reaction (since 11.2% of the patients received repeat transfusions within 2 weeks of a prior 
transfusion episode), a bacterial infection or even malaria. The role of such an underlying 
pathophysiology vis-à-vis the rate of alloimmunization needs to be explored in a future 
prospective study. Recently, inflammation was reported to be associated with increased RBC 
alloimmunization, in a murine model27. Owing to the fact that the patients were not being 
monitored for alloantibody formation, the rate of RBC alloimmunization may actually be higher 
than what was observed. This being a cross-sectional study, some RBC antibodies may have 
been missed because up to 25% of alloantibodies have been reported to disappear within a 
median 10 months of follow up.19  
Eighty percent of the detected alloantibodies corresponded to the Rh and MNS system antigens 
C, D and E; and S respectively (Table 2). Interestingly, 7 (23.3%) of the patients formed anti-D 
alloantibodies notwithstanding the local clinical transfusion practice in which ABO/D group 
 
compatible blood is transfused. Moreover, 5 (71%) of the patients who produced anti-D were 
females within the age range of 5 – 19 years and with no history of pregnancy. Since some of 
these patients had been typed as D positive by serology, we decided to investigate the molecular 
bases underlying these observations. Using an RHD-specific multiplex PCR, D genotyping of the 
7 SCD patients who were D-alloimmunized revealed that one of them was D negative, five had 
partial D (DVa in four patients and a probable DIIIb in the other), and the last one had a probable 
Rh D pseudogene (D negative by serology; all amplified exons present). The patient who was 
probably DIIIb had all the six RHD exons (3, 4, 5, 6, 7 and 9) tested and had been found to be D 
positive by serology. We could not proceed to perform DNA sequencing for confirmation of the 
probable RhD pseudogene or the DIIIb category because there was no more DNA available. These 
findings underscore the need to use monoclonal anti-D reagents that are capable of detecting D 
variants among blood donors and recipients and to improve the standards of 
immunohematological testing in Uganda. The antibodies encountered in other series3, 4, 5, 10, 28 
have most commonly been of C, E or K specificities. To prevent alloimmunization in SCD 
patients in the United States and Europe, the standard practice is to perform antigen matching for 
C, E, and K antigens for patients without prior alloantibody formation.29 Our findings indicate 
that anti-K is rare (3.3%) while anti-S is more common (13.3%) among alloimmunized SCD 
patients in this study. This is presumably because of a difference in the distribution of Kell and 
MNS phenotypes in Caucasian and Black populations. Accordingly, anti-S should be borne in 
mind in case a program of limited phenotype matching (i.e. for C, E and S antigens) to improve 
the care of already alloimmunized SCD patients in Uganda is to be considered in future.  
The effects of RBC alloimmunization in SCD patients may be examined in the context of the 
policy on laboratory and clinical transfusion practice in Uganda. This study has revealed the 
presence of clinically significant IgG alloantibodies in plasma of transfused SCD patients. 
Transfusion-acquired antibodies have been implicated in immediate and delayed transfusion 
reactions;2, 10, 16 some patients with multiple antibodies are difficult to cross-match and to 
transfuse;8, 21 others develop autoantibodies in addition to being alloimmunized;28, 30 and five 
nulliparous females in the present study were alloimmunized to the D antigen.  The current 
transfusion practice in Uganda does not involve the detection or monitoring of alloantibody 
formation and the clinical consequences thereof.  Besides ABO/D grouping and a saline cross-
match at room temperature, no other compatibility testing is performed. Therefore, we 
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bases underlying these observations. Using an RHD-specific multiplex PCR, D genotyping of the 
7 SCD patients who were D-alloimmunized revealed that one of them was D negative, five had 
partial D (DVa in four patients and a probable DIIIb in the other), and the last one had a probable 
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probably DIIIb had all the six RHD exons (3, 4, 5, 6, 7 and 9) tested and had been found to be D 
positive by serology. We could not proceed to perform DNA sequencing for confirmation of the 
probable RhD pseudogene or the DIIIb category because there was no more DNA available. These 
findings underscore the need to use monoclonal anti-D reagents that are capable of detecting D 
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have most commonly been of C, E or K specificities. To prevent alloimmunization in SCD 
patients in the United States and Europe, the standard practice is to perform antigen matching for 
C, E, and K antigens for patients without prior alloantibody formation.29 Our findings indicate 
that anti-K is rare (3.3%) while anti-S is more common (13.3%) among alloimmunized SCD 
patients in this study. This is presumably because of a difference in the distribution of Kell and 
MNS phenotypes in Caucasian and Black populations. Accordingly, anti-S should be borne in 
mind in case a program of limited phenotype matching (i.e. for C, E and S antigens) to improve 
the care of already alloimmunized SCD patients in Uganda is to be considered in future.  
The effects of RBC alloimmunization in SCD patients may be examined in the context of the 
policy on laboratory and clinical transfusion practice in Uganda. This study has revealed the 
presence of clinically significant IgG alloantibodies in plasma of transfused SCD patients. 
Transfusion-acquired antibodies have been implicated in immediate and delayed transfusion 
reactions;2, 10, 16 some patients with multiple antibodies are difficult to cross-match and to 
transfuse;8, 21 others develop autoantibodies in addition to being alloimmunized;28, 30 and five 
nulliparous females in the present study were alloimmunized to the D antigen.  The current 
transfusion practice in Uganda does not involve the detection or monitoring of alloantibody 
formation and the clinical consequences thereof.  Besides ABO/D grouping and a saline cross-
match at room temperature, no other compatibility testing is performed. Therefore, we 
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recommend a change in the policy of the Uganda Blood Transfusion Service to include 
laboratory and clinical guidelines on the prevention and management of immunological 




The authors wish to thank the staff of the Sickle Cell Clinic at Mulago National Referral Hospital 
in Kampala, Uganda, for the help in recruiting patients and taking off blood samples; and the 
Joint Clinical Research Center in Kampala, Uganda, for the storage of samples during the period 
of the study. They also extend their appreciation to the Sanquin Blood Supply in Leiden and 





1. Serjeant GR, Ndugwa CM. Sickle cell disease in Uganda: a time for action. E Afr Med J 
2003;80:384-7. 
2. Wayne AS, Kevy SV, Nathan DG. Transfusion management in sickle cell disease. Blood 
1993;81:1109-23. 
3. Blumberg N, Peth K, Ross K, Avila E. Immune response to chronic red blood cell transfusion. Vox 
Sang 1983;44:212-7.   
4. Orlina AR, Unger PJ, Koshy M. Post-transfusion alloimmunization in patients with sickle cell 
disease. Am J Hematol 1978;5:101-6. 
5. Coles SM, Klein HG, Holland PV. Alloimmunization in two multitransfused populations. Transfusion 
1981;21:462-6. 
6. Ambruso DR, Githens JH, Alcorn R, et al. Experience with donors matched for minor blood group 
antigens in patients with sickle cell anemia who are receiving chronic transfusion therapy. 
Transfusion 1987;27:94-8. 
7. Luban NLC. Variability in rates of alloimmunization in different groups of children with sickle cell 
disease: effect of ethnic background. Am J Pediatr Hematol Oncol 1989;11:314-9. 
8. Rosse WF, Gallagher D, Kinney TR, et al. Transfusion and alloimmunization in sickle cell disease: 
The Cooperative Study of Sickle Cell Disease. Blood 1990;76:143-7.  
9. Davies SC, McWilliam AC, Hewitt PE, et al. Red cell alloimmunization in sickle cell disease. Br J 
Haematol 1986;63:241-5. 
10. Cox JV, Steanne E, Cunningham G, Frenkel EP. Risk of alloimmunization and delayed hemolytic 
transfusion reactions in patients with sickle cell disease. Arch Intern Med 1988;148:2485-9. 
11. Sarnaik S, Schornack J, Lusher JM. The incidence of development of irregular red cell antibodies in 
patients with sickle cell anemia. Transfusion 1986;26:249-52. 
12. Castro O, Sandler G, Houston-Yu P, et al. Predicting the effect of transfusing only phenotype-
matched RBCs to patients with sickle cell disease: theoretical and practical implications. Transfusion 
2002;42:684-90. 
13. Moriera G, Bordin J, Kuroda A, Kerbauy J. Red cell alloimmunization in sickle cell disease: the 
influence of racial and antigenic pattern differences between donors and recipients in Brazil. Am J 
Hematol 1996;22:196-200. 
14. Olujohungbe A, Hambleton I, Stephens L, et al. Red cell antibodies in patients with homozygous 
sickle cell disease: a comparison of patients in Jamaica and the United Kingdom. Br J Haematol 
2001;113:661-5. 
 
195050-bw-Natukunda.indd   64 23-4-13   14:10
64 Chapter 4 65RBC alloimmunization in SCD
recommend a change in the policy of the Uganda Blood Transfusion Service to include 
laboratory and clinical guidelines on the prevention and management of immunological 




The authors wish to thank the staff of the Sickle Cell Clinic at Mulago National Referral Hospital 
in Kampala, Uganda, for the help in recruiting patients and taking off blood samples; and the 
Joint Clinical Research Center in Kampala, Uganda, for the storage of samples during the period 
of the study. They also extend their appreciation to the Sanquin Blood Supply in Leiden and 





1. Serjeant GR, Ndugwa CM. Sickle cell disease in Uganda: a time for action. E Afr Med J 
2003;80:384-7. 
2. Wayne AS, Kevy SV, Nathan DG. Transfusion management in sickle cell disease. Blood 
1993;81:1109-23. 
3. Blumberg N, Peth K, Ross K, Avila E. Immune response to chronic red blood cell transfusion. Vox 
Sang 1983;44:212-7.   
4. Orlina AR, Unger PJ, Koshy M. Post-transfusion alloimmunization in patients with sickle cell 
disease. Am J Hematol 1978;5:101-6. 
5. Coles SM, Klein HG, Holland PV. Alloimmunization in two multitransfused populations. Transfusion 
1981;21:462-6. 
6. Ambruso DR, Githens JH, Alcorn R, et al. Experience with donors matched for minor blood group 
antigens in patients with sickle cell anemia who are receiving chronic transfusion therapy. 
Transfusion 1987;27:94-8. 
7. Luban NLC. Variability in rates of alloimmunization in different groups of children with sickle cell 
disease: effect of ethnic background. Am J Pediatr Hematol Oncol 1989;11:314-9. 
8. Rosse WF, Gallagher D, Kinney TR, et al. Transfusion and alloimmunization in sickle cell disease: 
The Cooperative Study of Sickle Cell Disease. Blood 1990;76:143-7.  
9. Davies SC, McWilliam AC, Hewitt PE, et al. Red cell alloimmunization in sickle cell disease. Br J 
Haematol 1986;63:241-5. 
10. Cox JV, Steanne E, Cunningham G, Frenkel EP. Risk of alloimmunization and delayed hemolytic 
transfusion reactions in patients with sickle cell disease. Arch Intern Med 1988;148:2485-9. 
11. Sarnaik S, Schornack J, Lusher JM. The incidence of development of irregular red cell antibodies in 
patients with sickle cell anemia. Transfusion 1986;26:249-52. 
12. Castro O, Sandler G, Houston-Yu P, et al. Predicting the effect of transfusing only phenotype-
matched RBCs to patients with sickle cell disease: theoretical and practical implications. Transfusion 
2002;42:684-90. 
13. Moriera G, Bordin J, Kuroda A, Kerbauy J. Red cell alloimmunization in sickle cell disease: the 
influence of racial and antigenic pattern differences between donors and recipients in Brazil. Am J 
Hematol 1996;22:196-200. 
14. Olujohungbe A, Hambleton I, Stephens L, et al. Red cell antibodies in patients with homozygous 
sickle cell disease: a comparison of patients in Jamaica and the United Kingdom. Br J Haematol 
2001;113:661-5. 
 
195050-bw-Natukunda.indd   65 23-4-13   14:10
66 Chapter 4
15. Bashawri LAM. Red cell alloimmunization in sickle cell anemia patients. Eastern Mediterranean 
Health Journal 2007;13:1181-9. 
16. Vichinsky EP. Current issues with blood transfusion in sickle cell disease. Semin Hematol 
2001;38(Suppl):14-22. 
17. Tuck SM, Studd JWW, White JM. Sickle cell disease in pregnancy complicated by anti-U antibody. 
Case report. Br J Obs Gyn 1982;89:91-2. 
18. Diamond JW, Brown FL Jr, Bitterman P, et al. Delayed hemolytic transfusion reaction presenting as 
sickle-cell crisis. Ann Intern Med 1980;93:231-4. 
19. Schonewille H, Haak HL, van Zijl AM. RBC antibody persistence. Transfusion 2000;40:1127-31. 
20. Tahhan HR, Holbrook CT, Braddy LR, et al. Antigen-matched donor blood in the transfusion 
management of patients with sickle cell disease. Transfusion 1994;34:562-9. 
21. Vinchinsky EP, Earles A, Johnson RA, et al. Alloimmunization in sickle cell anemia and transfusion 
of racially unmatched blood. N Engl J Med 1990;322:1617-21. 
22. Klein HG, Anstee DJ. Immunology of red cells. In: Klein HG, Anstee DJ, editors. Mollison’s Blood 
Transfusion in Clinical Medicine. 11th Ed; 2005. Blackwell Publishing, Oxford; p. 48-113. 
23. Alarif L, Castro O, Ofosu, M, et al. HLA-B35 is associated with red cell alloimmunization in sickle 
cell disease. Clin Immunol Immunopathol 1986;38:178-83. 
24. Bauer MP, Wiersum-Osselton J, Schipperus M, et al. Clinical predictors of alloimmunization after red 
blood cell transfusion. Transfusion 2007;47:2066-71.  
25. Benacerraf B, McDevitt HO. Histocompatibility-linked immune response genes. A new class of genes 
that controls the formation of specific immune responses has been identified. Science 
1972;175:273-9. 
26. Maaskant-van Wijk PA, Faas BH, de Ruijter JA, et al. Genotyping of RHD by multiplex polymerase 
chain reaction analysis of six different RHD-specific exons. Tranfusion 1998;38:1015-21. 
27. Zimring JC, Hendrickson JE. The role of inflammation in alloimmunization to antigens on transfused 
red blood cells. Curr Opin Hematol 2008;15:631-5. 
28. Aygun B, Padmanabhan S, Paley C, Chandrasekaran V. Clinical significance of RBC alloantibodies 
and autoantibodies in sickle cell patients who received transfusions. Transfusion 2002;42:37-43.  
29. Josephson CD, Su LL, Hillyer KL, Hillyer CD. Transfusion in the patient with sickle cell disease: a 
critical review of literature and transfusion guidelines. Trans Med Rev 2007;21:118-33. 
30. Ahrens N, Pruss A, Mayer B, et al. Association between alloantibody specificity and autoantibodies 
to red blood cells. Transfusion 2008;48:20-24. 
 
 









PREVALENCE AND SPECIFICITIES OF 
 RED BLOOD CELL ALLOANTIBODIES 
 IN TRANSFUSED UGANDANS  












Bernard Natukunda, Henk Schonewille, Leo van de Watering and Anneke Brand. Prevalence and 
specificities of red blood cell alloantibodies in transfused Ugandans with diferent diseases. Vox Sanguinis, 
2009;98:167-171. 
 
195050-bw-Natukunda.indd   66 23-4-13   14:10
66 Chapter 4
15. Bashawri LAM. Red cell alloimmunization in sickle cell anemia patients. Eastern Mediterranean 
Health Journal 2007;13:1181-9. 
16. Vichinsky EP. Current issues with blood transfusion in sickle cell disease. Semin Hematol 
2001;38(Suppl):14-22. 
17. Tuck SM, Studd JWW, White JM. Sickle cell disease in pregnancy complicated by anti-U antibody. 
Case report. Br J Obs Gyn 1982;89:91-2. 
18. Diamond JW, Brown FL Jr, Bitterman P, et al. Delayed hemolytic transfusion reaction presenting as 
sickle-cell crisis. Ann Intern Med 1980;93:231-4. 
19. Schonewille H, Haak HL, van Zijl AM. RBC antibody persistence. Transfusion 2000;40:1127-31. 
20. Tahhan HR, Holbrook CT, Braddy LR, et al. Antigen-matched donor blood in the transfusion 
management of patients with sickle cell disease. Transfusion 1994;34:562-9. 
21. Vinchinsky EP, Earles A, Johnson RA, et al. Alloimmunization in sickle cell anemia and transfusion 
of racially unmatched blood. N Engl J Med 1990;322:1617-21. 
22. Klein HG, Anstee DJ. Immunology of red cells. In: Klein HG, Anstee DJ, editors. Mollison’s Blood 
Transfusion in Clinical Medicine. 11th Ed; 2005. Blackwell Publishing, Oxford; p. 48-113. 
23. Alarif L, Castro O, Ofosu, M, et al. HLA-B35 is associated with red cell alloimmunization in sickle 
cell disease. Clin Immunol Immunopathol 1986;38:178-83. 
24. Bauer MP, Wiersum-Osselton J, Schipperus M, et al. Clinical predictors of alloimmunization after red 
blood cell transfusion. Transfusion 2007;47:2066-71.  
25. Benacerraf B, McDevitt HO. Histocompatibility-linked immune response genes. A new class of genes 
that controls the formation of specific immune responses has been identified. Science 
1972;175:273-9. 
26. Maaskant-van Wijk PA, Faas BH, de Ruijter JA, et al. Genotyping of RHD by multiplex polymerase 
chain reaction analysis of six different RHD-specific exons. Tranfusion 1998;38:1015-21. 
27. Zimring JC, Hendrickson JE. The role of inflammation in alloimmunization to antigens on transfused 
red blood cells. Curr Opin Hematol 2008;15:631-5. 
28. Aygun B, Padmanabhan S, Paley C, Chandrasekaran V. Clinical significance of RBC alloantibodies 
and autoantibodies in sickle cell patients who received transfusions. Transfusion 2002;42:37-43.  
29. Josephson CD, Su LL, Hillyer KL, Hillyer CD. Transfusion in the patient with sickle cell disease: a 
critical review of literature and transfusion guidelines. Trans Med Rev 2007;21:118-33. 
30. Ahrens N, Pruss A, Mayer B, et al. Association between alloantibody specificity and autoantibodies 
to red blood cells. Transfusion 2008;48:20-24. 
 
 









PREVALENCE AND SPECIFICITIES OF 
 RED BLOOD CELL ALLOANTIBODIES 
 IN TRANSFUSED UGANDANS  












Bernard Natukunda, Henk Schonewille, Leo van de Watering and Anneke Brand. Prevalence and 
specificities of red blood cell alloantibodies in transfused Ugandans with diferent diseases. Vox Sanguinis, 
2009;98:167-171. 
 
195050-bw-Natukunda.indd   67 23-4-13   14:10
68 Chapter 5 69RBC alloantibodies in different diseases
Abstract 
Background and Objectives: Alloantibody formation against red blood cell (RBC) antigens is a 
common complication of transfusion therapy. However, the prevalence of RBC 
alloimmunization is hardly known in Black Africans. In Uganda, the practice is to transfuse 
ABO/D compatible blood without screening for immune antibodies. The aim of this study was to 
determine the prevalence and specificities of RBC alloantibodies in transfused Ugandans with 
different diseases.  
Materials and methods: Using a cross-sectional design, transfused patients at Mulago Hospital 
in Kampala, Uganda, were investigated. Demographic characteristics and transfusion histories 
were recorded. EDTA blood samples were obtained from consenting patients and RBC 
alloimmunization was demonstrated using standard immunohematological tests. 
Results: A total of 214 transfused patients (mean age, 30.3 years; F/M ratio, 1.0) were 
investigated. Thirteen patients (6.1%) possessed RBC alloantibodies whose specificities were 6 
anti-E; 3 anti-S; one each of anti-D, -K and - Lea; and two samples were pan-reactive. Eleven 
(84.6%) of the alloimmunized patients had experienced up to 10 transfusion episodes. The 
number of units of blood transfused and the transfusion episodes were significantly associated 
with the RBC alloimmunization rate (p=0.01).  
Conclusions: The prevalence of RBC alloimmunization in transfused Ugandans was 6.1% and 
was associated with the number of donor exposures. This immunization rate is similar to that 
observed in Caucasians, although patients with malaria were less likely to develop RBC 
antibodies. Alloantibodies were mainly against E and S antigens. We recommend the 
introduction of pre-transfusion antibody tests in Uganda depending on the recipient’s diagnosis.  
 






Red blood cell (RBC) alloimmunization is an important adverse effect that follows repeated 
transfusions with allogeneic blood [1]. It results from an immune response due to the genetic 
differences between blood donors and recipients. Immune anti-RBC antibodies are generally 
formed early in the course of multiple transfusions, usually before the 10th transfusion [2, 3]. In 
patients with disorders that often require multiple blood transfusions the rate of RBC 
alloimmunization has been reported in the range of 5 - 30% [2 - 10]. This range is even wider  
(3-76%) in patients with hemoglobinopathies [11 - 15]. Risk factors for RBC alloimmunization 
include female sex, a history of pregnancy, recipient clinical diagnosis and treatment, and racial 
differences between transfusion recipients and blood donors [16 - 18].  
Patients receiving chemotherapy for myeloproliferative disorders do not seem to be suppressed 
in terms of their ability to produce blood group alloantibodies. However, patients with 
lymphoproliferative disorders are generally characterized by an impaired immunologic response 
and therefore alloimmunization to RBC antigens following multiple transfusions is less common 
[2, 3, 19]. Absence or low rates of alloimmunization have been reported in some D negative 
AIDS patients receiving D positive RBC transfusions and in multiply transfused AIDS patients 
with AZT-associated anemia [20, 21]. Some reports indicate that multitransfused females 
register higher rates of alloantibody formation than males [18]. However, studies by Blumberg et 
al. [19] and Redman et al. [6] showed no difference in gender regarding alloimmunization rates.  
RBC alloimmunization is generally detected when patients need a blood transfusion. During pre-
transfusion testing, the patient’s blood sample is usually screened for unexpected alloantibodies 
[24]. Antibodies against antigens of the Rh and Kell blood group systems are the specificities 
most frequently found in alloimmunized patients in Western Europe and the United States [3, 5, 
6, 9]. In Uganda, no such pre-transfusion screening for immune antibodies is carried out on 
blood transfusion recipients. The aim of this study was to determine the prevalence and 
specificities of RBC alloantibodies in transfused Ugandan patients with different diseases.  
 
Materials and methods 
Patients 
Using a cross-sectional design, transfused patients with different diseases admitted at Mulago 
National Referral Hospital in Kampala, Uganda, were investigated. The initial part of the study 
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involved patient recruitment and blood sample collection and took place between 1st February 
and 31st July, 2008. Eligibility criteria included inpatients that were at least 2 years of age and 
had received at least 2 previous allogeneic blood transfusions – the second transfusion episode 
being more than 2 weeks before enrolment into the study. This was intended to enrol a group of 
participants that were likely to have become alloimmunized at an appropriate age and time after 
exposures to blood transfusions. Patients with hemoglobinopathies were being investigated in a 
parallel study and were excluded. Obstetric patients were also excluded from this study. In 
general, patients received ABO/D compatible and non-leucocyte depleted whole blood or packed 
RBC transfusions.  
Data collection 
Patients’ charts were reviewed for demographic characteristics and the transfusion history. In 
cases of incomplete or missing records, patients or their attendants were asked for additional 
information on the above history. The number of transfusion episodes, number of units of blood 
transfused, date of transfusion, indication for transfusion, age of first transfusion and for 
oncology patients whether they had received anti-cancer chemotherapy;  were recorded in a data 
collection form. The study was approved by the research and ethical committees at Mbarara 
University of Science and Technology, Mbarara, Uganda, and Makerere University Medical 
School, Kampala, Uganda.  
Laboratory investigations 
After consent, blood was drawn into ethylenediaminetetraacetic acid (EDTA) tubes for 
laboratory investigations. Plasma and buffy coat samples were removed and stored frozen at the 
Joint Clinical Research Center (JCRC) in Kampala, Uganda, until they were shipped to the 
Sanquin Blood Supply in Leiden, The Netherlands, for immunohematological studies. 
Plasma samples were screened for the presence of RBC alloantibodies by use of a standard 3-cell 
panel of reagent group O RBCs. In the indirect antiglobulin test (IAT), a LISS-enhanced gel 
centrifugation technique (DiaMed ID, Micro Typing System, Cressier sur Morat, Switzerland) 
with polyspecific antihuman globulin (rabbit anti-IgG and monoclonal anti-C3d) was used. 
When the antibody screening was positive, antibody identification was performed by testing the 
plasma samples with commercial panels of reagent RBCs, of selected phenotypes, by similar or 
additional methods whenever needed.  Patients were considered to be alloimmunized if 
 
antibodies to one or more RBC antigens could be identified. For one patient who possessed anti-
D alloantibodies, an RHD multiplex PCR was carried out to determine the genotype and hence 
the molecular basis of this observation. 
Statistical methods 
Statistical software packages Excel 5.0 (Microsoft, Redmond, CA, USA) and Statistical Package 
for the Social Sciences 12.0 (SPSS Inc., Chicago, IL, USA) were used for data management and 
analysis respectively. For univariate analysis of possible associations between RBC 
alloimmunization and gender, history of pregnancy, whole blood transfusion, diagnosis of 
malignancy, anti-cancer therapy and HIV positivity, the Chi-square test or Fisher’s exact test 
were used. Logistic regression analysis was used for continuous variables of a non-Gaussian 
distribution i.e. the age at the time of enrolment, the number of units of blood transfused, the 
number of transfusion episodes and the number of years since the last transfusion. Groups were 




We recruited 214 transfused inpatients at Mulago National Referral Hospital during the study 
period. Of these, 113 (52.8%) were females and among them, 77 (68.1%) had a history of 
pregnancy. The mean age at the time of blood collection was 30.3 (median, 29.5; range, 2-80) 
years. The patients had been transfused with a total of 1,869 (mean, 8.7; median, 5.0 and range, 
2-65) units of blood in 1,285 (mean, 6.0; median, 4.0 and range, 2-57) transfusion episodes. Half 
of the patients studied (108; 50.6%) had malignant disorders while 62 (29%) had infectious 
diseases (Table 1).  
Thirteen patients (6.1%; 95% CI: 3.0-10.0%) were found to be alloimmunized to RBC antigens; 
11 (84.6%) of them having experienced up to a maximum of 10 transfusion episodes. The 
number of units of blood transfused and the number of transfusion episodes were significantly 
associated with the rate of alloimmunization (p=0.01). Other demographic and transfusion 
characteristics of alloimmunized patients were not significantly different to those in the non-
immunized group (Table 2).   
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plasma samples with commercial panels of reagent RBCs, of selected phenotypes, by similar or 
additional methods whenever needed.  Patients were considered to be alloimmunized if 
 
antibodies to one or more RBC antigens could be identified. For one patient who possessed anti-
D alloantibodies, an RHD multiplex PCR was carried out to determine the genotype and hence 
the molecular basis of this observation. 
Statistical methods 
Statistical software packages Excel 5.0 (Microsoft, Redmond, CA, USA) and Statistical Package 
for the Social Sciences 12.0 (SPSS Inc., Chicago, IL, USA) were used for data management and 
analysis respectively. For univariate analysis of possible associations between RBC 
alloimmunization and gender, history of pregnancy, whole blood transfusion, diagnosis of 
malignancy, anti-cancer therapy and HIV positivity, the Chi-square test or Fisher’s exact test 
were used. Logistic regression analysis was used for continuous variables of a non-Gaussian 
distribution i.e. the age at the time of enrolment, the number of units of blood transfused, the 
number of transfusion episodes and the number of years since the last transfusion. Groups were 




We recruited 214 transfused inpatients at Mulago National Referral Hospital during the study 
period. Of these, 113 (52.8%) were females and among them, 77 (68.1%) had a history of 
pregnancy. The mean age at the time of blood collection was 30.3 (median, 29.5; range, 2-80) 
years. The patients had been transfused with a total of 1,869 (mean, 8.7; median, 5.0 and range, 
2-65) units of blood in 1,285 (mean, 6.0; median, 4.0 and range, 2-57) transfusion episodes. Half 
of the patients studied (108; 50.6%) had malignant disorders while 62 (29%) had infectious 
diseases (Table 1).  
Thirteen patients (6.1%; 95% CI: 3.0-10.0%) were found to be alloimmunized to RBC antigens; 
11 (84.6%) of them having experienced up to a maximum of 10 transfusion episodes. The 
number of units of blood transfused and the number of transfusion episodes were significantly 
associated with the rate of alloimmunization (p=0.01). Other demographic and transfusion 
characteristics of alloimmunized patients were not significantly different to those in the non-
immunized group (Table 2).   
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Table 1: Disease groups of the 214 Ugandan transfused patients and 
proportions of those who were alloimmunized in each group 
Disease group Patients (n; %) RBC Alloimmunized (n; %) 
Malignancies 108 (50.6) 9 (8.3) 
• Hematologic 64  4 
• Solid tumors 44  5 
Infectious diseases 62 (29.0) 2 (3.2) 
• Malaria 34  1 
• AIDS  24 1 
• Bacterial infections 4 0 
Others 44 (20.4) 2 (4.5) 
• Gastrointestinal disease 12 1 
• Renal disease 10 0 
• Trauma 10 0 
• Heart disease 7 1 
• Diabetes mellitus 3 0 
• Burns 2 0 
 
RBC antibodies 
Eleven of the alloimmunized patients produced a total of 12 RBC alloantibodies of known 
specificity. The remaining two patients possessed pan-reactive antibodies. The specificities of 
the alloantibodies identified were: anti-E, 6; anti-S, 3; and 1 each of anti-D, -K and -Lea. In one 
patient (9.1%), two alloantibodies, anti-E plus anti-K, presented as a combination; the rest of the 
alloantibodies were as single specificities. D genotyping on DNA isolated from the buffy coat of 




This cross-sectional study was undertaken to determine the prevalence and specificities of RBC 
alloantibodies in Ugandan patients who received blood transfusions. Out of 214 patients studied, 
13 (6.1%; 95% CI: 3.0-10.0) possessed RBC alloantibodies. This overall RBC alloimmunization 
 
prevalence is comparable with rates previously reported on patients receiving transfusion support 
for chronic renal failure and hematological disorders in developed countries [2, 3, 5-10]. The 
antibody specificities (anti-E, 6; anti-S, 3; anti-D, 1; anti-K, 1; anti-Lea, 1; and 2 pan-reactive) 
are also similar to the ones commonly detected and reported [3, 6, 9]. The only difference is the 
finding of a slight increase in the rate of alloimmunization against the S antigen. 
 
Table 2: Demographic variables and transfusion characteristics of alloimmunized                                              
and non-immunized Ugandan patients who received blood transfusions 
 Alloimmunized   
(n = 13) 
Non-immunized   
(n = 201) p-value 
Mean age in years (median; range) 34.8 (35.0; 2-75) 30.0 (28.0; 2-80) NS 
Sex ratio (F/M) 1.6 1.0 NS 
History of pregnancy (%) 62.5 67.6 NS 
Mean transfusion episodes (median; range) 11.8 (4.0; 2-57) 5.6 (4.0; 2-50) 0.01 
≤ 10 transfusion episodes (%) 84.6 90.5 NS 
Mean units of blood transfused  
(median; range) 16.2 (8.0; 2-65) 8.3 (5.0; 2-60) 0.01 
Transfusion with whole blood (%) 92.3 88.1 NS 
Patients with malignancy (%) 69.2 46.2 NS 
Patients received anti-cancer  
chemotherapy (%) 
55.6 50.5 NS 
HIV positive patients (%) 23.1 30.3 NS 
Mean years since the last transfusion 
(median; range) 
2.54 (0; 0-29) 1.36 (0; 0-49) NS 
      NS = p-value > 0.05 
Also, we recently found an increased number of alloantibodies (13.3% of all antibody 
specificities identified) with anti-S specificity in a parallel study on RBC alloimmunization in 
Sickle Cell Disease patients in Uganda [unpublished data]. There was a mixture of antibodies 
(anti-E and -K) in one of the alloimmunized patients which is comparable to the frequency of 
multiply alloimmunized patients in other studies [2, 9]. The patient who was alloimmunized to 
the D antigen – a 50 year old female with no history of pregnancy – had apparently been typed as 
D positive by serology. Using an RHD multiplex PCR [25], D genotyping was carried out on this 
patient and a partial D of the RoHar category was found. This emphasizes the requirement that 
transfusion laboratories should be supplied with blood grouping reagents that can detect D 
variants among blood donors (typed as D positive) and patients (typed as D negative).  
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Analysis of the transfusion characteristics revealed that the rate of RBC alloimmunization was 
significantly associated with the number of units of blood received and the number of transfusion 
episodes (p=0.01 in both cases) i.e. the alloimmunization risk increased with the number of 
donor exposures. This observation is in agreement with retrospective analyses by Fluit et al. [3] 
and Schonewille et al. [9]. According to Blumberg et al. [2], although the formation of RBC 
alloantibodies is influenced by the number of transfusions, most of the alloimmunization occurs 
early in the course of blood transfusion. This was also the case in 84.6% of alloimmunized 
patients in the present study. Female sex and a history of pregnancy were not associated with 
RBC alloimmunization. Our data indicate that 9 (8.3%) of 108 patients with malignant disorders 
became immunized to RBC antigens following blood transfusion and this prevalence is 
comparable with what has been observed in other studies on RBC alloimmunization in oncologic 
disorders [9]. Malaria is a serious disease and patients usually present with hemolytic anemia 
that may be severe. The effect of malaria infection on the pathogenesis of RBC alloimmunization 
remains to be elucidated. Recent reports by Hendrickson et al. demonstrated suppression of RBC 
alloimmunization by a bacterial endotoxin lipopolysaccharide (LPS) and an enhanced magnitude 
of RBC alloimmunization in a setting of viral-like inflammation, in murine models [26, 27]. In 
Uganda, severe malaria is a common indication for blood transfusion therapy and the occurrence 
of RBC alloantibodies in malaria patients in the present study was anticipated. However, only 
one patient (2.9%) was immunized in 34 transfused patients with severe malaria infection. These 
data suggest that there seems to be no enhanced RBC alloimmunization in patients with malaria. 
Absence of alloimmunization as a result of immunosuppressive effects of AIDS or anti-cancer 
chemotherapy has been reported in previous studies [20, 28]. However, in this study 5 (55.6%) 
of the 9 alloimmunized patients with cancer had been receiving anti-cancer chemotherapy. Also, 
one patient with AIDS – a 45 year old female who had received 11 units of whole blood in 3 
transfusion episodes – was alloimmunized to the E antigen. However, the fact that anti-E may 
sometimes be a naturally occurring antibody [29] cannot be excluded in this case.  
Thus, alloantibody formation remains a notable adverse effect of blood transfusion in the 
provision of clinical care even in a setting of immunesuppression, especially for cancer patients. 
This emphasizes the important role played by eliciting a good clinical history of previous blood 
transfusion(s) and routine laboratory screening for the presence of unexpected antibodies before 
transfusion. However, the implementation of routine antibody screening for all transfusion 
 
recipients in Uganda and in most of Sub-Saharan Africa is not currently feasible. This is because 
of the extra costs involved in the monthly procurement of reagent cell panels; the increased work 
load and hence additional staffing requirements for hospitals and transfusion services; the 
apparently low RBC alloimmune response rates in most of the transfusion recipients; the lack of 
organized administrative systems for laboratory record keeping and retrieval; and the lack of 
adequately qualified personnel in the fields of Immunohematology and Transfusion Medicine. In 
case of patients with malignant diseases, hemoglobinopathies or other disorders likely to require 
repeated blood transfusions there should be special considerations. For these patient categories 
that are at higher risk of RBC alloimmunization, we recommend the introduction of a pre-
transfusion typing and screening strategy [24] comprised of the following three tests: ABO/D 
grouping of the donor and recipient; IAT screening for irregular RBC antibodies in the 
recipient’s serum (a 3-cell panel); and a saline cross-match between the patient’s serum and the 
donor RBCs at room temperature. Any detected antibodies in the patients can be identified 
accordingly so that transfusion with antigen-negative blood is given. Regarding other transfusion 
recipients, we recommend the use of a complete cross-match [30] before blood transfusion i.e. 
incubation of the patient’s serum with the donor RBCs and addition of antihuman globulin 
serum. In so doing, we shall go a long way towards the prevention of morbidity related to 
immunological complications of blood transfusion in Ugandan patients with different diseases. 
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ABSTRACT 
Objectives: To determine the prevalence of RhD negativity and the rate of red blood cell (RBC) 
alloimmunization in Ugandan pregnant women. 
Aim: To identify the frequency and nature of maternal RBC alloimmunization in Uganda. 
Background: Haemolytic disease of the fetus and newborn (HDFN) results from maternal 
alloimmunization following exposure to allogeneic RBCs during pregnancy or blood transfusion. 
The prevalence of maternal RBC alloimmunization in Ugandans is not known.  
Materials and methods: Pregnant women at Mbarara Hospital, South Western Uganda, were 
investigated in a cross-sectional study. Demographics, transfusion and obstetric histories were 
recorded. Maternal RBC alloimmunization was demonstrated using immunohaematological 
techniques.  
Results: A total of 2001 pregnant women were recruited; 3.6% of them being RhD-negative. 
Forty five women (2.2%; 95% CI: 1.6-2.9) were found to be alloimmunized to RBC antigens. 
There were 38 RBC alloantibodies of known specificity including: anti-S, 12; anti-M, 11; anti-
Lea, 6; anti-D, 4; and 1 each of anti-K, -Fyb, -Jka, -Lua , and -Kpa. In two women (4.4%), there 
were antibody combinations (anti-M+S and -K+Kpa). Obstetric history, gestational age and 
previous immunizing events were not significantly associated with the rate of alloimmunization.  
Conclusions: This study revealed a maternal RBC alloimmunization rate of 2.2% which was 
comparable with findings from a Zimbabwean study where the prevalence was 1.7%. Given the 
6.0% prevalence of anti-D among RhD-negative women in our study and the high 
immunogenicity of the D antigen, programs for preventing anti-D alloimmunization and HDFN 
in Uganda should be considered seriously. 
 
Key words: Maternal alloimmunization, RBC alloantibodies, Pregnancy, Haemolytic disease of 
the newborn, Uganda. 
 
INTRODUCTION 
Rhesus sensitization was first reported in Africans by Zoutendyk in 1947 when he described 
three cases in South African Bantu (Jacob et al., 1959). Maternal alloimmunization is defined as 
the presence of irregular red blood cell (RBC) alloantibodies in the blood of a pregnant woman 
that can theoretically cause haemolytic disease of the fetus and newborn (HDFN).  Virtually all 
alloantibodies reactive by the indirect antiglobulin test (IAT) have been implicated in HDFN in 
different populations. Most severe HDFN associated with intrauterine death is reported in 
women with Rh-D, -c and K alloantibodies (van Kamp et al., 2004; Moise, 2008, Koelewijn et 
al., 2008). In Caucasians, the D antigen accounts for about 50% of cases of maternal 
alloimmunization; the remainder is mainly due to incompatibility to K, c, C/G, E, and Fya 
antigens and to low incidence antigens in the Rh, MNS, and Diego blood group systems (Heddle 
et al., 1993; Moise, 2008, Koelewijn et al., 2008). Before the introduction of anti-D 
immunoprophylaxis, HDFN due to anti-D affected approximately 1% of all newborns and was 
responsible for the death of 1 baby in every 2200 births in developed countries (Kumar & 
Reagan, 2005).  
The prevalence of D-negativity varies in different ethnic groups with approximately 15% of 
Caucasians, 8% of Blacks and 1% of Asians being D-negative (Reid & Lomas-Francis, 2004). A 
retrospective study in Zimbabwe showed that 191 (0.85%) of 22,493 infants had HDFN; 25 
(13.1%) and 163 (85.3%) of these having D- and ABO-HDFN respectively (Mandisodza et al., 
2008). However, in Zimbabwe only 3.3% of the population is D negative and anti-D prophylaxis 
is routinely available (Cakana & Ngwenya, 2000). In a recent study, the prevalence of RhD 
negative patients at Mbarara Regional Referral Hospital (MRRH) in Mbarara, Uganda, was 
found to be approximately 6.0% (Natukunda & Smit Sibinga, unpublished observations). No 
anti-D prophylaxis is provided at MRRH and other public hospitals in Uganda. The prevalence 
of maternal alloimmunization due to RhD and other RBC antigens in Ugandan women is not 
known. The aim of this study was to provide data on the frequency and nature of maternal RBC 
alloimmunization in pregnant women in South Western Uganda. The findings from this study 
might be of relevance in planning future management strategies for HDFN in Uganda. 
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STUDY DESIGN AND METHODS 
Study participants 
In a cross-sectional study, pregnant women attending the antenatal clinic and those in labour at 
Mbarara Regional Referral Hospital, Mbarara, Uganda, were consecutively enrolled between 
March 1st and May 31st, 2010. Informed consent was obtained from all participants. The 
demographic characteristics, obstetric and transfusion histories were recorded in a data collection 
form. Information regarding the ABO and RhD blood groups of the participants was retrieved 
from their antenatal cards whenever available. The study was approved by the research and 
ethics committees at Mbarara University of Science and Technology, Mbarara, Uganda. 
Laboratory investigations 
After consent, 4ml of whole blood was drawn from each participant and put in 
ethylenediaminetetraacetic acid (EDTA) tubes for laboratory investigations. Plasma samples 
were removed and stored frozen at -80C, at the Epicentre Mbarara Research Base, until they 
were shipped to the Sanquin Blood Supply in Leiden, the Netherlands for 
immunohaematological studies. The samples were screened for the presence of RBC 
alloantibodies by use of a standard 3-cell panel of reagent group O RBCs. In the indirect 
antiglobulin test (IAT), a LISS-enhanced gel centrifugation technique (DiaMed ID, Micro 
Typing System, Cressier sur Morat, Switzerland) with polyspecific antihuman globulin (rabbit 
anti-IgG and monoclonal anti-C3d) was used. When the antibody screening was positive, 
antibody identification was performed by testing the plasma samples with commercial panels of 
reagent RBCs, of selected phenotypes, by similar or additional methods whenever needed. 
Participants were considered to be alloimmunized if antibodies to one or more RBC antigens 
could be identified.  
Statistical methods 
Statistical software packages (Excel 5.0, Microsoft, Redmond, WA; and Statistical Package for 
the Social Sciences 12.0, SPSS, Inc., Chicago, IL) were used for data management and analysis, 
respectively. For univariate analysis of possible associations between maternal RBC 
alloimmunization and age at the time of enrolment, gestational age, parity, history of blood 
transfusion, previous Caesarean deliveries, and a history of antepartum haemorrhage, the Chi-
 
square test or Fisher’s exact test were used. Groups were assumed to differ significantly when 




We recruited a total of 2001 pregnant women at Mbarara Regional Referral Hospital during the 
3-month study period. Of these, 717 (35.8%) were in labour and admitted to the maternity ward 
while the others (n=1284) were outpatients attending the antenatal clinic with a mean gestational 
age of 27.2 (median, 28; range, 10 - 42) weeks. The mean age at the time of enrolment was 25.1 
(median, 24; range, 14 - 46) years. The mean parity was 2.6 (median, 2; range, 1-12) with 687 
(34.3%) women being primigravidae. Of 1881 women typed for their RhD status, 67 (3.6%) 
were RhD negative.  
Table 1: RBC alloimmunization and immunizing events among 2001 pregnant women                                          
in different age groups at Mbarara Regional Referral Hospital in Mbarara, Uganda 
 Maternal age (years) 
 14 - 19 20 - 35 >35 
Total 
Number of women (n) 263 1634 104 2001 
Parity (median, range) 1 (1-4) 2 (1-12) 6 (1-12) 2 (1-12) 
History of immunizing event1  4 (1.5) 307 (18.8) 40 (38.5) 351 (17.5) 
Alloimmunized women 10 (3.8) 30 (1.8) 5 (4.8) 45 (2.2) 
Number of antibodies (n) 11 30 6 47 
Women with panreactive or aspecific antibodies 3 (1.1) 4 (0.2) 2 (1.9) 9 (0.4) 
Women with clinically significant antibodies  5 (1.9) 21 (1.3) 3 (2.9) 29 (1.4) 
Clinically significant antibodies (n) 6 21 4 31 
    Anti-S 2 9 1 12 
    Anti-M 2 9 0 11 
    Anti-D 1 3 0 4 
    Anti-K, -Fyb, -Jka or -Kpa, 1 1 2 4 
  Data presented as number (%) unless stated otherwise. 1 Caesarean delivery, antepartum  haemorrhage, 
  blood transfusion  
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In the obstetric history, 186 (9.3%) participants reported having delivered by Caesarean section 
and 14 (7.5%) of them had received a blood transfusion; 159 (7.9%) participants had experienced 
a prior antepartum haemorrhage (APH) of whom 59 (37.1%) had also been transfused. A history 
of blood transfusion for non-obstetric indications was recalled by 5 women. Overall, 78 
participants (3.9%) gave a history of past exposure to blood transfusion. 
Table 2: Demographic variables, transfusion history and obstetric characteristics of RBC immunized                    
and non-immunized pregnant women at Mbarara Regional Referral Hospital in Mbarara, Uganda1
Demographics 
Immunized women  
(n=45) 






Age in years  24.9 (24; 17-37) 25.1 (24; 17-37) 25.1 (24; 14-46) 
Gestational age ≤28 weeks 18 (2.4)2 13 (1.8)2 715 (36.6)3
Parity:     
         Primiparae 20 (2.9) 13 (1.9) 667 (34.1) 
         Para 2 - 5 23 (2.0)  15 (1.3) 1135 (58.0)   
         Para >5   2 (1.3)  1 (0.6) 154 (7.9) 
History of sensitizing events  8 (2.3) 6 (1.7) 343 (17.5) 
Multiple sensitizing events4 1 (1.4) 0 72 (3.7) 
No sensitizing events 37 (2.2) 23 (1.4) 1613 (82.5) 
1 Data are reported as mean (median; range) or number (percentage). 2 Percentage per row calculated with 
total number of immunized and non-immunized women for: gestational age ≤28 weeks, parity, history of 
sensitizing events, multiple sensitizing events and no sensitizing events as the denominator; respectively. 
3 Percentage per row calculated with total number of non-immunized women as the denominator.  
4 Caesarean delivery and blood transfusion or antepartum haemorrhage and blood transfusion. 
 
Maternal RBC alloimmunization 
Forty five women (2.2%; 95% CI: 1.6-2.9) were found to be alloimmunized to RBC antigens; 20 
(44.4%) of them being primigravidae. Only 1 (2.2%) of the alloimmunized women recalled a 
history of previous blood transfusion. The proportions of alloimmunized women and the 
antibodies relevant for HDFN in different age groups are shown in Table 1. Maternal age (<20, 
20-35 and >35 years), parity (primiparae, para 2-5 and para >5), past history of sensitizing events 
(Caesarean deliveries and APH with or without blood transfusions, blood transfusions for non-
obstetric indications) and the gestational age (first, second or third trimester) at enrolment were 
 
neither significantly associated with the overall rate of alloimmunization nor with the rate of 
formation of clinically significant alloantibodies (p>0.2 for all). Table 2 summarizes the 
demographic variables, transfusion history and obstetric characteristics of the 2001 pregnant 
women studied at Mbarara Regional Referral Hospital.   
 
RBC antibody specificities 
There were 38 RBC alloantibodies of known specificity produced by 36 of the alloimmunized 
women. The remaining 9 women possessed non-specific (n=6) or pan-reactive antibodies (n=3). 
The alloantibody specificities identified were: anti-S, 12; anti-M, 11; anti- Lea, 6; anti-D, 4; and 
1 each of anti-Fyb, -K, -Jka, -Lua , and -Kpa. These presented as antibody combinations of anti-
M+S and anti-K+ Kpa in two of the women (4.4%); the remaining of the identified alloantibodies 
were as single specificities.  
 
DISCUSSION 
In this cross-sectional study, 45 out of 2001 Ugandan pregnant women had RBC alloantibodies 
giving an overall maternal alloimmunization rate of 2.2% (95% CI: 1.6 - 2.9). Out of 47 
alloantibodies detected, 31 antibodies (66.0%) in 29 women (1.4%) can be considered clinically 
relevant with reported potential to cause HDFN (Daniels, 2002). These included 4 anti-D, 12 
anti-S, 11 anti-M, and 1 each of anti-K, -Fyb, -Jka, and -Kpa. A limitation of our study was the 
inability to determine the RBC antigens from newborns, to confirm the paternal alloantigen 
origin. We presume, however, that most of these alloantibodies were formed against paternally 
derived fetal RBC antigens since none of the alloimmunized women with clinically significant 
antibodies reported a history of prior blood transfusion, although anti-M is known for its 
occurrence as a natural antibody. The overall prevalence of maternal RBC alloimmunization is 
comparable with findings from a study in Zimbabwe by Cakana et al. (2000) in which 50 out of 
3000 pregnant women (1.7%) had RBC antibodies. In this study, however, only seven women 
(0.2%) possessed antibodies clinically significant for HDFN (i.e. 4 anti-D, 2 anti-E, and 1 anti-
Jsb). Recently, Belinga et al. (2009) reported a higher prevalence of maternal RBC 
alloimmunization in 15 of 225 (6.7%) Cameroonian women and of these, 9 women (4.0%) 
possessed clinically relevant RBC alloantibody specificities (i.e. anti-D).  
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occurrence as a natural antibody. The overall prevalence of maternal RBC alloimmunization is 
comparable with findings from a study in Zimbabwe by Cakana et al. (2000) in which 50 out of 
3000 pregnant women (1.7%) had RBC antibodies. In this study, however, only seven women 
(0.2%) possessed antibodies clinically significant for HDFN (i.e. 4 anti-D, 2 anti-E, and 1 anti-
Jsb). Recently, Belinga et al. (2009) reported a higher prevalence of maternal RBC 
alloimmunization in 15 of 225 (6.7%) Cameroonian women and of these, 9 women (4.0%) 
possessed clinically relevant RBC alloantibody specificities (i.e. anti-D).  
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Maternal age, parity, history of sensitizing events and gestational age were not significantly 
associated with the rate of alloimmunization. In a Dutch study, previous RBC transfusion was 
the most important risk factor for non-D alloimmunization during pregnancy (Koelewijn et al., 
2009). We previously showed that severe anaemia due to malaria was the indication for 
transfusion in 39% of Ugandan blood recipients and that 83% of them were young children 
(Natukunda et al., 2010a). It is possible that not all the women in the current study could recall 
being transfused in early childhood, which may explain the absence of previous transfusion as a 
risk factor for maternal alloimmunization. Since parity increases with age, the clinically relevant 
RBC alloimmunization rate might also rise with maternal age. However, the alloimmunization 
frequency in our teenage pregnant women was comparable to the older women (p=0.7) and 
remarkably, primiparae showed the highest immunization rate. One could speculate that 
persistence of an antibody formed after an unrecognized transfusion during childhood explains 
antibody prevalence in the young women, while a high parity is responsible for antibody 
prevalence in the older women. Transfusion recipients in Uganda are more likely to become 
alloimmunized because of substandard pre-transfusion practices in some clinical and laboratory 
settings. Notably, we previously observed nulliparous sickle cell patients who produced anti-D 
post-transfusion despite a local transfusion policy of matching for the RhD antigen, suggesting 
RBC typing errors (Natukunda et al., 2010b). 
Anti-S alloantibodies were the most frequent RBC antibody specificity found. We have 
previously reported a high frequency of anti-S alloimmunization following blood transfusion in 
the Ugandan population as well (Natukunda et al., 2010b; Natukunda et al., 2010c). Therefore, 
anti-S may be considered for future studies in S-negative pregnant women to evaluate the 
associated incidence of (severe) HDFN. Anti-M was the second most frequent antibody. Due to 
the fact that low titer anti-M alloantibodies are rarely implicated in HDFN (Koelewijn et al., 
2008; Wikman et al., 2007), and case reports suggest that HDFN is restricted to titers above 128, 
we carried out titrations for this specificity in 9 samples for which sufficient plasma was 
available. The titers were ≤32 in all the samples (data not shown). Therefore, the clinical 
significance of anti-M as a cause of HDFN in Ugandan women is not likely.  
The frequency of anti-D immunization among RhD negative women was 6.0%. Of the four 
women with anti-D, three were multigravidae (gravida 2-6) while the fourth one was a 
primegravida at 26 weeks of gestation and she had no history of prior sensitizing events.  One of 
 
the multigravidae women with anti-D alloimmunization was in her sixth pregnancy and she also 
had a history of prior Caesarean delivery. The anti-D alloimmunization frequency herein 
reported is comparable to that in Caucasians before the introduction of Rh immune globulin 
(RhIG) prophylaxis (Woodrow & Donohue, 1968).  Therefore, programs for prevention of 
maternal anti-D alloimmunization might be put in place in Uganda given the high 
immunogenicity of the D antigen. Although pregnant women are routinely tested for ABO and 
RhD blood groups during the antenatal booking visit, they are currently not screened for the 
presence of RBC alloantibodies. We recommend that all RhD negative pregnant women should 
be screened for alloanti-D. This will help to identify those RhD negative women who require 
anti-D prophylaxis, in particular within 72 hours postpartum when an RhD positive baby has 
been delivered. In the current study this policy might, in theory, have prevented anti-D in three 
out of the four cases. Challenges associated with implementation of this policy in Uganda 
include lack of constant availability of anti-D immunoglobulin, insufficient reagents for 
alloantibody screening, and absence of laboratory facilities for estimation of FMH – the 
Kleihauer-Betke acid elution technique (Kleihauer et al., 1957; BCSH Guidelines, 1999) or flow 
cytometry (Nance et al., 1989; Nelson et al., 1998) – in order to determine the correct dosage for 
RhIG immunoprophylaxis. For those RhD-negative mothers who are found to be already 
alloimmunized, they should be followed up serologically and management strategies for safe 
delivery of the baby are required (Bowman, 1997), the lack of facilities and expertise for 
intrauterine transfusions notwithstanding. The affected neonate might then benefit from intensive 
phototherapy and exchange transfusions (Gottstein & Cooke, 2003). 
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Abstract 
Aims/Objectives: To determine the cost-effectiveness of introducing red blood cell (RBC) 
alloantibody screening as part of pre-transfusion serologic testing in Ugandan hospitals. 
Background: Pre-transfusion immunohaematologic testing in Uganda is currently limited to 
ABO/D typing plus room temperature (RT) saline cross-matches with no screening for irregular 
RBC alloantibodies. 
Materials and methods: Cost-effectiveness was evaluated from the health care providers’ 
perspective. Costs of reagents, apparatus and drugs were estimated in 2011 US dollars. We 
compared a ‘limited testing scenario’ covering 10,000 multiply transfused patients in 15 referral 
hospitals with a ‘universal testing scenario’ involving all the 100,000 blood recipients in 65 
district and referral hospitals countrywide per annum. Testing strategies included tube and gel 
techniques for RBC alloantibody screening and complete cross-matches.  
Results: RBC alloantibody screening using the gel method in the ‘limited testing scenario’ was 
the most expensive strategy costing US$23.60 while the cheapest strategy was to perform 
complete cross-matches countrywide using the tube method at a cost of US$8.57 per patient. 
Compared to No Screening, introduction of the universal TubeCC method was estimated to cost 
US$174,675 and would theoretically prevent 5,490 haemolytic transfusion reactions (HTRs) 
annually. Complete cross-matches using the tube method dominated the other testing strategies 
(i.e. they were the most cost-effective option). Compared to this testing strategy, other options 
were more expensive with no effect on health gains.  
Conclusion: Introduction of RBC alloantibody screening as part of pre-transfusion 
immunohaematologic testing in Uganda appears to be cost-effective and would contribute to 
improving blood transfusion safety. 
 
Key words: cost-effectiveness, pre-transfusion testing, RBC alloantibody screening, Uganda  
 
Introduction 
The purpose of pre-transfusion testing is to select, for each patient, blood components that when 
transfused will have acceptable survival and will not cause clinically significant destruction of 
the recipient's red blood cells (RBCs). If performed properly, pre-transfusion tests will detect 
most clinically significant unexpected alloantibodies and ensure that the patient is issued the 
designated blood components that are ABO/D compatible. Pre-transfusion testing consists of a 
series of serologic tests plus clerical and history checks that take place within the larger process 
of RBC administration. Elements of pre-transfusion testing include obtaining a labelled patient 
blood sample, comparing identifying information on the blood request form with that on the 
blood sample, checking previous transfusion records and history, testing patient sample for 
ABO/D types, screening patient sample for unexpected RBC alloantibodies, identifying the 
alloantibodies detected and performing a cross-match (BCSH Guidelines, 1996; Shulman et al., 
2001).  
In Ugandan hospitals, pre-transfusion testing is currently limited to ABO/D typing plus room 
temperature (RT) saline cross-matches without the addition of antihuman globulin (AHG) 
reagent. No screening for irregular alloantibodies is carried out putting immunized blood 
recipients at risk of haemolytic transfusion reactions (HTRs). Transfusion-induced RBC 
alloantibodies have been implicated in both acute and delayed HTRs (Cox et al., 1988; 
Vichinsky, 2001). Immune mediated HTRs may result in severe sequelae including disseminated 
intravascular coagulation, renal failure, and death (Hillman, 1979; Capon & Goldfinger, 1995). 
RBC transfusions to immunized patients with clinically significant antibodies require the 
availability of compatible blood units lacking the antigens to which the antibodies are directed. 
Recent studies reported a 6.1% rate of RBC alloimmunization following blood transfusion 
among Ugandans with different diseases (Natukunda et al., 2010a; Natukunda et al., 2010b). 
The authors recommended that there was a need to improve pre-transfusion testing in Uganda, 
including the introduction of RBC alloantibody screening, in order to prevent the occurrence of 
HTRs. However, introducing RBC alloantibody screening would increase the costs. Therefore, 
we carried out an economic evaluation on whether it would be cost-effective to roll out such a 
program in Uganda. Economic evaluation [which can be defined as the ‘comparative analysis of 
alternative courses of action in terms of both their costs and consequences’ (Drummond et al., 
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intravascular coagulation, renal failure, and death (Hillman, 1979; Capon & Goldfinger, 1995). 
RBC transfusions to immunized patients with clinically significant antibodies require the 
availability of compatible blood units lacking the antigens to which the antibodies are directed. 
Recent studies reported a 6.1% rate of RBC alloimmunization following blood transfusion 
among Ugandans with different diseases (Natukunda et al., 2010a; Natukunda et al., 2010b). 
The authors recommended that there was a need to improve pre-transfusion testing in Uganda, 
including the introduction of RBC alloantibody screening, in order to prevent the occurrence of 
HTRs. However, introducing RBC alloantibody screening would increase the costs. Therefore, 
we carried out an economic evaluation on whether it would be cost-effective to roll out such a 
program in Uganda. Economic evaluation [which can be defined as the ‘comparative analysis of 
alternative courses of action in terms of both their costs and consequences’ (Drummond et al., 
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2004)] is important because resources are scarce and choices must be made concerning their 
deployment. Cost-effectiveness analysis (CEA) guides us in minimizing the opportunity cost by 
allocating resources where more wealth will be created. The goal of CEA is to improve the 
population’s health by using available resources in the most effective way (Pereira, 2000). There 
is a need to streamline pre-transfusion testing procedures in Uganda by screening for unexpected 
RBC alloantibodies, both in the interests of cost-effectiveness and patient safety.    
Materials and Methods 
Using the health care providers’ perspective, we evaluated the cost-effectiveness of introducing 
pre-transfusion RBC alloantibody screening in Uganda for the following three scenarios:  
1. Blood transfusion recipients with sickle cell disease (SCD), cancer and other multiply 
transfused (OMT) patients (‘limited testing scenario’)  
2. All blood transfusion recipients in public hospitals (‘universal testing scenario’) 
3. No Screening at all (the current scenario) 
According to the Uganda Blood Transfusion Service (UBTS), there were 187,000 units of blood 
collected in 2009 in Uganda. Given a discard rate of 7.2% for blood (Kajja et al., 2010), 
approximately 173,536 units were administered and the remaining 13,464 units were discarded. 
A recent study by Natukunda et al. (2010c), reported that the mean number of units of blood 
transfused per recipient per year at Mbarara Regional Referral Hospital was 1.7. The total 
number of patients transfused countrywide i.e. in 65 hospitals in one year (in the ‘universal 
testing scenario’) was therefore estimated to be 100,000. In the above report from a regional 
referral hospital, 10.3% of all blood recipients in 2008 were cancer, SCD and OMT patients. 
Thus, the number of patients who would receive blood transfusions in 15 referral hospitals 
annually (in the ‘limited testing scenario’) was estimated to be 10,000.  
Testing strategies 
To estimate the costs involved in RBC alloantibody screening, complete cross-matches and 
management of HTRs in the limited and universal testing scenarios, the following four screening 
strategies were evaluated:  
(i) TubeSCREEN: A tube method with normal saline and addition of AHG reagent followed by 
alloantibody identification in case of a positive antibody screen and an RT saline cross-match. 
 
(ii) TubeCC: A tube method for a complete (indirect antiglobulin test, IAT) cross-match 
followed by antibody identification in case of a positive cross-match. 
(iii) GelSCREEN: A manual LISS gel technique with Cellbind Screen® cards followed by 
alloantibody identification in case of a positive antibody screen and an RT saline cross-match. 
(iv) GelCC: A manual LISS gel technique with Cellbind Screen® cards for a complete (IAT) 
cross-match followed by antibody identification in case of a positive cross-match. 
We assumed that patients in either cohort received one unit of whole blood or an equivalent 
amount of RBC component. Therefore, alloantibody screening (using reagent RBCs) and cross-
matching (using donor RBCs) of the patient’s serum occurred only once. Testing procedures 
were as outlined (Appendix 1 and 2). 
Risk for haemolytic transfusion reactions (HTRs) 
In recent cross-sectional studies by Natukunda et al. (2010a; 2010b), the prevalence of RBC 
alloimmunization in transfused Ugandans with SCD and other diseases was reported to be 6.1% 
(95% confidence intervals: 3.0 – 10.0%). We assumed that an equivalent proportion of recipients 
(i.e. 610 patients in the ‘limited testing scenario’ and 6,100 recipients in the ‘universal testing 
scenario’) were at risk of developing HTRs on subsequent exposure to allogeneic blood 
transfusion, unless they were screened for RBC alloantibodies or complete cross-matches were 
performed during pre-transfusion testing. To quantify the beneficial effects of putting resources 
towards improved pre-transfusion testing in Uganda by introducing RBC alloantibody screening, 
costs for the management of an HTR were analyzed. It was assumed that 10% of the HTR cases 
prevented would be severe. 
Costs 
The costs of reagents, apparatus and drugs were quoted from the latest price catalogues of two 
leading Ugandan pharmaceutical distributors (Joint Medical Store [JMS] and National Medical 
Stores [NMS], Kampala, Uganda) and Cellbind Screen®, Sanquin reagents, Amsterdam, the 
Netherlands (Appendix 1, 2 and 3). Current salary scales from the Ugandan Ministry of Health 
were used in the calculation of laboratory and clinical staff costs per hospital (2 laboratory 
technicians, 2 enrolled nurses and 1 medical doctor). Laboratory instruments (centrifuges, 
incubators, dispensers, working tables etc) were to be purchased for all the hospitals involved. 
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Also, the costs per HTR prevented were calculated and these included laboratory investigations 
and treatment (Appendix 3). All costs were calculated in 2011 US dollars and there was no 
discounting used for future costs because all expenses occurred within one year. 
Cost-effectiveness 
The incremental cost-effectiveness ratio (ICER) was estimated for each cohort of recipients i.e. 
the additional costs of a screening strategy divided by the additional health gains (HTRs 
prevented) compared with the next least expensive strategy. Strategies that cost more and 
prevented less HTRs were excluded. Additionally, the relative cost-effectiveness to the current 
strategy was estimated by dividing the additional costs and HTRs prevented relative to No 
Screening. 
Budget Impact 
The budget impact for implementing the most cost-effective screening strategy, i.e. the net cost 
to the health care system in Uganda, was estimated for both the limited and universal cohorts. 
 
Results 
Base case analysis 
The estimated costs of the four testing strategies and management of an HTR are shown in Table 
1. Alloantibody screening for multiply transfused blood recipients in referral hospitals using the 
gel method (limited GelSCREEN) was the most expensive strategy costing US$23.60 per patient. 
 
Table 1. Costs of the screening strategies investigated and the management                                                  
of a haemolytic transfusion reaction (HTR). 
 Cost per scenario (US$) 
Cost item (per patient) Limited Universal 
TubeCC 8.75 8.57 
TubeSCREEN 10.16 9.99 
GelCC 20.50 18.98 
GelSCREEN 23.60 22.07 
Management of a patient with an HTR 111.92 111.92 
 
 
On the other hand, the cheapest strategy was universal TubeCC at a cost of US$8.57 per patient. 
The cost of management of an HTR was estimated at US$111.92 per patient. 
The annual cost of testing all blood recipients in Uganda would range from US$857,405 to 
2,207,363 for universal TubeCC and universal GelSCREEN, respectively (Table 2). In 
comparison, introduction of pre-transfusion testing in only multiply transfused patients in 15 
regional referral hospitals would range from US$87,509 to 235,969 annually for limited TubeCC 
and limited GelSCREEN, respectively. The net cost, hence the budget impact of introducing pre-
transfusion immunohaematologic testing in Uganda, is shown in Table 2 column ΔC. The budget 
impact for all transfusion recipients per annum ranged from US$174,675 to 1,524,633 for 
universal TubeCC and universal  GelSCREEN, respectively; while that in the ‘limited testing 
scenario’ was estimated to be in the range of US$19,236 to 167,696 for limited TubeCC and 
limited GelSCREEN, respectively. 
 
Table 2. Base case analysis for the four strategies to improve pre-transfusion testing  
in Uganda using either the limited or universal scenario relative to No Screening. 
Testing strategy Costs (US$) HTRs ∆C ∆E 
Cost-effectiveness 
ratio relative to 
‘No Screening’  
No Screening 682,730* 0 - - - 
limited GelSCREEN  850,425 610 167,696 610 275 
universal GelSCREEN  2,207,363 6,100 1,524,633 6,100 250 
limited GelCC  819,482 610 136,753 610 224 
universal GelCC 1,897,932 6,100 1,215,202 6,100 199 
limited TubeSCREEN 716,095 610 33,366 610 55 
universal 
TubeSCREEN 
1,016,385 6,100 333,656 6,100 55 
limited TubeCC  701,966 610 19,236 610 32 
universal TubeCC  857,405 6,100 174,675 6,100 29 
    HTRs, haemolytic transfusion reactions; ∆C = costs of the scenario relative to ‘No Screening’; ∆E = 
number of  HTRs prevented; * Equivalent to the cost of investigation and treatment of all HTRs occurring 
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The costs and effects of the four testing strategies proposed in improving pre-transfusion testing 
in Uganda are shown in Table 2. When the cost-effectiveness ratios (CERs) relative to No 
Screening were calculated, it was found that those for universal TubeCC and limited TubeCC 
were the lowest and most favourable. The CER for universal TubeCC versus No Screening was 
US$29 while that for limited TubeCC versus No Screening was US$32 per HTR prevented 
(Figure 1). Therefore limited TubeCC was less cost effective than universal TubeCC and it was 
formally excluded by extended dominance. All other strategies showed higher costs and less or 
equal HTR prevention and were therefore dominated by universal TubeCC. 
For Uganda, the per capita gross national income (GNI) in 2011 was US$490. To achieve a one 
to three times the GNI per capita per disability-adjusted life year (DALY) averted threshold of 
cost-effectiveness for universal TubeCC, the DALYs prevented per HTR should be at least 0.06 
and 0.02, respectively. 
 
 
Figure 1. Total costs and HTRs prevented in the four screening strategies for the limited (open symbols) 
and universal (closed symbols) cohorts of transfused Ugandans. The CER of the limited TubeCC relative 
to No Screening was US$32 per HTR prevented. Therefore, the limited TubeCC was formally excluded 
by extended dominance. HTR = haemolytic transfusion reaction; lim = limited; uni = universal. 
 
Sensitivity analysis 
Sensitivity analyses were performed to determine which parameters had substantial impact on 
costs and outcomes. The prevalence of RBC alloimmunization in transfused Ugandans was 
assigned a range of 3 – 10% according to the published 95% confidence intervals (Natukunda et 
al., 2010a; Natukunda et al., 2010b). The proportion of HTRs that became severe was assumed 
to range from 5 – 20%. Other parameters (i.e. costs of antibody tests, management of HTRs, 
personnel and equipment) were varied using lower and upper limits of 50% and 200% of their 
original values respectively. Univariate sensitivity analyses revealed that the cost-effectiveness 
of universal TubeCC relative to No Screening was very sensitive to the test costs and the 
prevalence of RBC alloimmunization (Figure 2). Doubling the test costs to US$17.15 yielded a 
CER of US$169 per HTR prevented, a 6-fold increase in the base case value. TubeCC remained 
the most cost-effective strategy of the four strategies investigated. Decreasing the test costs to 
50% of the base case value (i.e. to US$4.29 per patient) would achieve cost savings for universal 
TubeCC. The break-even point for cost savings was estimated at US$6.83, test costs below this 
value would make TubeCC a cost saving intervention. At a 2-fold increase in the TubeCC and 
TubeSCREEN costs, TubeCC still remained the most cost-effective strategy. Universal 
TubeSCREEN would become most cost-effective at costs higher than US$10.16 per patient for 
TubeCC. GelCC would be a dominant strategy if costs decreased from US$18.98 to 6.83 per 
patient. 
The prevalence of alloimmunization had a profound impact on cost-effectiveness. Using the 
lower limit of the 95% confidence interval yielded a 6-fold higher CER for universal TubeCC 
relative to No Screening (Figure 2). TubeCC remained the most cost-effective strategy and at an 
alloimmunization prevalence rate higher than 7.7%, it would become cost saving. 
Halving the costs of HTR management would yield a 3-fold higher CER. Universal TubeCC 
screening would become cost saving at HTR management costs higher than US$140.56. The 
severity of an HTR had a modest impact on cost-effectiveness. The sensitivity of the CERs to 
personnel and equipment costs was also very limited (Figure 2). The univariate sensitivity 
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Figure 2. Tornado diagram showing the sensitivity of the cost-effectiveness ratio in the universal 
TubeCC screening strategy relative to No Screening. The solid line represents the base case cost-
effectiveness ratio of US$29 per HTR prevented. Open and solid bars depict an estimation using lower or 





Using the health care providers’ perspective, we investigated the cost-effectiveness of 
introducing RBC alloantibody screening in Uganda and found that it would be cost-effective. We 
assessed the ‘limited’ and ‘universal’ testing scenarios using tube and gel tests for alloantibody 
screening and complete cross-matches. To our knowledge, this is the first ever CEA study on 
pre-transfusion testing in Uganda and Africa at large. The cheapest (universal TubeCC) and the 
most expensive (limited GelSCREEN) strategies ranged from US$8.57 – 23.60 per patient, with 
a cost difference of US$15.03. In general, gel techniques were more expensive than tube tests. 
Furthermore, TubeCC dominated all the other testing strategies (i.e. it was the most cost-
effective option). Alloantibody screening was a more expensive option than complete cross-
matches without an effect on health gains relative to No Screening. CERs for all the testing 
 
strategies were in the range of US$29 – 275 per HTR prevented. According to the WHO and 
World Bank thresholds for cost-effectiveness, universal TubeCC becomes a highly cost-effective 
intervention if DALYs per HTR prevented are higher than 0.06 and below 0.02 DALYs per HTR 
prevented, TubeCC does not become cost-effective.  
To our knowledge, disability and quality of life weights for HTRs are not yet published. Our 
estimated DALYs per prevented range of 0.02 to 0.06 would correspond to 7 – 22 days of 
complete disability, or 14 – 44 days of 50% disability, comparable to severe chronic obstructive 
pulmonary disease, schizophrenia, and neurological sequelae of malaria (WHO, 2004). 
Multivariate and univariate sensitivity analyses revealed that the cost-effectiveness of improved 
pre-transfusion testing was sensitive to test costs, the prevalence of alloimmunization and HTR 
management costs, in descending order. Univariate sensitivity analysis showed that the cost of 
TubeCC had to rise substantially before it was to become less cost-effective than other screening 
strategies. Also, a modest reduction in test costs for universal TubeCC would yield a cost-saving 
strategy.  
A limitation of our study was that the analysis was based on a key assumption that the number of 
patients who would develop HTRs was equivalent to those who possessed transfusion-induced 
RBC alloantibodies. Whereas the prevalence of RBC alloantibodies was reported at 6.1% in 
transfused Ugandans in cross-sectional studies (Natukunda et al., 2010a; Natukunda et al., 
2010b), the actual alloimmunization frequency might even be higher since alloantibodies are 
known to disappear with time (Schonewille et al., 2000) negating the assumption that we could 
have overestimated the number of HTRs. At a slightly higher alloantibody prevalence of 7.7% 
the TubeCC strategy showed cost savings in the sensitivity analysis. This may well reflect the 
case with SCD and OMT patients. On the other hand, in first-time transfusion recipients (e.g. 
obstetric patients) the prevalence of RBC alloantibodies may be lower and hence less favourable 
cost-effectiveness can be expected from improved pre-transfusion testing. Data on the 
occurrence of HTRs in transfused Ugandans are lacking and there are no prospective studies on 
the frequency of post-transfusion RBC alloimmunization. We relied on clinical experience in the 
base case analysis. Because of the underlying statistical distribution, it is likely that costs of HTR 
management were higher relative to the base case value. The actual frequency of HTRs and 
associated management costs in sub-Saharan Africa warrants further research. 
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Furthermore, TubeCC dominated all the other testing strategies (i.e. it was the most cost-
effective option). Alloantibody screening was a more expensive option than complete cross-
matches without an effect on health gains relative to No Screening. CERs for all the testing 
 
strategies were in the range of US$29 – 275 per HTR prevented. According to the WHO and 
World Bank thresholds for cost-effectiveness, universal TubeCC becomes a highly cost-effective 
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These findings provide additional evidence to support our earlier recommendations (Natukunda 
et al., 2010a; Natukunda et al., 2010b) that there was a need to introduce RBC alloantibody 
screening in Uganda for multiply transfused patients and those with prior blood transfusion or 
pregnancy. Our current health economic evaluation shows that universal TubeCC should be 
implemented in Uganda to prevent immunohaemolytic complications in transfused patients. Gel 
technology, based on the principle of controlled centrifugation of RBCs through a dextran-
acrylamide-gel, is reported to have some advantages over tube tests. The technique addresses 
issues of standardization and the RBC washing step before the AHG phase is entirely eliminated 
saving time and requiring less skill (Lapierre, 1990; Delaflor-Weiss & Chizhevsky, 2005). 
However, in this health economic evaluation, gel technology was not found to be a cost-effective 
strategy. The cost of GelCC testing should have to decrease by more than 64% to become more 
cost-effective than the other screening strategies investigated. Introduction of RBC alloantibody 
screening calls for improvements in standards of laboratory and clinical transfusion practice. 
Issues of documentation on operational procedures, guidelines, manuals, storage conditions, 
error reporting and quality assessment schemes need to be addressed. Laboratory staff should 
liaise with their clinical colleagues and re-design blood request forms to allow for a record of 
alloantibody screening results (historical and/or current). Records on RBC alloimmunization 
should be properly kept by the local hospital transfusion laboratory and copies thereof given to 
the patients so as to prevent future HTRs. Since transfusion laboratory technicians are already 
conversant with saline tests, only limited extra training will be needed for them to appreciate the 
additional AHG phase with the introduction of universal TubeCC.  
In conclusion, introduction of RBC alloantibody screening in Uganda appears to be cost-
effective and would contribute towards improvement in blood transfusion safety. Therefore 
policy makers and other stakeholders should consider the implementation of the above 
recommendations on improved pre-transfusion testing. The UBTS can play an important role by 
supplying the necessary laboratory reagents to hospitals alongside blood components and in the 
overall monitoring of the program. 
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Appendix 1: A tube method with normal saline and addition of AHG reagent 
The tube method would be performed in a 12 x 75 mm glass tube with two drops of plasma 
being transferred using a plastic pipette. One drop of 3 - 4% RBC suspension and 2 drops of 
saline solution would be incubated for 10 minutes at 37C and test reactants would be washed 4 
times before adding 2 drops of AHG reagent. Reactions would then be read macroscopically. 
Estimated costs calculated in performing tube tests are summarized in Table 3. 
Appendix 2: A manual LISS gel technique with Cellbind Screen® cards 
Fifty microlitres of each test cell reagent and 25 µL of patient’s plasma would be transferred 
using an automatic pipette into the appropriate microtubes and the Cellbind cards would be 
incubated for 15 minutes at 37C in a Cellbind incubator. Cellbind screen gel cards would then 
be centrifuged for 10 minutes in a Cellbind centrifuge and read macroscopically. In this 
technology, the washing of test reactants and RBC button re-suspension steps are eliminated. 
Estimated costs calculated in performing gel technique tests are summarized in Table 4. 
Appendix 3: Management of a haemolytic transfusion reaction (HTR) 
Whenever a HTR was suspected, the transfusion would be stopped immediately and the patient 
hydrated with Normal Saline. Vigorous supportive care (to the patient’s airway, blood pressure, 
urine output, and heart rate) would be applied while clerical and serologic investigations and 
notification of the blood provider were being carried out. The HTR would then be managed 
according to the laboratory and clinical findings. Average costs estimated in the management of 










Table 3. Costs of RBC alloantibody screening and identification tests, including RT and complete cross-
matches, using the tube method (US$1 = 2400 UG Shillings on 20.02.2011) 
 
(a) Antibody screening      








patient (Sh) US Dollars 
100 Khan tubes  43,400 434 3 1,302  
100 Pasteur pipettes  16,000 160 3 480  
K7210 Cellbind P3, 3x10 mL 48.3  3 drops 725  
Coombs' AHG reagent   10,000  6 drops 300  
10820 Normal Saline 500 mL  789 0.0789 24 drops 1.9  
Subtotal      2,809 1.17 









patient (Sh) US Dollars 
100 Khan tubes  43,400 434 16 6,944  
100 Pasteur pipettes  16,000 160 16 2,560  
10820 Normal Saline 500 mL 789 0.0789 128 drops 10.1  
Coombs' AHG reagent  10,000  32 drops 1,600  
K7230 Cellbind D16, 16x3 mL 114.1 €  16 drops 6,270  
Subtotal      17,384 7.24 









patient (Sh) US Dollars 
100 Khan tubes  43,400 434 1 434 0.18 
100 Pasteur pipettes  16,000 160 2 320 0.13 
Subtotal      754 0.31 









patient (Sh) US Dollars 
100 Khan tubes  43400 434 1 434 0.18 
100 Pasteur pipettes  16000 160 2 320 0.13 
Coombs' AHG reagent   10000  2 drops 100 0.04 
Subtotal      854 0.35 
(e) Staff costs       
Laboratory technologists    Time (min)     Cost/min  Labour (US$) 
 TubeSCREEN   60 0.0189 1.13 
 TubeCC    45 0.0189 0.85 
(f) Equipment costs      
   Tests per annum/hosp Cost/annum Cost/test  US$) 
Limited scenario  666.67 $208.08 0.312 
Universalscenario  1538.46 $208.08 0.135 
Overall total cost of Tube test per patient    (US$) 
  limited TubeSCREEN (a+b+c+e+f)  10.16 
  universal TubeSCREEN (a+b+c+e+f)  9.99 
  limited TubeCC (b+d+e+f)  8.75 
  universal TubeCC (b+d+e+f)  8.57 
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Table 4. Costs of RBC alloantibody screening and identification tests, including RT and                                     
complete cross-matches, using the gel technique (US$1 = 2,400 UG Shillings on 20.02.2011) 
 
(a) Antibody screening      






patient UG Sh US$ 
K7000 Cellbind screen, 48x6 tests 174.7 3 microtubes 1.82 6,006 2.5 
K7210 Cellbind P3, 3x10 mL 48.3 150 uL 0.72 2,376 0.99 
                Pipette tips, 500 in a pack  3 tips  122 0.05 
Subtotal      8,504 3.54 







patient UG Sh US$ 
K7000 Cellbind screen, 48x6 tests 174.7 16 microtubes 9.7 32,010 13.34 
K7230 Cellbind ID16, 16x3 mL 114.1 800 uL 1.9 6,270 2.6 
               Pipette tips, 500 in a pack  16 tips  652 0.27 
Subtotal      38,932 16.21 







patient UG Sh US$ 
100 Khan tubes  43,400 1 434 434 0.18 
100 Pasteur pipettes  16,000 2 320 320 0.13 
Subtotal     754 754 0.31 







patient UG Ss US$ 
K7000 Cellbind screen, 48x6 tests 174.7 1 microtube 0.6 1,980 0.83 
  Pipette tips, 500 in a pack  1 tip  40 0.02 
Subtotal      2,020 0.85 
(e) Staff costs       




 GelSCREEN       45 0.0189 0.85 
 GelCC        40 0.0189 0.75 
(f) Equipment costs      
   Tests per annum/hosp Cost/annum 
Cost/test 
(US$) 
   Limited scenario  666.67 1792.05 2.688 
  Universal scenario  1538.46 1792.05 1.165 
Overall total cost of gel test per patient    (US$) 
  limited GelSCREEN (a+b+c+e+f)  23.60 
  universal GelSCREEN (a+b+c+e+f) 22.07 
  limited GelCC (b+d+e+f)  20.50 





Table 5. Estimated costs involved in the laboratory investigation and treatment per HTR prevented.                       
Severe HTR was assumed to occur in 10% of all HTR cases. 
Item Cost (US$) 
Repeat blood group; cross-match; and DAT (tube method)  4.49 
Repeat blood group; cross-match; and DAT (gel method) 5.32 
Alloantibody screening (tube method) 1.20 
Alloantibody screening (gel method) 3.54 
Haematology and clinical chemistry tests 23.00 
Drug treatment for a mild HTR 1.05 
Drug treatment for a severe HTR 2.23 
Additional blood component therapy 50.00 
Dialysis for acute renal failure (with tubular necrosis) 316.60 
Staff costs: lab technologists, nurses and a medical doctor – mild HTR; tube method  2.82 
Staff costs: lab technologists, nurses and a medical doctor – severe HTR; tube method 3.96 
Staff costs: lab technologists, nurses and a medical doctor – mild HTR; gel method 2.55 
Staff costs: lab technologists, nurses and a medical doctor – severe HTR; gel method 3.69 
Equipment costs per HTR; limited scenario (tube method) 0.31 
Equipment costs per HTR; universal scenario (tube method) 0.14 
Equipment costs per HTR; limited scenario (gel method) 2.69 
Equipment costs per HTR; universal scenario (gel method) 1.16 
Cost of each HTR management; limited scenario (tube method) 109.58 
Cost of each HTR management; universal scenario (tube method) 109.56 
Cost of each HTR management; limited scenario (gel method) 115.04 
Cost of each HTR management; universal scenario (gel method) 113.51 
Average cost of investigation and treatment of each HTR 111.92 
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8.1 Blood transfusion in Uganda   
In 1986, the International Community responded to the new and then little known HIV/AIDS 
epidemic by setting up, under the WHO, a global program on AIDS. At about the same time, the 
European Commission (EC) started providing technical and financial support to safe blood 
interventions in under-resourced countries (Gerard et al., 1995). EC assistance enabled the 
government of Uganda to rejuvenate the Uganda Blood Transfusion Service (UBTS).  
According to the WHO (2002), there are four key objectives for blood transfusion services to 
ensure blood safety: 
(1) Establishment of a well-organized, nationally-coordinated blood transfusion service that can 
provide adequate and timely supplies of safe blood for all patients in need. 
(2) Collection of blood only from voluntary non-remunerated donors (VNRD) from low-risk 
populations. 
(3) Testing of all donated blood for transfusion-transmissible infections (TTIs), blood grouping 
and compatibility testing. 
(4) The appropriate clinical use of blood, including the use of alternatives to transfusion 
(crystalloids and colloids) wherever possible, and the safe administration of blood and blood 
products. 
A well-organized blood transfusion service, with quality systems in all stages of the transfusion 
process, is a prerequisite for the safe and effective use of blood and blood products. Several 
systems for provision of blood are currently operational in Africa. The hospital-based system 
consists of transfusion units attached to the main laboratories of a hospital, most of which use 
donor replacement schemes, or a centralized transfusion centre that usually has a system for 
voluntary, altruistic donors. Many African countries have a hybrid system that incorporates 
certain centralized functions such as transfusion guidelines and collection from voluntary donors 
into their hospital-based system (Bates et al., 2007). In Uganda, a national blood policy was 
developed and there is a centralized system consisting of a national blood transfusion centre in 
Kampala, the capital, that operates the services for the whole country with seven regional blood 
banks and six collection centres. For a population of about 33 million people, approximately 
203,000 units of blood were collected in 2011. Blood is collected from VNRD (who are mainly 
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students in secondary schools) and screened for TTIs at the regional centres before it is 
distributed to respective hospitals countrywide. Standard operating procedures (SOPs) for donor 
recruitment, donor selection and counselling have been introduced and blood bank staff trained 
on screening procedures for TTIs and on quality assurance.  
Shortages of blood for transfusion usually occur in times of high demand (such as during malaria 
seasons and school holidays) and hospitals have to mobilize replacement donors locally. During 
such shortages, blood from replacemnet donors may be the only life-saving option in emergency 
cases with severe obstetric haemorrhage or severe malarial anaemia in children. Thus, there are 
both the centralized and hospital-based models of blood supply in Uganda. Actually, the 
hospital-based replacement system of blood supply would be the better suited alternative for 
Uganda. It has been shown  - at least in three sub-Saharan countries studied - that blood collected 
from replacement/family donors and first time VNRD has a similar prevalence of viral infections 
and in both donor populations safety increment is provided by repeat donations and using the 
same quality control criteria for both donations ( Allain, 2010a; 2010b). Although the WHO 
objectives for blood safety (2002) include VNRD donations only, this is not yet fulfilled in most 
African countries and still shortages of blood for emergencies occur. Considering that safety is 
not the issue, replacement donors could fill this gap. Obviously drawbacks of a 
fragmented hospital-based blood service need to be solved. However, the lack of equipment for 
blood processing, poor quality of testing kits and inadequate staff are some of the disadvantages 
of a hospital-based system. Cooperation with the centralized blood supply system e.g. through 
national validation by exchanging blood samples or even viral screening of donors at the regional 
blood service may safeguard the quality of viral testing countrywide. The lack of facilities for 
blood component separation is, however, widespread in the whole country. Like hospital-based 
blood banks, most regional blood centres are currently unable to produce blood components 
especially platelets and frozen fresh plasma. For the patients in need of the above component 
therapy (e.g. those with acquired coagulation disorders and/or malignancies), blood prescribers 
have to arrange special orders from the UBTS headquarters in Kampala or they decide to give 
fresh whole blood transfusions as an alternative. Currently, the cost of a unit of blood in Uganda 
is approximately 50 US dollars including the recruitment of low-risk donors, testing, blood 
grouping, processing, storage and transportation. The Uganda government, with assistance from 
development partners, meets these financial needs of the UBTS. Any hospital in the country can 
 
access the blood supply free of charge, with no cost recovery arrangements in place. However, 
one may raise questions on whether such a centralized system (top-down approach) would be 
sustainable in the long term, in developing countries like Uganda, in the event that there was no 
more financial support from external funders. Most sub-Saharan African countries without 
external financial support have been found to pay 2 – 4 times for their VNRD blood more than 
replacement donor blood (Bates & Hassal, 2010). In Africa, it would be preferable to initially 
establish safe, efficient and cost-effective hospital-based blood banks with a local donor base and 
then build upwards to regional and national transfusion centres (bottom-up approach). This 
would retain both VNRD and replacement donors since only repeat donation provides added 
blood safety and should be promoted (Allain, 2010a). 
Despite the substantial progress made in the area of blood safety in Uganda, less attention has 
been paid to overall transfusion safety. There is still a challenge in the appropriate clinical use of 
blood and the safe administration of blood and blood products (WHO strategic objective 4 
outlined above). Transfusion safety can be distinguished from blood safety. Blood safety 
concerns the safety of the component: it is largely the responsibility of blood collectors and has 
been a primary focus of both regulators and standard-setting agencies in the blood industry. In 
contrast, transfusion safety focuses on the overall process which results in the delivery of 
transfusion therapies to patients. Transfusion safety includes blood safety but also includes 
additional critical steps that relate to the medical use of components and the outcome of the 
recipient. These latter steps occur largely within the hospital and include the medical decision to 
transfuse, the collection of pre-transfusion samples, laboratory practices and the bedside 
administration of blood components (Dzik, 2003). Assessment of the clinical transfusion practice 
at Mbarara Regional Referral Hospital in South Western Uganda (Chapter 3) showed that 
documentation of the transfusion process was inadequate, monitoring of blood recipients was   
poor, and there was no hospital transfusion committee. Similar challenges in transfusion practice 
have been reported elsewhere in Uganda (de Graaf et al., 2009). Additionally, pre-transfusion 
RBC alloantibody screening tests were not being carried out in all hospitals in the whole country. 
Therefore, from both clinical and laboratory standpoints, the practice of immunohaematology 
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8.2  Maternal RBC alloimmunization 
Haemolytic disease of the fetus and newborn occurs when maternal IgG antibodies cross the 
placenta to the fetal circulation causing RBC destruction with consequent anaemia, jaundice or 
hydrops fetalis. In different populations, all alloantibodies reactive by the IAT have been 
implicated in causing HDFN. However, alloimmunization to the RhD antigen is the commonest 
cause of severe HDFN. Although there is no cure, blood transfusion technology provides 
information necessary for the diagnosis, clinical management and prevention of HDFN. Such 
information is used to identify the specific fetomaternal incompatibility, to provide the safest 
possible blood for transfusion therapy, and to identify the candidates for RhIG 
immunoprophylaxis. 
The intention of the study on maternal RBC alloimmunization was to provide denominator data 
on the extent of the problem in South Western Uganda and to make recommendations for the 
prevention of HDFN in the country. In Uganda, the prevalence of maternal alloimmunization due 
to RhD and other RBC antigens was hitherto unknown before the publication of our research 
findings. We observed RBC alloantibodies in 45 out of 2001 pregnant women i.e. an overall 
maternal alloimmunization rate of 2.2% (95% CI: 1.6 - 2.9). There were 31 clinically significant 
alloantibodies (Chapter 6) with reported potential to cause HDFN (Daniels, 2002) i.e. anti-D, 4; 
anti-S, 12; anti-M, 11 and 1 each of anti-K, -Fyb, -Jka, and -Kpa. Our key finding was a 6.0% 
frequency of anti-D immunization among RhD negative women who contributed 3.6% of the 
study population. This high RBC alloimmunization frequency is comparable to that reported in 
Caucasians before the introduction of RhIG prophylaxis (Woodrow & Donohue, 1968).  
Pregnant women in Uganda are routinely tested for ABO/RhD blood groups during the antenatal 
booking visit, but they are not screened for the presence of RBC alloantibodies. Thus, babies of 
immunized pregnant women are at an increased risk of HDFN. Since there is no anti-D 
prophylaxis provided in public hospitals, programs for prevention of maternal anti-D 
alloimmunization should be put in place in Uganda. We recommend that all RhD negative 
pregnant women should be screened for alloanti-D at the first prenatal visit. RhD negative 
women who are not yet alloimmunized require anti-D prophylaxis within 72 hours of delivering 
RhD positive babies. This will protect future RhD negative pregnancies from HDFN. Therefore, 
RhIG should be put on the Uganda National Essential Drugs list for supply to all public 
hospitals. Antenatal administration of RhIG at 28 weeks of gestation in the RhD-negative woman 
 
with no evidence of anti-D alloimmunization will be hampered by the uncertainty of the fetal D 
phenotype. To determine the correct dosage of RhIG, Kleihauer’s acid elution technique of 
differential staining is the most feasible and affordable method for estimation of transplacental 
FMH in the Ugandan setting. However, this method - whose principle depends on the number of 
RBCs containing fetal haemoglobin (HbF) - may overestimate the FMH since some adults may 
have hereditary persistence of HbF and the level of maternal HbF has been reported to rise above 
the upper limit of the normal in about 25% of pregnant women (Klein & Anstee, 2005). Other 
technologies such as the use of flow cytometry are not currently affordable for routine use in 
Uganda. 
For the RhD-negative mothers who are already alloimmunized, assessment of the severity of 
HDFN will mainly consist of closely monitoring the antibody titers. This is because expertise for 
fetal Doppler ultrasonography and invasive techniques such as serial amniocentesis and fetal 
blood sampling is still lacking locally. Given that there are also no facilities for intrauterine 
transfusions, management options for affected pregnancies remain controlled early delivery and 
neonatal phototherapy with or without exchange transfusions. As a tool for predicting the 
severity of neonatal disease, tests for Hb, bilirubin and DAT should be carried out on cord blood 
in an RhD positive baby whose mother is alloimmunized. Besides pregnancy, RhD haemolytic 
disease can follow mismatched blood transfusions. We recently detected post-transfusion anti-D 
alloimmunization in nulliparous SCD patients (Chapter 4) presumably following pre-transfusion 
testing errors. Urbaniak & Robertson (1981) reported that about 90% of RhD negative persons 
will make anti-D if exposed to a sufficient dose of RhD positive RBCs by transfusion. To 
prevent transfusion-induced maternal RBC alloimmunization, we recommend the transfusion of 
RhD negative RBCs to RhD negative recipients particularly in young females and those in the 
child bearing age.   
8.3  Post-transfusion RBC alloimmunization 
We demonstrated the presence of unexpected alloantibodies in the plasma of 39 out of 642 
transfusion recipients studied (428 of them having SCD) i.e. an overall RBC alloimmunization 
rate of 6.1% (95% CI: 3.0 - 10.0%). This frequency of RBC alloantibody formation was within 
the reported range, of 2 - 15%, from previous studies on RBC alloimmunization in chronically 
transfused patients with various haematologic and oncologic disorders (Blumberg et al., 1984; 
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Heddle et al., 1995; Hoeltge et al., 1995; Seyfried et al., 1999; Shonewille et al., 1999). 
Although higher rates of RBC alloimmunization (ranging up to 76%) have been reported among 
transfused SCD patients (Moriera et al., 1996; Olujohungbe et al., 2001; Aygun et al., 2002; 
Castro et al., 2002; Ameen et al., 2009), our findings (Chapter 4) showed that there was no 
difference in the anti-RBC alloimmune response between SCD and OMT Ugandan patients with 
different diseases. Both groups of blood transfusion recipients had an equal RBC 
alloimmunization frequency of 6.1%. Several factors have been put forward to explain the 
previously reported increased incidence of RBC alloimmunization in SCD patients such as an 
altered immune response, increased frequency of transfusions, the chronic inflammation 
associated with the disease itself, or lack of phenotypic compatibility between donors and 
recipients (Ambruso et al., 1987; Caccese et al., 1987; Cox et al., 1988). However, the low rate 
of RBC alloantibody formation observed among Ugandan SCD patients suggests that some of 
the mechanisms above are less important than the probable high phenotypic compatibility 
between blood donors and SCD patients who were black Ugandans in both cases. This 
proposition is supported by findings from a Jamaican study in which a cohort of transfused SCD 
patients had a low RBC alloimmunization rate of 2.6% due to the high racial homogeneity 
among blood donors and the patients (Olujohungbe et al., 2001).  RBC alloimmunization rates in 
chronically transfused SCD patients also reportedly decreased from a historic 3% per unit to 
0.5% per unit with the use of phenotypically matched units of RBCs in the Stroke Prevention 
Trial in the United States with C, E and Kell matching (Vichinsky et al., 2001). However, the 
lower prevalence of antibodies in transfused SCD patients in Uganda may be due to the low 
transfusion load (a median 3 units of blood were transfused). Due to the shortcomings of a cross-
sectional design, some RBC alloantibodies might have been missed since they have been 
reported to disappear with time (Schonewille et al., 2000; Reverberi, 2008). The above findings 
show that extended phenotype matching for SCD patients may not be relevant in Uganda and 
Africa at large. 
Additional recipient-related factors influence the possibility of a patient to mount an immune 
response to blood transfusion. Table 8.3.1 shows a comparison of demographic variables, 
transfusion characteristics and other recipient factors in all alloimmunized and non-immunized 
SCD and OMT recipients in our research project. Female gender and number and events of RBC 
exposure are major risk factors. Whereas, the recipient’s immune status has been suggested to 
 
influence the rate of RBC alloimmunization with immunesuppressed recipients failing to become 
alloimmunized (Calvery et al., 1991; Boctor et al., 2003), our findings indicated that 
immunesuppressed patients with HIV and cancer were not impaired and patients with 
inflammatory states did not have enhanced capacity to form anti-RBC alloantibodies (Chapter 
5).  
 
Table 8.3.1: Demographic variables, transfusion characteristics and recipient-related factors of all the 





Recipient age ≤10 years  11 (28.2) 213 (35.3) 0.31 
Recipient age ≥40 years   5 (12.8) 72 (11.9) 0.80 
Female-to-male ratio 1.8 1.0 0.10 
Adult females (≥18 years) 12 (30.8) 133 (22.1) 0.23 
History of pregnancy  7 (58.3) 88 (66.2) 0.64 
>10 transfusion episodes  7 (17.9) 58 (9.6) 0.10 
Mean units of blood transfused  13.8 (5.0; 2-65) 7.8 (4.0; 2-100) 0.052 
Mean transfusion episodes  9.4 (4.0; 2-57) 5.6 (4.0; 2-80) 0.044 
Recipients with malignancy 6 (15.4) 93 (15.4) 1.0 
Immunesuppressed recipients (HIV infection; 
history of anti-cancer chemotherapy)  
8 (20.5) 112 (18.6) 0.83 
Recipients with inflammation (malaria; bacterial 
and viral infections, excluding HIV)  
20 (51.3) 352 (58.4) 0.41 
* Data are reported as number (%) or mean (median; range), unless otherwise specified. 
 
Clinically significant RBC alloantibodies have been reported to occur about twice as often in 
women compared to men (Spielmann & Siedl, 1974; Raki et al., 1999).  Our findings on post-
transfusion RBC alloimmunization indicated that a positive history of pregnancy (58.3%) of 
adult women was not associated with higher alloimmunization prevalence (66% in non-
immunized recipients). Nevertheless female gender was associated with immunization (in a ratio 
of 1.8:1) suggesting another contribution from pregnancy, such as fetomaternal chimerism that 
can also be established after (unnoticed) abortions. Recent murine studies suggest that the 
inflammatory status of the recipient at the time of the transfusion may influence rates of RBC 
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Trial in the United States with C, E and Kell matching (Vichinsky et al., 2001). However, the 
lower prevalence of antibodies in transfused SCD patients in Uganda may be due to the low 
transfusion load (a median 3 units of blood were transfused). Due to the shortcomings of a cross-
sectional design, some RBC alloantibodies might have been missed since they have been 
reported to disappear with time (Schonewille et al., 2000; Reverberi, 2008). The above findings 
show that extended phenotype matching for SCD patients may not be relevant in Uganda and 
Africa at large. 
Additional recipient-related factors influence the possibility of a patient to mount an immune 
response to blood transfusion. Table 8.3.1 shows a comparison of demographic variables, 
transfusion characteristics and other recipient factors in all alloimmunized and non-immunized 
SCD and OMT recipients in our research project. Female gender and number and events of RBC 
exposure are major risk factors. Whereas, the recipient’s immune status has been suggested to 
 
influence the rate of RBC alloimmunization with immunesuppressed recipients failing to become 
alloimmunized (Calvery et al., 1991; Boctor et al., 2003), our findings indicated that 
immunesuppressed patients with HIV and cancer were not impaired and patients with 
inflammatory states did not have enhanced capacity to form anti-RBC alloantibodies (Chapter 
5).  
 
Table 8.3.1: Demographic variables, transfusion characteristics and recipient-related factors of all the 





Recipient age ≤10 years  11 (28.2) 213 (35.3) 0.31 
Recipient age ≥40 years   5 (12.8) 72 (11.9) 0.80 
Female-to-male ratio 1.8 1.0 0.10 
Adult females (≥18 years) 12 (30.8) 133 (22.1) 0.23 
History of pregnancy  7 (58.3) 88 (66.2) 0.64 
>10 transfusion episodes  7 (17.9) 58 (9.6) 0.10 
Mean units of blood transfused  13.8 (5.0; 2-65) 7.8 (4.0; 2-100) 0.052 
Mean transfusion episodes  9.4 (4.0; 2-57) 5.6 (4.0; 2-80) 0.044 
Recipients with malignancy 6 (15.4) 93 (15.4) 1.0 
Immunesuppressed recipients (HIV infection; 
history of anti-cancer chemotherapy)  
8 (20.5) 112 (18.6) 0.83 
Recipients with inflammation (malaria; bacterial 
and viral infections, excluding HIV)  
20 (51.3) 352 (58.4) 0.41 
* Data are reported as number (%) or mean (median; range), unless otherwise specified. 
 
Clinically significant RBC alloantibodies have been reported to occur about twice as often in 
women compared to men (Spielmann & Siedl, 1974; Raki et al., 1999).  Our findings on post-
transfusion RBC alloimmunization indicated that a positive history of pregnancy (58.3%) of 
adult women was not associated with higher alloimmunization prevalence (66% in non-
immunized recipients). Nevertheless female gender was associated with immunization (in a ratio 
of 1.8:1) suggesting another contribution from pregnancy, such as fetomaternal chimerism that 
can also be established after (unnoticed) abortions. Recent murine studies suggest that the 
inflammatory status of the recipient at the time of the transfusion may influence rates of RBC 
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alloantibody formation (Zimring & Hendrickson, 2008), an observation also not confirmed in our 
patient cohort. The number of transfusion episodes and units of blood transfused was 
significantly associated with the rate of alloimmunization. This is consistent with previous 
reports that have shown an association between RBC alloimmunization and increased number of 
donor exposures (Davies, et al., 1986; Rosse et al., 1990) [Table 8.3.1]. Thus, RBC 
alloimmunization remains a significant complication of allogeneic transfusions, especially in 
Uganda where blood products are not appropriately selected or fully cross-matched. 
Thirty five (83.3%) of the 42 clinically significant alloantibodies detected were directed against 
antigens of the Rh and MNS blood group systems i.e. anti-C, 2; anti-Cw, 1; anti-D, 8; anti-E, 16; 
anti-M, 1; and anti-S, 7. Multiple alloantibody specificities were demonstrable in 6 (15.4%) of 
the 39 alloimmunized recipients. This was comparable to the frequency of multiply 
alloimmunized patients in other studies (Schonewille et al., 1999). The occurrence of post-
transfusion anti-D alloimmunization indicates the presence of laboratory typing errors or the 
transfusion of RhD positive units to antigen negative recipients regardless of the local 
transfusion policy. Noteworthy is the fact that five of the patients who produced anti-D 
alloantibodies were nulliparous females aged between 5 and 19 years and these were at risk of 
producing future babies with RhD haemolytic disease. This underscores the need for improved 
pre-transfusion testing including the use of quality typing antisera and screening for immune 
alloantibodies. Currently, pre-transfusion testing in Uganda does not involve the detection or 
monitoring of alloantibody formation and its clinical consequences. ABO and RhD grouping are 
followed by an abbreviated RT saline cross-match with no other compatibility testing performed.  
 
8.4  Conclusion and recommendations  
Alloimmunization to RBC antigens is usually only appreciated when the laboratory detects an 
antibody in the serum of the subject.  Immunization, however, may exist and not be recognized 
because: the serum is not examined at the appropriate time following antigenic challenge; the 
antibody strength is below the threshold for detection; the target reagent cells do not possess the 
corresponding antigen; serological test conditions are not optimal; or there is a cellular, not 
humoral, immune response.  While the rate of RBC alloimmunization reported herein lies within 
the expected ranges, our research project had some limitations. Due to the cross-sectional 
designs employed, a snapshot of transfused patients and pregnant women was studied and 
 
therefore these data were by no means conclusive and likely underestimated the true 
immunization risks.  Since we had to freeze and then ship the samples to Europe several months 
after collection, we could not use self RBCs as autocontrols and neither could we determine the 
co-existence of autoimmunization. However, the findings herein presented are quite significant 
and should form the bases for policy changes in Uganda on pre-transfusion and antenatal testing. 
In future, there is a need to design larger, multicentre, prospective studies to determine the actual 
nature and frequency of the immune response to RBC and other blood cell antigens vis-à-vis the 
prognoses of transfusion recipients and pregnant women in Uganda, especially in this era of 
universal leucocyte depletion of blood products and therapeutic use of novel immunosuppressive 
drug regimens. We highly recommend the introduction of RBC alloantibody screening during 
pre-transfusion testing in Uganda. Our research findings from the cost-effectiveness analysis 
study (Chapter 7), which showed that such a program would be cost-effective, are in support of 
this recommendation.  Laboratory manuals for improved pre-transfusion testing and standard 
operating procedures for improved clinical transfusion and obstetric practice should be 
formulated and operationalized within Uganda and other African countries that currently do not 
use standard immunohaematologic techniques. Consequently, the morbidity and mortality related 
to RBC alloimmunization and the immunohaemolytic consequences thereof, including HTRs and 
HDFN, will be significantly prevented while reducing the associated financial burden in many 
African countries with restricted health budgets.  
 
There is a need to introduce antenatal and pre-transfusion screening tests for detection of RBC 
alloantibodies in pregnant women and transfusion recipients in Uganda. We specifically 
recommend the introduction of the following testing strategies:  
(a) For pregnant women during the antenatal booking visit: 
• Carry out ABO and RhD grouping of the women; 
• Screen for the presence of alloanti-D in the serum of all RhD negative women; and 
• If the antibody screen is positive, monitor the strength of alloanti-D using serial titrations 
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(b) For those with a history of previous pregnancy or blood transfusion(s) or in SCD, cancer and 
OMT patients: 
• Carry out ABO and RhD grouping of the donor and recipient;  
• Screen for irregular RBC alloantibodies in the recipient’s serum using tube or gel test 
methods (37C IAT with a 3-cell panel);  
• Identify all the detected alloantibodies; and 
• Carry out an RT saline cross-match between the patient’s serum and the selected donor 
RBCs.  
• If a cell panel analysis cannot be performed a cross-match including AHG should be 
performed. 
(c) For other blood transfusion recipients 
• Carry out ABO and RhD grouping of the donor and recipient; and  
• Carry out a complete cross-match between the patient’s serum and the donor RBCs (37C 
incubation of the patient’s serum with donor RBCs and addition of AHG serum). In case 
the complete cross-matches are positive, antibody identification should be carried out so 
that antigen negative blood is given to the recipients.  
In so doing, there will be a reduction in the risk of HDFN, RBC alloimmunization, AHTRs, 
DSTRs and DHTRs (the frequency of post-transfusion immune haemolytic reactions in 
Ugandans is currently unknown), and challenges associated with the lack of compatible blood for 
alloimmunized transfusion recipients will be solved. 
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Summary 
Red blood cell (RBC) alloantibodies are formed after exposure to foreign RBC antigens in cases 
of blood transfusion, transplantation or pregnancy. The reported RBC alloimmunization 
frequency in ABO- and D-matched transfusion recipients varies between less than 1 to more than 
70 percent; and is dependent on antigen immunogenicity, duration of transfusion therapy, and 
genetic and environmental factors. Why an immune response is or is not mounted against a 
particular incompatible antigen is, however, unknown. Upon subsequent exposure to blood 
transfusions, more than 20 percent of alloimmunized patients form additional RBC antibodies. 
Multiple alloantibody specificities are seen in up to 70 percent of the recipients, depending on 
the transfusion frequency. RBC alloantibodies can cause haemolytic disease of the fetus and 
newborn or acute and delayed haemolytic transfusion reactions, leading to potentially serious 
clinical consequences.  
 
Chapter 1 
In this chapter, the phenomenon of post-transfusion and maternal RBC aloimmunization is 
briefly introduced. The fact that pre-transfusion RBC screening tests and complete cross-matches 
are not carried out in Ugandan public hospitals is mentioned. Also, the paucity of data on RBC 
alloantibody formation in transfused Ugandans is underlined. Finally, a number of research 
questions pertinent to the subject of RBC alloimmunization in Uganda are outlined. 
Chapter 2 
The relevant scientific literature on post-transfusion and maternal RBC alloimmunization is 
reviewed in Chapter 2. The chapter begins with a short history of post-transfusion and maternal 
RBC alloimmunization, following the discovery of the Rh blood group system by P. Levine and 
R. Stetson in 1939.  Next, we briefly review the diversity of human blood groups together with 
their functional heterogeneity.    
In the pathogenesis of post-transfusion RBC alloimmunization, pathways for immune 
recognition of alloantigens, the role of costimulatory molecules, and types 1 and 2 immune 
responses are highlighted. The nature of RBC alloantibodies - “naturally occurring” or 
“immune” - is also discussed. Naturally occurring antibodies are most often IgM while immune 
alloantibodies are usually of the IgG isotype. Antibodies are considered to be clinically 
 
significant if they have caused HTRs, HDFN or unacceptably short survival of the transfused 
RBCs.  
The frequency and nature of post-transfusion RBC alloimmunization in different populations of 
blood recipients, including SCD and OMT patients, is presented. A number of studies discussing 
RBC alloimmunization frequencies in SCD and OMT patients (ranging from 2.6 - 76% and 5 - 
30% respectively) are also reviewed. Lastly, the literature on HDFN resulting from maternal 
RBC alloimmunization is presented.  
Chapter 3 
In this chapter, the clinical transfusion practice at Mbarara Regional Referral Hospital (MRRH) 
in South Western Uganda was assessed. Clinical data on the indications for blood transfusion, 
blood ordering practices and the post-transfusion complications related to RBC alloimmunization 
were collected.  In 2008, there were 1674 blood recipients on all the five wards at MRRH and 
58.4% of them were given whole blood transfusions. The mean number of units per recipient 
was 1.7 and the crossmatch-to-transfusion ratio was 1.3. The four most frequent indications for 
transfusion were malaria (38.8%), bleeding (27.1%) other infections (16.1%) and cancer (6.6%). 
Transfusion reactions were recorded for ten (0.6%) patients. Although no evidence of blood 
wastage was adduced, inadequacies were noted in the documentation of the transfusion process. 
We recommended the establishment of a hospital transfusion committee which would train staff, 
put in place local guidelines on the appropriate use of blood, design a standard ‘blood transfusion 
form’ for monitoring transfusions, and investigate consequences of RBC alloimmunization e.g. 
haemolytic transfusion reactions. 
Chapter 4 
The occurrence of RBC alloantibodies in 428 transfused SCD patients, who were mainly 
children (median age, 12 years), was investigated in a cross-sectional study. There were 26 
patients with anti-RBC antibodies giving an alloimmunization rate of 6.1% (95% CI: 4.0% - 
9.0%). Thirty RBC alloantibody specificities were found, with 20 (66.7%) and 5 (16.6%) 
belonging to the Rh and MNS blood group systems respectively. Anti-D alloimmunization was 
observed in five nulliparous females, irrespective of the local transfusion policy of matching for 
the RhD antigen. Alloanti-S antibodies contributed 80% of the detected specificities in the MNS 
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blood group system. Eleven of the alloantibodies (36.7%) presented as multiple antibody 
combinations. Of the immunized patients with specific antibodies, 19 (79.2%) produced only one 
antibody while 5 (20.8%) had multiple antibodies. The rate of RBC alloimmunization was 
significantly associated with the number of units of blood transfused (i.e. the number of donor 
exposures). However, the alloantibody prevalence was low compared to other studies in 
transfused SCD patients presumably because of a low transfusion load in this study (median 
number of units transfused = 3) and due to the racial homogeneity between blood donors and 
SCD patients in Uganda. 
Chapter 5 
To determine the prevalence and identify the specificities of RBC alloantibodies in transfused 
Ugandans with different diseases, we recruited 214 recipients at Mulago National Referral 
Hospital during a six-month study period. Of these, 113 (52.8%) were females and among them, 
77 (68.1%) had a history of pregnancy. The patients had a mean age of 30.3 years and they had 
been transfused with a total of 1,869 units of blood in 1,285 transfusion episodes. Of the patients 
studied, 108 (50.6%) had malignant disorders i.e. haematologic, 64; and solid tumours, 44; while 
62 (29%) had infectious diseases i.e. malaria, 34; AIDS, 24; and bacterial infections, 4. There 
were 13 patients (6.1%; 95% CI: 3.0 - 10.0%) found to possess RBC alloantibodies; 11 (84.6%) 
of them having experienced up to a maximum of 10 transfusion episodes.  The alloimmunization 
rate of 6.1% in this study was similar to that observed in Caucasian blood recipients. The number 
of units of blood transfused and the number of transfusion episodes were significantly associated 
with the rate of alloimmunization. Eleven of the alloimmunized patients produced a total of 12 
RBC alloantibodies of known specificity. The specificities of the alloantibodies identified were: 
anti-E, 6; anti-S, 3; and 1 each of anti-D, -K and -Lea. In one patient (9.1%), two alloantibodies, 
anti-E plus anti-K, presented as a combination; the rest of the alloantibodies were as single 
specificities. Immunosuppressed patients with AIDS and cancer became alloimmunized. Patients 
with malaria were less likely to develop alloantibodies. Depending on the recipient’s diagnosis, 





In this chapter, the prevalence of maternal alloimmunization was studied in 2001 Ugandan 
pregnant women in a three-month cross-sectional study. While 717 (35.8%) of the women were 
in labour and admitted to the maternity ward, the others (n=1284) were outpatients attending the 
antenatal clinic. The mean age at the time of enrolment was 25.1 years and the mean parity was 
2.6. Out of the 1881 women typed for their RhD status, 67 (3.6%) were RhD negative. Overall, 
78 participants (3.9%) gave a history of past exposure to blood transfusion. Forty five women 
(2.2%; 95% CI: 1.6 - 2.9) were found to be alloimmunized to RBC antigens; 20 (44.4%) of them 
being primigravidae. Only 1 (2.2%) of the alloimmunized women recalled a history of previous 
blood transfusion. There were 38 RBC alloantibodies of known specificity produced by 36 of the 
alloimmunized pregnant women i.e. anti-S, 12; anti-M, 11; anti- Lea, 6; anti-D, 4; and one each 
of anti-Fyb, -K, -Jka, -Lua, and -Kpa. These presented as antibody combinations of anti-M+S and 
anti-K+ Kpa in two of the women (4.4%); the remaining of the identified alloantibodies were as 
single specificities. To prevent HDFN, the introduction of RhIG prophylaxis in Ugandan public 
hospitals was recommended given the high rate of maternal anti-D alloimmunization herein 
reported and the high immunogenicity of the D antigen. 
Chapter 7 
A study to determine the cost-effectiveness of introducing RBC alloantibody screening as part of 
pre-transfusion testing in Uganda was carried out.  Cost-effectiveness was evaluated from the 
health care providers’ perspective. We compared a ‘limited testing scenario’ covering 10,000 
multiply transfused patients in 15 referral hospitals with a ‘universal testing scenario’ involving 
all the 100,000 blood recipients in 65 district and referral hospitals countrywide per annum. 
Testing strategies included tube and gel techniques for RBC alloantibody screening and complete 
cross-matches. RBC alloantibody screening using the gel method in the ‘limited testing scenario’ 
was the most expensive strategy costing US$23.60 while the cheapest strategy was to perform 
complete cross-matches countrywide using the tube method at a cost of US$8.57 per patient. 
Complete cross-matches using the tube method dominated the other testing strategies (i.e. they 
were the most cost-effective option). Therefore, introduction of RBC alloantibody screening as 
part of pre-transfusion immunohaematologic testing in Uganda appears to be cost-effective and 
would contribute to improving blood transfusion safety. 
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Chapter 8 
A general discussion on the research findings reported in this thesis is presented in this chapter. 
In Uganda, blood transfusion services are centrally organized with regional blood centers across 
the country. Donated blood is tested for TTIs – including Syphilis, Hepatitis B and C, and HIV – 
and a documented quality system is in place. In hospitals, ABO/D typing and RT saline cross-
matches are carried out before transfusion. However, RBC alloantibody screening is not 
performed during pre-transfusion and antenatal testing in the whole country. Therefore, 
alloimmunized blood recipients and babies of RhD negative mothers are at high risk of serious 
morbidity and mortality due to HTRs and HDFN respectively. Research findings in this thesis 
showed that one in every 16 transfused Ugandans and a similar number of RhD negative 
pregnant women possess clinically significant RBC alloantibodies in their plasma. Hence, we 
herein recommend the introduction of alloanti-D screening in all RhD negative pregnant women; 
and screening for the presence of irregular RBC alloantibodies in the plasma of potential blood 
recipients with a history of prior exposure to RBCs through transfusion(s) or pregnancy. Any 
detected alloantibodies will be identified and antigen negative blood transfused. Complete cross-
matches (as opposed to the currently performed RT saline cross-matches) are also recommended 
for the rest of blood transfusion recipients. In so doing, the new measures will improve the health 
of Ugandans by reducing the risk of RBC immunohaemolytic complications including 
alloimmunization, acute and delayed HTRs, and HDFN. 
 
Samenvatting 
Rode bloedcel (RBC) antistoffen worden gevormd na contact met vreemde RBC antigenen na 
bloedtransfusie, transplantatie of zwangerschap. De frequentie van RBC alloimmunisatie, na 
transfusie van ABO en D gematchte transfusies, varieert tussen minder dan 1 tot meer dan 70 
procent en is afhankelijk van de antigeen immunogeniciteit, duur van de transfusie therapie en 
genetische en omgevingsfactoren. Waarom een immuun reactie wel of niet wordt opgewekt 
tegen een zeker antigeen is vooralsnog grotendeels onbekend. Patiënten die eenmaal antistoffen 
hebben gevormd hebben een meer dan 20 procent hogere kans op de vorming van meerdere 
antistoffen na volgende transfusies. Afhankelijk van de transfusie frequentie kunnen meerdere 
antistof specificiteiten worden gevonden in 70 procent van de patiënten. RBC alloantistoffen 
kunnen hemolytische ziekte van de foetus en pasgeborene (HZFP) veroorzaken en 
verantwoordelijk zijn voor acute en uitgestelde hemolytische transfusiereacties (HTR), beiden 
met potentieel ernstige klinische consequenties. 
 
Hoofdstuk 1 
In dit hoofdstuk zijn post-transfusie en maternale RBC alloimmunisatie kort ingeleid. Het feit dat 
pre-transfusie RBC antistof screenings testen en complete kruisproeven niet worden uitgevoerd 
in Ugandese publieke ziekenhuizen wordt benoemd. Tevens wordt benadrukt dat er nauwelijks 
gegevens zijn over alloantistof vorming in Ugandese transfusie ontvangers. Dit heeft geleid tot 
een aantal relevante onderzoeksvragen met betrekking tot RBC alloimmunisatie in Uganda. 
Hoofdstuk 2 
Relevante wetenschappelijke literatuur over post-transfusie en maternale RBC alloimmunisatie 
wordt besproken in hoofdstuk 2. Het hoofdstuk begint met post-transfusie en maternale RBC 
alloimmunisatie in historisch perspectief, gevolgd door de ontdekking van het Rhesus 
bloedgroep systeem door P. Levine en R. Stetson in 1939. Vervolgens is een korte beschrijving 
gegeven van de humane bloedgroep diversiteit en hun functionele heterogeniciteit. 
Met betrekking tot de pathogenese van post-transfusie RBC alloimmunisatie worden pathways 
voor immuun herkenning van alloantigenen, de rol van costimulatoire moleculen en type 1 en 2 
immuun reacties besproken. De oorsprong van RBC alloantistoffen – “natuurlijk voorkomend” 
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of “immuun” – wordt besproken. Natuurlijk voorkomende antistoffen zijn veelal IgM terwijl 
immuun antistoffen meestal van het IgG type zijn. Antistoffen worden als klinisch relevant 
geduid als zij HTR, HZFP of onacceptabel korte overleving van getransfundeerde RBC kunnen 
veroorzaken. Vervolgens worden aanbevolen immunohematologische pre-transfusie procedures 
besproken. De frequentie en oorsprong van post-transfusie RBC alloimmunisatie in verschillende 
transfusie ontvangers zoals sikkelcel (SCD) patiënten en andere ziekten (OMT) waarbij frequent 
getransfundeerd wordt gepresenteerd. Een aantal studies over RBC alloimmunisatie frequentie in 
SCD en OMT, met frequenties tussen 2,6-76% en 5-30% respectievelijk, worden besproken. Als 
laatste wordt de literatuur over HZFP veroorzaakt door maternale RBC alloimmunisatie 
besproken. 
Hoofdstuk 3 
Voor dit hoofdstuk werd de klinische transfusie praktijk in het Mbarara Regional Referral 
Hospital (MRRH) in Zuid-West Uganda onderzocht. Klinische gegevens met betrekking tot 
transfusie indicaties, bloed bestelling en post-transfusie complicaties gerelateerd aan RBC 
alloimmunisatie werden verzameld. In 2008 waren er 1674 transfusie ontvangers op de 5 
afdelingen van het MRRH en 58,4% van hen ontvingen volbloed transfusies. Het gemiddelde 
aantal eenheden per transfusie ontvanger was 1,7 en de kruisproef-transfusie ratio was 1,3. De 
vier meest voorkomende indicaties voor transfusie waren malaria (38,8%), bloeding (27,1%), 
andere infecties (16,1%) en maligniteit (6,6%). Transfusie reacties werden gemeld bij 10 (0,6%) 
patiënten. Ondanks dat er geen harde bewijzen waren voor bloed verspilling, waren er wel hiaten 
in de dokumentatie van de transfusie keten. Voorgesteld wordt om een ziekenhuis transfusie 
commissie in te stellen, die vervolgens verantwoordelijk is voor opleiding van personeel, 
implementatie van lokale procedures met betrekking tot juist gebruik, ontwikkeling van een 
standaard ‘transfusie aanvraag formulier’ om transfusies te monitoren en onderzoek te doen naar 
de consequenties van RBC alloimmunisatie zoals hemolytische transfusie reacties. 
Hoofdstuk 4 
Het vóórkomen van RBC allantistoffen in 428 getransfundeerde SCD patiënten, voornamelijk 
kinderen (mediane leeftijd 12 jaar), werd onderzocht in een cross-sectionele studie. Er waren 26 
patiënten met anti-RBC antistoffen resulterend in een alloimmunisatie frequentie van 6,1% (95% 
 
BI 4,0-9,0%). Er werden 30 antistof specificiteiten gevonden, waarvan 20 (66,7%) en 5 (16,6%) 
behorend tot de respectievelijk Rhesus en MNS bloedgroep systemen. Anti-D alloimmunisatie 
werd gevonden bij 5 vrouwen die nooit zwanger waren geweest, ondanks het lokale transfusie 
beleid om D compatibel te transfunderen. Alloanti-S antistoffen waren verantwoordelijk voor 
80% van de antistoffen gericht tegen antigenen in het MNS bloedgroep systeem. Elf antistoffen 
(36,7%) werden gevonden in combinatie met andere antistoffen. Van de patiënten bij wie de 
antistof specificiteiten bepaald konden worden hadden 19 (79,2%) patiënten één antistof en 5 
(20,8%) patiënten meerdere antistoffen. De antistof frequentie was geassocieerd met het aantal 
transfusies (donor exposities) dat patiënten hadden ontvangen. De antistof frequentie was laag 
vergeleken met andere studies in getransfundeerde SCD patiënten, mogelijk doordat het aantal 
getransfundeerde eenheden in onze studie laag (mediaan 3 eenheden) was en er raciale 
homogeniciteit bestond tussen de bloed donoren en SCD patiënten in Uganda. 
Hoofdstuk 5 
Om de prevalentie en specificiteit van RBC alloantistoffen in getransfundeerde Ugandezen met 
verschillende ziekten te onderzoeken werden 214 transfusie ontvangers gedurende een periode 
van 6 maanden in het Mulago National Referral Hospital onderzocht. Van deze patiënten waren 
113 (52,8%) vrouwen en 77 (68,1%) waren zwanger geweest. De patiënten hadden een 
gemiddelde leeftijd van 30,3 jaar en in totaal 1869 eenheden bloed ontvangen gedurende 1285 
transfusie episoden. Van de bestudeerde patiënten hadden 108 (50,6%) een maligne ziekte, 
waarvan 64 haematologisch en 44 solide tumoren, 62 patiënten een infectieuze aandoening, 
waarvan 34 malaria, 24 AIDS en 4 bacterieel en de overige 44 patiënten hadden 
gastrointestinale, nier en hartziekten (29), trauma (10) diabetes mellitus (3) en brandwonden (2). 
Dertien patiënten (6,1%; 95% BI: 3,0-10,0%) hadden RBC antistoffen en 11 (84,6%) van hen 
hadden tot maximaal 10 transfusie episoden meegemaakt. De alloimmunisatie frequentie van 
6,1% was vergelijkbaar met Kaukasische transfusie ontvangers. Het aantal toegediende eenheden 
en transfusie episoden was significant geassocieerd met de immunisatie frequentie. De elf 
geïmmuniseerde patiënten hadden 12 antistof specificiteiten t.w. 6x anti-E, 3x anti-S, 1x anti-D, -
K en -Lea. Bij één patiënt (9,1%) waren twee antistoffen aantoonbaar met anti-E en anti-K 
specificiteit, de andere patiënten hadden één antistof specificiteit. Ook patiënten met 
immunosuppressie t.g.v. AIDS en kanker hadden antistoffen gevormd, terwijl patiënten met 
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malaria minder vaak antistoffen hadden. Afhankelijk van de diagnose van de ontvanger wordt 
introductie van pre-transfusie antistof screening in Uganda aanbevolen.  
Hoofdstuk 6 
In dit hoofdstuk is de prevalentie van maternale alloimmunisatie in een cross-sectioneel 
onderzoek bij 2001 Ugandeze zwangeren gedurende een periode van 3 maanden bestudeerd. Bij 
717 (35,8%) vrouwen werd het onderzoek ten tijde van de bevalling verricht terwijl zij 
opgenomen waren op de ‘maternity’ afdeling en bij de resterende vrouwen (n=1284) tijdens 
bezoek aan de antenatale kliniek. De gemiddelde leeftijd was 25,1 jaar en de gemiddelde pariteit 
2,6 keer. Van de 1881 vrouwen bij wie de D bloedgroep bepaald kon worden waren 67 (3,6%) D 
negatief. Een transfusie in het verleden werd opgegeven door 78 vrouwen. Antistoffen tegen 
RBC antigenen waren aantoonbaar bij 45 vrouwen (2,2%; 95% BI: 1,6-2,9%), waarvan bij 20 
(44,4%) vrouwen tijdens hun eerste zwangerschap. Een transfusie in het verleden werd maar 
opgegeven door één (2,2%) vrouw met antistoffen. Bij 36 vrouwen konden in totaal 38 
antistoffen gespecificeerd worden, t.w. 12x anti-S, 11x anti-M, 6x anti-Lea, 4x anti-D en 1x anti-
Fyb, -K, -Jka, -Lua en -Kpa. Bij twee (4,4%) vrouwen waren multiple antistoffen aanwezig, t.w. 
anti-M + -S en anti-K + -Kpa en de anderen hadden één antistof specificiteit. Om HZFP te 
voorkomen wordt de introductie van RhIg profylaxe aanbevolen, gegeven de hoge frequentie van 
maternale anti-D immunisatie gevonden in dit onderzoek en de hoge immunogeniciteit van het D 
antigeen. 
Hoofdstuk 7 
Een onderzoek werd gedaan naar de kosten-effectiviteit van introductie van RBC antistof 
screening als onderdeel van pre-transfusie onderzoek in Uganda. De kosten-effectiviteit werd 
geëvalueerd vanuit het ‘health care providers’’ perspectief. Een ‘beperkt test scenario’ uitgaande 
van 10000 multiple getransfundeerde patiënten in 15 referentie ziekenhuizen werd vergeleken 
met een ‘universeel test scenario’, waarbij uitgegaan werd van alle 100000 transfusie ontvangers 
in 65 district en referentie ziekenhuizen in heel Uganda jaarlijks. De testen voor antistof 
screening en complete kruisproeven bestonden uit de ‘buisjes-methode’ en de ‘gel-techniek’. 
Antistof screening met de gel-techniek in het beperkt test scenario bleek de meest dure (US$ 
23,60) en volledige kruisproef met de buisjes-methode en het universele test scenario de minst 
 
dure (US$ 8,57) strategie. De complete kruisproef met de buisjes-methode was het meest kosten-
effectief en domineerde over alle andere strategieën. Introductie van RBC antistof screening als 
onderdeel van pre-transfusie immunohematologisch onderzoek blijkt kosten-effectief en draagt 
bij aan verbetering van de bloed transfusie veiligheid in Uganda. 
Hoofdstuk 8 
In dit hoofdstuk wordt een algemene discussie gegeven van de bevindingen van het onderzoek 
voor dit proefschrift. In Uganda zijn bloed transfusie diensten centraal georganiseerd met 
regionale centra verdeeld over het hele land. Gedoneerd bloed wordt getest op via bloed 
overdraagbare ziekten (TTIs), - syphilis, hepatitis B en C en HIV- en een gedocumenteerd 
kwaliteitssysteem is aanwezig. In de ziekenhuizen wordt voor iedere transfusie de ABO en D 
bloedgroep bepaald en een zout-kruisproef gedaan. Onderzoek naar de aanwezigheid van RBC 
antistoffen voor transfusie en bij zwangerschap wordt niet uitgevoerd in Uganda. Hierdoor lopen 
ontvangers van bloed en babies van D-negatieve moeders een hoog risico op ernstige morbiditeit 
en mortaliteit ten gevolge van respectievelijk HTRs en HZFP. De bevindingen van het onderzoek 
beschreven in dit proefschrift laten zien dat één op elke 16 getransfundeerde Ugandezen en een 
vergelijkbaar aantal D-negatieve zwangere vrouwen klinisch relevante RBC antistoffen heeft. 
Wij bevelen de introductie aan van alloanti-D screening bij D negatieve zwangere vrouwen en 
screening op irregulaire RBC antistoffen in het plasma van potentiële transfusie ontvangers met 
een voorgeschiedenis van blootstelling aan RBCs door transfusie of zwangerschap. Bij een 
positieve antistof screening wordt de specificiteit bepaald en antigeen compatibel bloed 
getransfundeerd. Complete kruisproeven (in tegenstelling tot de huidige zout-kruisproef bij 
kamertemperatuur) worden ook aanbevolen voor alle andere ontvangers van bloed. Deze nieuwe 
maatregelen zullen de gezondheid van Ugandezen bevorderen door vermindering van het risico 
op RBC immunohematologische complicaties zoals alloimmunisatie, acute en vertraagde HTRs 
en HZFP. 
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